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Abstract 
Oncolytic viruses selectively target and kill cancer cells by direct lysis  and by stimulating a 
tumour antigen specific immune response. These promising therapeutic agents target 
multiple cancers and one such agent, T-Vec (Talimogene laherparepvec) has been licensed for 
treatment of malignant melanoma. 
We investigated the potential of Coxsackievirus A21 (CVA21) as a treatment for bladder and 
pancreatic cancers. The human bladder cancer cell-lines were tested and cytolytic ability of 
CVA21 depended on the expression of the intercellular adhesion molecule -1 (ICAM-1) viral 
entry receptor which was increased by Mitomycin C, this led to enhanced viral replication and 
cell death. CVA21 oncolysis induced immunogenic apoptosis as characterised by an increase 
in expression of ICD markers and apoptosis markers . In addition, MB49/ICAM-1 bladder 
cancer cells undergoing CVA21-induced ICD led to MB49 tumour rejection in a syngeneic 
murine bladder cancer model, protection was provided by CD4+ T cells.  
We evaluated the mechanism of resistance to CVA21 infection in human pancreatic cancer 
cell-lines. Despite the presence of high ICAM-1, BxPC-3 cell-line was resistant to CVA21 
oncolysis and no viral protein was detected. As no genetic mutation was detected in the 
ICAM-1, an investigation of the mutational background revealed a lack of KRAS mutations in 
the BxPC-3 cell-line. This lack of KRAS mutation has previously shown to be involved in 
resistance to virus susceptibility.  
The therapeutic potential of CVA21 was evaluated by a murine bladder cancer model. 
Although, CVA21 intratumoural administration delayed tumour growth for a short time. 
There were limitations such as unrestricted tumour growth and short life-span of the model 
due to which the evaluation of virus induced immune targets for potential combinational 
approaches was not possible. 
Although, CVA21 has shown its benefit as monotherapy both in cell-lines and in in vivo model 
systems emerging data shows enhanced treatment efficacy using oncolytic viruses in 
combination with other immune modulatory agents.  
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CHAPTER 1: INTRODUCTION 
1.1 Cancer: Hallmarks  
Tumorigenesis is a complex process and is characterised by the six core hallmarks postulated 
by Weinberg et al (Figure 1.1) (Hanahan & Weinberg, 2000; Hanahan & Weinberg, 2011; 
Marchini et al, 2016). These hallmarks of cancer will be discussed briefly.  
Whilst, normal cells require growth signals and receptor-ligand signalling to undergo mitosis, 
cancer cells divide in the absence of growth stimulation via ligand independent signalling  
which makes them self-sufficient in growth signals (Hanahan & Weinberg, 2000; Hanahan & 
Weinberg, 2011; Marchini et al, 2016). Cancer cells acquire this ability to self-replicate by 
producing their own mitotic growth factors such as transforming growth factor alpha (TGF α) 
and epidermal growth factor receptor (EGF-R) (Hanahan & Weinberg, 2000; Hanahan & 
Weinberg, 2011; Marchini et al, 2016). Additionally, normal cells are exposed to anti-growth 
signals to maintain homeostasis by arresting cell growth. Cancer cells avoid anti-growth 
signals by disrupting the anti-proliferative pathways, one such example is the retinoblastoma 
protein (Rb) pathway. In the Rb pathway, transforming growth factor beta (TGF-β) maintains 
cell growth suppression however, cancer cells become unresponsive to TGF-β and its 
receptors are down regulated leading to cancer cell proliferation (Hanahan & Weinberg, 
2000; Hanahan & Weinberg, 2011). Furthermore, normal cells undergo a crisis state after 
multiple cell cycles as the shortened telomere cannot protect chromosome ends. However, 
cancer cells have telomerase enzymes which add nucleotide sequences at the end of the 
chromosome making the cancer cells’ replicative potential unlimited (Hanahan & Weinberg, 
2000; Hanahan & Weinberg, 2011). Tumour cells can also create an imbalance between 
angiogenesis inducers and inhibitors thus, activating the ‘angiogenic switch’  which leads to 
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blood vessel dilation and sprouting of new vessels. This provides more blood supply, nutrients  
and oxygen to the hypoxic and necrotic tumour microenvironment resulting in exponential 
tumour growth (Hanahan & Weinberg, 2000; Hanahan & Weinberg, 2011). At a later stage in 
the disease, cancer cells migrate from the primary tumour site to a distant site with better 
nutrient and oxygen supply, forming metastases. The altered function of cell adhesion 
molecules and integrins such as cell adhesion molecules (CAMs) and E-cadherin leads to the 
metastatic and invasive phenotype (Hanahan & Weinberg, 2000; Hanahan & Weinberg, 
2011).One of the main characteristics of cancer cells is evading cell death, cancer cells have 
mutated tumour suppressor protein, p53. The p53 pro-apoptotic protein induces cell cycle 
arrest and its inactivation results in over expression of anti-apoptotic genes such as B-cell 
lymphoma 2 (Bcl-2) and B-cell lymphoma-extra-large (Bcl-XL) leading to uncontrollable cell 
expansion (Hanahan & Weinberg, 2000; Hanahan & Weinberg, 2011). A recent review by 
Weinberg et. al  highlighted the importance of two emerging hallmarks which play a role in 
cancer development (Hanahan & Weinberg, 2011). These include, the ability of cancer cells 
to re-programme the metabolic potential to provide for increase glucose demand of 
neoplastic cells and evasion of the immune response by inhibitory molecules such as TGF -β, 
myeloid derived suppressor cells (MDSCs) and T regulatory cells (Hanahan & Weinberg, 2011). 
Notably, there are also two enabling hallmarks which contribute to the establishment of six 
core and two emerging hallmarks (Hanahan & Weinberg, 2011). Firstly, genomic instability 
leads to an increase in mutational burden in tumour cells leading to production of variants of 
tumour cells which are better adapted to survive in the microenvironment (Hanahan & 
Weinberg, 2011). Secondly, a tumour promoting inflammatory microenvironment supplies 
growth, proangiogenic and survival factors to sustain proliferation and limit tumour cell death 
(Hanahan & Weinberg, 2011). 
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In order to eradicate cancers the uncontrolled tumour proliferation, aberrant growth 
suppression signalling pathways, evasion of immune mediated control, pro-tumour 
inflammation, tumour metastasis and resistance to cell death need to be targeted by cancer 
therapies. Additionally, a therapy that promotes anti-inflammatory and a tumour-suppressive 
microenvironment will further provide treatment success. In this study we mainly focused on 
Figure 1.1 The core, emerging and enabling hallmarks that lead to a neoplastic disease, adapted from (Bartlett 
et al, 2013; De Munck et al, 2017; Hanahan & Weinberg, 2000; Hanahan & Weinberg, 2011). 
The 6 core characteristics that lead to progression of cancer include s elf-sufficiency in growth signals, evasion of 
growth suppressors, unlimited replicative potential, recruitment of new blood vessels, activation of metastatic 
potential and resistance to cell death. 
Two emerging hallmarks recently postulated to play a role in cancer development are ability of cancer cells to re-
programme their metabolic potential and evade an anti -cancer immune response. Additionally, two enabling 
hallmarks which contribute to establishment of six core hallmarks and two emerging hallmarks are genomic 
instability and protumorigenic tumour microenvironment. 
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two cancers, bladder and pancreatic. Utilising these two solid cancers, we looked at some 
aspects of hallmarks of cancers such as resistance to cell death, tumour promoting 
inflammation and evasion of immune mediated immune response and how those can be 
targeted using tumour specific immunotherapy. 
1.1.1 Bladder Cancer 
Bladder cancer is the 9th most common cancer in the world and the 13th most common cause 
of death related to cancer worldwide (Sanli et al, 2017). The risk of bladder cancer increases 
with age and it is more common in men than women (Anastasiadis & de Reijke, 2012). Bladder 
cancer is categorised into non-muscle invasive accounting for approximately 75 % of all 
bladder cancer cases and muscle invasive which is reported in 25 % of the cases (Kobayashi 
et al, 2015). Non-muscle invasive bladder cancer (NMIBC) can be subdivided into superficial 
cancer which is limited to the bladder lumen and is representative of a low grade disease 
whereas carcinoma in situ (CIS) consists of cluster of flat dysplastic cells which lead to muscle 
invasive disease (Kobayashi et al, 2015). Bladder cancer has a high frequency of occurrence, 
elevated rate of progression and recurrence. Recurrence of bladder cancer is a serious 
challenge in the management of NMIBC as approximately 60-70 % of NMIBC cases recur and 
20-30 % progress to an invasive disease (Aldousari & Kassouf, 2010). The frequency of relapse 
and progression makes bladder cancer one of the most expensive cancers to treat and 
manage (Burger et al, 2013). 
1.1.1.1 Risks  
One of the leading causes of bladder cancer is smoking which is responsible for 50 % of all 
bladder cancer cases (Burger et al, 2013). Smoking attributes to 25 % of all bladder cancer 
cases in women and 50-60 % in men in Western countries (Pashos et al, 2002). Tobacco 
smoking exposes the bladder to aromatic hydrocarbons and amines which are carcinogenic 
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(Burger et al, 2013). Carcinogens in tobacco lead to the four-fold increase in risk of developing 
bladder cancer in smokers (Burger et al, 2013; Kobayashi et al, 2015; Lunt et al, 2012). 
Occupational hazards such as exposure to benzene derivatives in dyes, paints, and petroleum 
products lead to 20 % of all bladder cancer cases and increase the incidence of bladder cancer 
(Burger et al, 2013; Lunt et al, 2012). There is some evidence of genetic predisposition to 
urinary bladder cancer. For example N-acetyltransferase and Glutathione S- transferase Mu 1 
genes encode enzymes responsible for metabolising and detoxifying chemicals from smoke 
(Sanli et al, 2017). Genome wide association studies have also found genetic variations in 
solute carrier family 14 member 1 gene which encodes urea transporter, and changes in it 
can lead to an increase concentration of urine and carcinogen exposure to the bladder 
urothelium (Sanli et al, 2017). 
1.1.1.2 Symptoms, diagnosis and staging  
Some clinical signs seen in early stages of bladder cancer are haematuria, increase in urgency 
and frequency to urinate (Sanli et al, 2017). To confirm the presence of malignant disease 
transurethral biopsy via cystoscopy and urine cytology is performed, any cancerous lesions or 
histological findings are investigated (Sanli et al, 2017). To classify cancer stage and improve 
accuracy, the upper urinary tract is also imaged using computed tomography (CT) scan, 
magnetic resonance imaging (MRI) and ultrasound (Sanli et al, 2017). Bladder cancer stages 
are classified based on the invasiveness of the Tumour (T), the tumour spread to the lymph 
Nodes (N) and Metastasis (M) to distant sites such as the prostate and vagina, etc. (Kobayashi 
et al, 2015). The TNM staging classification is used for bladder cancer diagnosis (Fig ure 1.2).  
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1.1.1.3 Management and Treatment  
It is very crucial to stage bladder cancer accurately as wrong staging can lead to incorrect 
treatment regime leading to cancer progression. NMIBC is mainly treated with transurethral 
resection (TUR) which is sufficient in most cases but there are high chances of incomplete 
resection due to tumour location and size. Therefore, a second TUR is recommended a few 
weeks after the first one followed by surveillance for 5 years in low risk patients and adjuvant 
therapy for 1-3 years in patients with high risk disease (Sanli et al, 2017). Approximately, 60-
90 % of cases will recur when treated with TUR alone (Aldousari & Kassouf, 2010). Another 
way of managing NMIBC, mainly CIS, is immunotherapy. One such treatment is Bacillus 
Calmette–Guérin (BCG), a live attenuated mycobacteria, initially designed to vaccinate 
against Tuberculosis (Anastasiadis & de Reijke, 2012; Fuge et al, 2015). It was observed that 
Figure 1.2 Stages of bladder cancer development and their treatments, adapted from (Kobayashi et al, 2015). 
The earliest stage in bladder cancer development is known as carcinoma in situ (CIS) which has a high degree 
of dysplasia, it is non-muscle invasive and can be treated with transurethral resection (TUR) and BCG 
immunotherapy. As the disease progresses, tumour cells invade muscles and enter the connective tissues 
underneath the bladder epithelial layer (T1) treated by intravesical chemotherapy and cystectomy. Invasion by 
tumour cells of smooth muscles layers (T2), fat layers (T3), vagina, prostate, abdominal wall and uterus (T4) is 
indicative of late stage bladder cancer which is managed by cystectomy and systemic chemotherapy .  
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patients treated with BCG had lower rate of bladder cancer (Fuge et al, 2015). Since then BCG 
has been used as a treatment for NMIBC, particularly for CIS, leading to its approval by the 
U.S Food and Drug Administration (FDA) in 1990 (Aldousari & Kassouf, 2010; Anastasiadis & 
de Reijke, 2012). BCG elicits an anti-tumour effect by inducing an inflammatory immune 
response (Koya et al, 2006; Pasula et al, 2002). Infection of bladder cancer cells occurs upon 
interaction of fibronectin, an extracellular matrix protein with the fibronectin attachment 
protein (FAP) of Mycobacterium Tuberculosis (Pasula et al, 2002). An immune reaction is 
triggered upon internalisation of BCG evidenced by the release of cytokines (interleukins (IL) 
1, 6  and 12) in urine and activation of antigen-presenting cells (APC) (Fuge et al, 2015). As a 
result, cytotoxic T lymphocytes and natural killer T cells are activated which induce an anti -
tumour immune response (Fuge et al, 2015; Koya et al, 2006).  BCG is relatively well-tolerated 
but has been shown to be fatal in some cases due to systemic spread of BCG 
immunocompromised patients (Fuge et al, 2015). BCG can cause BCG-osis which is a systemic 
infection that results in BCG absorption into the blood stream (Lukacs et al, 2013). 
Approximately 5 % of patients develop serious side-effects to BCG such as haematuria, co-
current cystitis, fever, pneumonia and allergic reaction (Barocas et al, 2012; Fuge et al, 2015). 
Of the patients who do not respond to BCG (approximately 30 %), 95 % have increased risk of 
developing progressive disease in 5 years (Fuge et al, 2015; Pashos et al, 2002). For high grade 
NMIBC, adjuvant chemotherapy is administered after surgery such as Mitomycin C. 
Mitomycin C, a chemotherapy derived from Streptomyces is an anti-cancer and antibacterial 
drug (Barocas et al, 2012).  Mitomycin C is an alkylating agent that targets deoxyribonucleic 
acid (DNA) and induces double stranded breaks herein. Damage to the DNA of cancer cells is 
particularly effective because of their rapid division and dependence on downstream protein 
synthesis (Pashos et al, 2002). Mitomycin C causes local side-effects due to its high molecular 
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weight, 41 % of all cases develop cystitis which can cause frequent urination, discomfort and 
pain; some patients develop allergic reactions and leukopenia although it is rare (Barocas et 
al, 2012; Pashos et al, 2002). Doxorubicin, Epirubicin and Valrubicin chemotherapeutic agents 
are also used to treat NMIBC (Barocas et al, 2012; Pashos et al, 2002). Although, studies have 
shown a 40 % decrease in recurrence after one year when a single dose of intravesical therapy 
is given 24 hours post TUR, these chemotherapeutic agents are known to cause bladder 
irritation, reduction in urine capacity and cystitis (Pashos et al, 2002). 
Muscle Invasive bladder cancers are treated with aggressive chemotherapy, bladder resection 
and/or radiotherapy (Sanli et al, 2017). For better survival outcome, lymph node dissection is 
also performed. To treat metastatic bladder cancer, a combination of platinum based 
chemotherapy is administered systemically such as combination of cisplatin, methotrexate 
and vinblastine (CMV) or methotrexate, vinblastine, doxorubicin and cisplatin (MVAC) (Sanli 
et al, 2017). Current conventional therapies do delay disease progression, however, the risk 
of recurrence and threat of disease advancement to muscle invasive is still high.   
1.1.2 Pancreatic cancer 
Pancreatic cancer is associated to a very poor prognosis, with only 5 % of patients having a 5 
year survival expectancy. Patients with local advanced disease have a median survival of 6 to 
10 months whereas in metastatic disease the median survival is reduced to 3 to 6 months  
(Hidalgo, 2010; Kamisawa et al, 2016; Stromnes & Greenberg, 2016; Watson et al, 2016). 
Approximately, 90 % of all pancreatic cancers are pancreatic ductal adenocarcinoma (PDAC) 
originating from exocrine pancreatic ducts (Watson et al, 2016). PDAC mostly occurs in the 
elderly population, mean age at occurrence is 75 for women and 71 for men (Watson et al, 
2016). The lack of early disease symptoms and manifestation of clinical detectable disease at 
advanced stage makes PDAC a challenging malignancy to treat (Chen et al, 2017). 
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1.1.2.1   Risks 
PDAC is a heterogeneous and complex disease. Most of the PDAC cases are due to sporadic 
mutations (80 %) whereas only 10 % of carcinomas are due to familial germline mutations  
(Hidalgo, 2010; Kamisawa et al, 2016). Most patients with established, advanced PDAC have 
either one or more of the following genetic mutations. Kirsten rat sarcoma virus (KRAS) gene 
mutation is found in 90 % of carcinomas and transcription of mutated KRAS leads to defective 
RAS protein stimulation resulting in activation of proliferative signalling pathways (Deer et al, 
2010). Mutation of the cyclin-dependent kinase Inhibitor 2A (CDKN2A) gene is carried by 95 
% of PDAC tumours and leads to lack of G1-S cell cycle regulator protein P16. 50-75 % of PDAC 
tumours carry the tumour protein p53 (TP53) mutation leading to a lack of cell cycle arrest 
and DNA repair (Ducreux et al, 2015; Iacobuzio-Donahue et al, 2012).  
Life style factors such as smoking leads to a 75 % increase in the risk of developing PDAC even 
after 10 years of cessation, according to a meta-analysis study (Iodice et al, 2008; Kamisawa 
et al, 2016). Whereas chronic pancreatitis leads to approximately 5 % increase in disease risk 
development (Bansal & Sonnenberg, 1995; Ducreux et al, 2015; Kamisawa et al, 2016; 
Raimondi et al, 2010). Diabetes and increase in body mass index also lead to enhanced risk of 
PDAC occurrence (Arslan et al, 2010; Ducreux et al, 2015; Kamisawa et al, 2016). According to 
results from three meta-analysis studies, patients with diabetes for 10 years have a 30-50 % 
greater risk of developing PDAC (Bosetti et al, 2014). 
1.1.2.2    Symptoms, diagnosis and stages 
At the early stage of disease development, pancreatic cancer is asymptomatic. As the disease 
progresses common signs are weight loss, obstructive upper duodenum, jaundice, diabetes, 
abdominal pain, back pain, bloating, vomiting and nausea (DiMagno, 1999; Ducreux et al, 
2015; Hidalgo, 2010; Kamisawa et al, 2016). 
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In the early stage of pancreatic cancer diagnosis, analysis for carcinoembryonic antigen (CEA) 
and carbohydrate antigen 19-9 (CA 19-9) serum biomarkers is performed (Ducreux et al, 2015; 
Kamisawa et al, 2016; Ni et al, 2005). CT and MRI scanning is performed with or without the 
aid of contrast medium for disease staging, assessment of metastatic lesions and invasion  
(Ducreux et al, 2015; Kamisawa et al, 2016; Zhang et al, 2012). Endoscopic ultrasound is used 
to further stage the disease and fine-needle biopsies are obtained for disease confirmation 
through histology providing a 95 % diagnostic accuracy (Ducreux et al, 2015). 
Pancreatic cancer stages are classified according to the American Joint Committee TNM 
classification (Edge & Compton, 2010; Hidalgo, 2010). The tumour stage helps determine 
whether surgery is appropriate. Stages 1-2 are limited to the pancreas whereas in stage 3 the 
tumour grows beyond the pancreas taking over the portal and splenic veins (Bilimoria et al, 
2007; Hidalgo, 2010). However, stages 1-3 are resectable as veins can be reconstructed post-
surgery (Bilimoria et al, 2007; Hidalgo, 2010). Stage 4 is unresectable and invasive, the tumour 
invades lymph nodes, mesenteric artery and nearby organs such as  the liver and lungs 
(Bilimoria et al, 2007; Hidalgo, 2010; Watson et al, 2016). 
1.1.2.3    Management and Treatment 
Pancreatic cancer is a challenging disease to treat as it is mostly detected at an advanced 
stage, less than 20 % patients are eligible for surgery at the time of diagnosis with pancreatic 
cancer (Ducreux et al, 2015). The treatment regime varies according to the stage of disease 
(Figure 1.3). During resection either the bottom, top or whole pancreas along with 
splenectomy is performed (Kamisawa et al, 2016). Patients are given adjuvant chemotherapy, 
Gemcitabine is the most commonly administered drug after a randomised study evidenced 
its better response rate over 5 fluorouracil (Burris et al, 1997; Ducreux et al, 2015; Hidalgo, 
2010; Kamisawa et al, 2016). For advanced disease stage, the FOLFIRINOX regimen 
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(oxaliplatin, irinotecan, fluorouracil, folinic acid along with radiotherapy) is provided (Ducreux  
et al, 2015; Kamisawa et al, 2016). For invasive and metastatic disease palliative care and 
systemic chemotherapy is used (Hidalgo, 2010; Kamisawa et al, 2016). 
 
 
Conventional therapies have been unable to improve the overall median survival or survival 
rate of pancreatic cancer, in fact the 5 year survival post-surgery is less than 20 % in pancreatic 
cancer patients (Chen et al, 2017). There is urgent need for novel therapies to manage 
pancreatic cancer due to the limited therapeutic benefit provided by current therapies, 
absence of early diagnostic biomarkers, high mortality rate and detection of disease at the 
advanced stage (Chen et al, 2017). Pancreatic cancer is one of the most stroma rich cancers. 
The stroma consists of fibroblasts, cytotoxic tumour specific T cells, antigen presenting cells, 
cytokines, blood vessels and growth factors (Feig, 2012). This heterogeneous environment 
provides multiple targets for immunotherapeutic exploration (Feig, 2012). PDAC is alleged to 
Figure 1.3 Treatment used in different stages pf pancreatic cancer, adapted (Kamisawa et al).  
For treatment of pancreatic cancer a multidisciplinary approach is taken and based on the cancer stage 
radiation therapy, chemotherapy, surgery or palliative care is provided. For the small percentage of patients 
with resectable tumours surgery is the best option followed by adjuvant chemotherapy whilst border-line 
resectable tumour is treated with combination of chemotherapy and radiation. In metastatic disease systemic 
chemotherapy, radiotherapy and palliative care is provided. 
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be non-immunogenic due to the presence of an immunosuppressive tumour 
microenvironment. A study by Eric et al. using granulocyte macrophage colony stimulating 
factor (GM-CSF) in combination with cyclophosphamide showed conversion of non-
immunogenic disease to immunogenic as evidenced by an increase in T cell infiltration and 
improved overall PDAC patient survival (Lutz et al, 2014). 
Although in recent years therapies have been developed to specifically target tumour cells, 
little improvement has been seen in cancer free survival and disease prognosis (De Munck et 
al, 2017). Surgery, chemotherapy and radiotherapy still remain the most promising treatment 
option for most cancers. A more targeted and tumour specific approach needs to be 
investigated to overcome the shortcomings of current therapies. In order to establish a 
successful cancer therapy, it is important to understand the development of tumour cells and 
evasion from immune mediated control which could provide potential therapeutic targets.  
1.2 Immune surveillance and editing – three stages of cancer 
development  
 
The term immune surveillance was coined in the mid-20th century by Burnet and Thomas, 
who proposed that tumour associated antigens induce T cell stimulation and result in 
protection of the host from neoplastic growth in its early stage (Dunn et al, 2002; Kim et al, 
2007). Published data has demonstrated that both an innate and adaptive immune response 
is important for immune surveillance and deficiency in immunological components lead to 
increased susceptibility to spontaneous and chemically induced tumours . The role of 
interferon gamma (IFN γ) in tumour protection was evidenced by rejection of transplanted 
tumours upon production of endogenous IFN γ and formation of spontaneous fibrosarcomas 
in BALB/c mice treated with IFN γ neutralising antibody (Dighe et al, 1994; Dunn et al, 2002; 
Kaplan et al, 1998). The second significant progress was the development of spontaneous 
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tumours with the chemical carcinogen methylcholanthrene (MCA) treatment in C57BL/6 mice 
deficient in perforin, a pore forming protein which aids in granzyme entry. NK cells play a 
crucial role in the control of tumour cells deficient in major histocompatibility complex (MHC) 
class I by perforin-dependent cell lysis (Dunn et al, 2002; van den Broek et al, 1996). Perforin 
is an important component of the natural killer T (NKT) cell exocytosis pathways  and CD8+ 
cytotoxic T lymphocytes cell mediated killing. A study by Mark et al. showed that perforin 
deficient mice were more susceptible to lymphomas when compared to their wild-type 
counterparts (Russell & Ley, 2002; Smyth et al, 2000). The third and most substantial key 
development in confirmation of an immune surveillance was founded due to animal studies 
on mice with the recombinase activating gene (RAG)-2 deletion (Shinkai et al, 1992). RAG-2 is 
a DNA repair enzyme exclusively for lymphocytes and in its absence immature B and T cells 
are generated. Inbred mice with the RAG-2 deletion do not carry lymphocytes with specific 
antigen receptors which leads to an increase in spontaneous and MCA induced tumour 
development (Dunn et al, 2002; Shankaran et al, 2001). In humans, epidemiological evidence 
suggests that individuals suffering from primary immunodeficiency have an increased risk of 
cancer development (Mortaz et al, 2016). For instance, patients carrying common variable 
immunodeficiency which results in low antibody levels have increased incidence of bladder, 
breast and stomach cancers (Mortaz et al, 2016). Additionally inflammatory bowel disease 
can such as Crohn's disease can lead to increased incidence of developing small intestine and 
colon cancer (Freeman, 2008). 
The role of immune surveillance in tumour clearance is evident from studies done on 
immunodeficient mice and human highlighting components of both innate and adaptive 
immune system such as IFN γ, macrophages, NKT cells, perforin and RAG-2 are important. 
However, advancement in immunological techniques further demonstrated the role of the 
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immune system not only in tumour control but also in the sculpting of neoplastic disease 
defined by the term ‘cancer immunoediting’. Immune-editing commences in 3 steps 
beginning with elimination of tumours due to immune surveillance mechanisms followed by 
a period of immune mediated latency known as equilibrium. In the third stage, tumour cells 
escape immune mediated attack and grow uncontrolled without immunological restriction 
(Dunn et al, 2002; Dunn et al, 2004; Kim et al, 2007; Mittal et al, 2014) (Figure 1.4).  
 
36 
 
 
Figure 1.4 Stages of immunoediting in tumour development presented in the Schreiber model, adapted from (Dunn 
et al, 2002). 
The process of immunoediting is characterised by the 3 E’s . In the early stages of cancer development immune 
surveillance eliminates tumour cells. In the second stage of equilibrium selective pressure by the immune system 
leads to incomplete tumour clearance and survival of less immunogenic tumour variants with high mutations. These 
cancer cells exist in equilibrium with immune cells but are not completely cleared by the immune system. Finally with 
increase of tumor cell mutational load and a ccumulation of immune-resistant variants, cancer cells escape the 
immune system mediated control and grow uncontrollably to shape an advanced, clinically detectable disease.  
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In the first elimination stage of cancer immunoediting process, neoplastic cells grow and 
recruit blood vessels leading to vasculature disruption and inflammation that leads to 
recruitment of innate immune cells (Dunn et al, 2002). NK cells, NKT cells, and gamma delta 
T cells (γδ T cells) recognise and kill tumour cells leading to IFN γ release (Dunn et al, 2002). 
IFN γ induces tumour cell death and limits proliferation by chemokine production (CXCL9, 
CXCL10 and CXCL11) (Dunn et al, 2002). Chemokines limit tumour growth by hindering 
angiogenesis directly and by recruiting NK cells and macrophages which induce more tumour 
kill by TNF-related apoptosis-inducing ligand (TRAIL) and perforin (Dunn et al, 2002). Tumour 
debris is taken up by dendritic cells (DC) and translocated into draining lymph nodes. DC 
stimulate CD4+ Th cells that produce IFN γ leading to stimulation of tumour-specific CD8+ T 
cells (Dunn et al, 2002). This leads to destruction of remaining tumour cells by cytotoxic T 
cells.  
In the equilibrium stage, the surviving tumour cells and host immune response reach a stage 
of latency where IFN γ and T cells exert selective pressure on tumour cells which restricts 
tumour growth but fails to completely eliminate them (Dunn et al, 2002; Dunn et al, 2004). 
During this period of selection, most of the tumour variants die, however, this leads to 
production of new variants carrying a high mutational load. The cancer cell genome 
undergoes plasticity as a result of chromosomal dysfunction, nucleotide excision repair and 
microsatellite instability and gives rise to less immunogenic cells that resist immune mediated 
clearance (Dunn et al, 2004; Lengauer et al, 1998).  As a result, tumour cells escape from the 
immune attack leading to uncontrolled expansion and clinically detectable malignancy (Dunn 
et al, 2002).  
The stages of immunoediting are ideal targets for cancer immunotherapy which can aid in 
tumour elimination, ensure stable long-term disease in equilibrium stage or prevent cancer 
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cells from escaping immune mediated control. Studies have reported tumour escape can also 
be due to changes in the tumour cells themselves such as down regulation of MHC class I 
which affects antigen processing and presentation. Furthermore, an immunosuppressive 
microenvironment due to the presence of suppressive cytokines such as TGF-β, IL-10 or 
regulatory T cells and co-inhibitory molecule (e.g. CTLA-4 and PD-L1) expression also induces 
a pro-tumorigenic phenotype (Dunn et al, 2004). An understanding of tumour 
microenvironment and its components will provide with possible immunotherapy targets to 
enhance tumour surveillance and prevent tumour escape from immune mediated control.  
1.3 Tumour microenvironment 
In the tumour microenvironment non-malignant cells and transformed cells interact which 
often leads to a pro-tumorigenic and tumour promoting phenotype (Balkwill et al, 2012; Zou, 
2005). Components of the tumour microenvironment include innate immune cells such as 
macrophages, DC, neutrophils, MDSCs, and NKT cells which exist along with T and B cells from 
the adaptive arm of the immune system surrounded by stroma consisting of fibroblasts, 
endothelial cells and pericytes (Balkwill et al, 2012; Grivennikov et al, 2010; Hanahan & 
Weinberg, 2000; Hanahan & Weinberg, 2011; Mantovani et al, 2008; Zou, 2005) (Figure 1.5). 
Tumour masses consist of malignant cancer cells and non-cancerous immune cells, their 
plasticity and heterogeneity pose a challenge to treatment options. An understanding of the 
constituents of tumour cells will guide development of future therapies.   
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Figure 1.5 Cellular constituents found in and around the tumour mass, adapted from (Kerkar & Restifo, 2012). 
The tumour mass consists of neoplastic cells and non-malignant immune cells which together form a regulatory 
network. Constituents of tumour microenvironment include innate immune cells such as MDSCs, DC, macrophages, 
eosinophil, basophil, monocytes and also adaptive immune cells such as NK cells, cytotoxic T cells, T helper cells and T 
regulatory cells. The presence and expression level of anti -inflammatory and pro-inflammatory cells in this complex 
network dictates either a pro-tumorigenic or anti -tumorigenic microenvironment leading to either tumour elimination 
or escape of tumour cells resulting in an advanced disease.  
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The expression level of immune cells mediators and suppressors dictates a pro-tumorigenic 
or anti-tumorigenic phenotype. Pro-inflammatory tumour environment is provided by 
cytotoxic CD8+ T cells, CD4+ T cells, NKT cells and NK cells. Cytotoxic CD8+ T cells play a crucial 
role in tumour elimination due to antigen specific killing and their infiltration is associated 
with a good disease prognosis as seen in breast, ovarian, lung, bladder and prostate cancers 
(Fridman et al, 2012).  The anti-tumour effect of cytotoxic CD8+ T cells is supported by NKT 
cells and Th1 (CD4+ T cells) (Balkwill et al, 2012; Zou, 2005). Th1 are characterised by IL-1 and 
IFN γ production and increased infiltration in the tumour bed provides improved overall 
survival in pancreatic cancer, multiple myeloma, breast cancer, ovarian cancer, colon cancer 
and melanoma patients (Fridman et al, 2012). NKT cells provide anti-tumorigenic immunity 
as they aid in DC maturation and can directly kill circulating tumour cells (Balkwill et al, 2012; 
Larsen et al, 2014). Recently Tsuyoshi et al. has shown increased NK cell infiltration in 
colorectal carcinoma patient mucosa which correlated with improvement in disease free 
survival (Tachibana et al, 2005).  
Anti-inflammatory and suppressive tumour microenvironment is maintained by regulatory T 
cells, MDSCs, tumour associated macrophages (TAMS) and inhibitory cytokines. Regulatory T 
cells are characterised by CD25+ FoxP3+ phenotype and are linked to a worse disease 
prognosis (Fridman et al, 2012). Regulatory T cells induce the production of suppressive 
cytokines such as IL-10, TGF-β which blunt the effect of CD4+ T cells, CD8+ T cells and NKT cells 
(Kerkar & Restifo, 2012). Regulatory T cells also express co-inhibitory molecules such as 
cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) and programmed cell death protein 1 
(PD-1) that interact with ligands on the APC thus, maintaining a suppressive and tolerogenic 
environment (Betts et al, 2006; Campbell & Koch, 2011; Kerkar & Restifo, 2012). Link between 
poor disease prognosis and increased T regulatory cells has been previously stated. Dominik 
41 
 
et al. reported high FoxP3 expression in ovarian cancer patients which correlated with poor 
overall survival. This finding was also supported by Nobuyoshi et al. who showed high 
regulatory T cell infiltration was associated with poor prognosis in PDAC (Hiraoka et al, 2006; 
Wolf et al, 2005). Another constituent of the complex tumour mass network is MDSCs which 
are immature myeloid and myeloid progenitor cells that originate in the neoplastic 
environment (Gabrilovich & Nagaraj, 2009; Sica, 2007). MDSCs expand in the presence of GM-
CSF, prostaglandins and vascular endothelial growth factor (VEGF) and dampen anti-tumour 
immune responses (Kerkar & Restifo, 2012). T cells’ proliferative ability is impaired by 
arginase produced by MDSCs which depletes L-arginine leading to impaired T cell maturation 
and cytokine manufacture (Balkwill et al, 2012; Gabrilovich & Nagaraj, 2009; Zea et al, 2005). 
Arnold et al. showed high expression of arginase producing MDSCs in renal cancer patients 
(Zea et al, 2005). MDSCs also stimulate regulatory T cells, dampen CD8+ T cell mediated 
damage by down regulation of MHC I and produce reactive oxygen species (Gabrilovich & 
Nagaraj, 2009; Gabrilovich et al, 2012).  MDSCs migrate to the tumour bed where they quickly 
differentiate into TAMS which are important players in tumorigenesis (Gabrilovich & Nagaraj, 
2009; Gabrilovich et al, 2012; Sica, 2007). Macrophages are divided into M1 and M2 
(Mantovani et al, 2008; Mantovani & Sica, 2010; Qian & Pollard, 2010; Sica  et al, 2006). M1 
phenotype is triggered by IFN γ and other pro-inflammatory cytokines such as tumour 
necrosis factor alpha (TNF α), IL-12, IL-6 whereas M2 macrophages are induced by IL-10, IL-4 
and TGF-β (Mantovani & Sica, 2010). The M2 phenotype is mostly found in the tumour 
microenvironment and enhances tumour reshaping, angiogenesis and metastasis  mainly by 
inducing a hypoxic environment and inhibitory cytokines (Mantovani & Sica, 2010; Qian & 
Pollard, 2010; Sica et al, 2006). Clinical and preclinical evidence reports poor disease 
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prognosis with increased tumour associated macrophage expression, M2 phenotype which 
stimulate TGF-β, IL-10 and IL-4 secretion (Fridman et al, 2012). 
The efficient release of tumour-associated antigens (TAA) into the draining lymph nodes is 
prevented by tumour stroma and dense extracellular matrix which leads to dysfunctional APC 
and aberrant T cell infiltration.  DC in the tumour microenvironment undergo pro-tumorigenic 
changes as a result of impaired maturation, suppression by VEGF and IL-6 leading to a 
tolerogenic state or unresponsive T cells  (Gabrilovich et al, 2012; Zou, 2005). An imbalance 
between co-inhibitory and stimulatory molecules leads to tumour cell escape (Figure 1.6). 
According to Zou at al. and others the main cause of poor immunity seen in cancer is due to 
absence of danger inflammatory signals and cytokines stimulated in response to danger 
Associated Molecular Patterns (DAMPS) and pathogen-associated molecular patterns  
(PAMPS) (Grivennikov et al, 2010; Zou, 2005). 
Figure 1.6 Imbalance between the suppressive and effective immune cell phenotypes in tumour 
microenvironment , adapted from (Zou, 2005). 
Immune cells, mediator and cytokines in the milieu of tumour microenvironment can be divided in to two 
sections, one being the tumour suppressive arm which leads to a pro-inflammatory phenotype and the other 
being the effective arm which leads to anti -inflammatory immune response. Suppressive tumour  
microenvironment consists of regulatory T cells, MDSCs, TAMS and inhi bitory cytokines such as TGF-β and IL-10. 
Whereas the effective tumour microenvironment consists of TAA specific CD8 + T cells, Th1 and NKT cells as well  
as immune stimulatory cytokines IL-12, IL-6 and GM-CSF. Tumour cells maintain a tumour suppressive and 
tolerogenic environment due to which disease progresses to advanced and metastatic stages.  
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Tumour cells activate negative regulatory signalling pathways that inhibit an effective anti -
cancer immune response (Chen & Mellman, 2017). In normal cells regulatory inhibitory 
interactions such as immune checkpoints maintain homeostasis and tolerance. However, 
tumour cells expressing immune checkpoint ligands limit T cell activation and function 
resulting in escape of tumour cells from immunosurveillence (Chen & Mellman, 2017; Pardoll, 
2012). CTLA-4 is a co-stimulatory molecule that is a negative regulator of T cell activation. 
CTLA-4 competes with CD28 on T cells to bind to CD80 and CD86 ligands on APC resulting in 
T cell activation termination (Chen & Mellman, 2017; Sharma & Allison, 2015). Another 
inhibitory molecule, PD-1 plays a role in T cell expansion and priming, binds to PD-ligand 1 
(PD-L1) on APCs and attenuates T cell activity (Chen & Mellman, 2017; Sharma & Allison, 
2015). Cancer cells utilise these inhibitory pathways and terminate the anti-tumour immune 
response (Figure 1.7). The resistance by tumour cells against T cell mediated immune control 
can be can be overcome by inhibiting immune checkpoint interactions. Improved clinical 
efficacy provided by immune checkpoint inhibitors (anti-PD-1, anti-PD-L1 and anti-CTLA-4) led 
to their approval by FDA for use in bladder cancer, melanoma, kidney cancer, head and neck 
cancers and lung cancer (De Munck et al, 2017; https://medi-paper.com/approved-
immunotherapies/, accessed on 7 Dec 2017). 
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The inhibitory and suppressive microenvironment in and around the tumour cells enables 
them to thrive in equilibrium with immune cells and/or escape the immune system mediated 
control, growing into an advanced metastatic disease. An ideal immunotherapy would tip the 
balance of the suppressive tumour microenvironment to a more effector immune phenotype 
to reawaken the immune system against cancer.  
1.3.1 Inflamed versus non-inflamed tumours – Cancer-immune set point 
The success of cancer immunotherapy relies on characteristics of the tumour and its 
microenvironment. The presence or absence of tumour infiltrating lymphocytes define three 
distinct patterns of the tumour milieu (Figure 1.8).  
Figure 1.7  Cross presentation between antigen presenting cell and T cell, adapted from (Sharma et al, 2011). 
 
(A) Tumour derived peptides are presented to the T cell receptor (TCR) by MHC, binding of co-stimulatory 
molecules is necessary for successful T cell  activation. CD28 on T cell  binds to CD80 on APC cells , results in 
activation of T cells. (B) Activation of TCR also induces CTLA-4 production which has higher binding affinity to 
CD80, this interaction is immunosuppressive, resulting in T cell  inhibition. PD1 on T cell  binds to PD-L1 on APC 
resulting in an inhibitory effect. Immune checkpoint inhibitors are antibodies that block immune checkpoints 
and lift the brakes from the immune system thus restoring T cell  function.  
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Inflamed tumours have pre-existing tumour infiltrating lymphocytes, IFN γ producing 
cytotoxic CD8+ T cells, increased expression of immune checkpoints and a high mutational 
load (Hegde et al, 2016). Immunotherapies work best in inflamed tumours as they revive pre-
existing tumour specific T cells. The increased mutational load leads to production of neo-
antigens, enhances antigenic load thus enabling the immune system to better recognise 
tumour cells as ‘foreign’ (Chen & Mellman, 2017; Hegde et al, 2016).  In tumours with 
excluded immune infiltrates dissemination of T cells to the tumour centre is prevented by the 
immunosuppressive stroma (MDSCs, regulatory T cells, TAMs) and angiogenesis (Hegde et al, 
Figure 1.8 Continuum of cancer immunity, adapted from (Hegde et al, 2016).  
Tumours can be either inflamed or non-inflamed, the histological images show representative tissues stained for 
CD8+ T cells displaying three distinct patterns. Inflamed tumours have pre-existing immunity, increased infiltration 
of IFN γ, immune checkpoints and tumour infi ltrating lymphocytes (TIL) with high mutational load. These tumour 
types respond well to immunotherapy as they are better recognised by the immune system as ‘foreign’. Excluded 
tumours carry high mutational load, due to the presence of suppressive stroma, MDSCs and angiogenesis T cell  
infi ltration is l imited to tumour edges. Non-inflamed tumours are immunogenically ignorant, carry no mutations 
or immune cell  infi ltrates therefore, these cells proliferate at a higher rate and respond poorly to 
immunotherapies. Non-inflamed tumours can be converted to inflamed tumours  using combinational therapy 
approaches. 
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2016). However, non-inflamed and ‘desert tumours’ are immunogenically ignorant, lack T cell 
infiltrates and/or antigen presentation machinery such as MHC I, seldom express PD-L1, are 
highly replicative and carry less mutations (Hegde et al, 2016). These tumours can be 
converted to an inflamed phenotype using combinational therapeutic approaches. In order 
for a cancer immunotherapy to be effective, a cancer-immune set point must be overcome 
which is characterised by the equilibrium between the immune stimulatory factors minus the 
inhibitory factors (Chen & Mellman, 2017). An inflamed tumour with tumour infiltrating 
lymphocytes and its stimulatory microenvironment favours success of immunotherapy as 
evidenced by the benefit of Lambrolizumab (anti PD-1) and Ipilimumab (anti- CTLA-4) in 
advanced melanoma patients (Hamid et al, 2013; Schadendorf et al, 2015).  
Over the last decade our understanding of the mechanism of cancer development has vastly 
increased however, it has not translated to improvement in overall survival as cancer still has  
a high mortality rate. However, more recent investigational studies have focused on more 
potent, less invasive and more targeted cancer therapy approaches. The immune system 
plays an important role in tumour clearance and control, recent success with immune 
checkpoint therapy is evidence that targeting the tumour immunology is a promising 
approach. Immunotherapies target the tumour environment to make it more receptive to 
therapy and break the immune tolerant and suppressive microenvironment. One ideal cancer 
immunotherapy candidate for making an immunogenically silent, cold and ignorant tumour 
inflamed, is oncolytic virotherapy.  
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1.4 Oncolytic Virus Immunotherapy  
Oncolytic viruses are a selective therapeutic agent that target and kill tumour cells, leaving 
normal cells unharmed (Figure 1.9). The concept of oncolytic virotherapy was introduced in 
the mid-1800s when it was observed that infectious disease resulted in short period of 
remission and reduction of tumours (Kelly & Russell, 2007; Zamarin & Palese, 2012). In the 
1950s viruses were evaluated in murine cancer models which led to studies in humans. With 
the risk of virulence linked to human viruses, future studies mainly focused on animal viruses 
to treat cancers an early prototype of oncolytic virus  (Zamarin & Palese, 2012). Advancement 
in techniques to genetically modify viruses to eliminate their virulence factor and limit 
replication to cancer cell led to FDA approval of first oncolytic virus, Talimogene 
laherparepavec (T-VEC) in the clinic (discussed later) (Andtbacka et al, 2015). 
Since the last 20 years oncolytic viruses have shown promising development with ten viruses 
entering clinical studies (Aurelian, 2013). These have shown clinical benefit and good 
tolerability with mild toxicity. However, some disadvantages seen with various oncolytic 
viruses minimise their therapeutic effect (Fukuhara et al, 2016).  A few include limited 
penetration into the tumour mass, clearance by antiviral immune response, restriction of 
spread by neutralising antibodies and virus sequestration in liver and spleen (Aurelian, 2013). 
These limitations can be addressed by combination studies and modification of viruses. Few 
examples include, Adenoviruses which can be sequestered by binding to Kupffer cells in the 
liver and this can be avoided by coating virus with biocompatible polymer which promotes  
protein stimulation (Aurelian, 2013). Viruses can be protected from neutralising antibodies 
by masking them in carrier cells such as immune effector cells. Increased vascular penetration 
and infection by Reovirus was seen after injection of VEGF and arming virus with immune 
48 
 
modulatory agents such as GMCSF in HSV can enhance activation of tumour specific innate 
and adaptive immune response (Aurelian, 2013). 
The preference of oncolytic viruses to infect cancer cells over normal cells of the body is due 
to tumour biology (Russell et al, 2012). Tumour cells create an immunosuppressive innate and 
adaptive phenotype which protects them from anti-tumour immune responses however, this 
area of 'immune privilege' makes cancer cells more prone to infection and destruction by 
oncolytic viruses (Lichty et al, 2014). As highlighted in section 1.1 Hallmarks of cancer, tumour 
cells proliferate uncontrollably in the presence of aberrant cell death pathways (evade 
apoptosis) and growth signals, these factors contribute to preferential infection and spread 
of oncolytic virus in the tumour bed as compared to normal cells  (Hanahan & Weinberg, 2000; 
Lichty et al, 2014).  
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Oncolytic viruses can be naturally occurring or genetically modified. Naturally occurring 
oncolytic viruses take advantage of defective signalling pathways in cancer cells that enable 
tumour cells to maintain high growth rate, therefore these viruses preferentia lly grow in 
cancer cells as opposed to normal cells of the body (Choi et al, 2016). Some cancer cells over 
express receptors which are crucial for viral entry such as over expressed CD46 surface 
receptor in colon and breast cancer is utilised by measles virus. Membrane receptor, 
Reduced expression of viral entry receptors 
and intact antiviral interferon response 
l imit virus cytolytic effect in normal cells. 
Selective replication of virus in cancer 
cells due to aberrant antiviral interferon 
response and overexpression of viral 
entry receptors. 
Newly synthesized virus, 
infects more cancer cells. 
Virus 
Figure 1.9 Naturally occurring oncolytic viruses induce selective tumour cell lysis.  
Naturally occurring oncolytic viruses induce tumour cell  lysis due to aberrant antiviral responses, over 
expression of viral entry receptors and high proliferative capacity of such cells. Viruses replicate readily in cancer 
cells leading to lysis of target cells and rel ease of newly synthesized virions which infect neighbouring cancer 
cells. Due to intact interferon antiviral pathways and reduced expression of viral entry receptors on normal cells, 
viruses are unable to replicate and disseminate in these cells.  
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intercellular adhesion molecule 1 (ICAM-1) is used by coxsackievirus A21 (CVA21) to enter 
melanoma, bladder, prostate and breast cancer and poliovirus utilises CD155 as a crucial 
membrane receptor for entry in Glioblastoma brain tumours (Choi et al, 2016) . Other 
examples of naturally occurring viruses include, newcastle disease virus, myoxma virus, 
reovirus and coxsackieviruses which preferentially grow in cancer cells due to over expression 
of viral entry receptor or aberrant antiviral responses (Choi et al, 2016).  Additionally, viruses 
such as adenovirus, herpesvirus and vaccinia virus can be genetically modified to enhance 
their tumour selectivity (Choi et al, 2016; Kaufman et al, 2015). For instance, the thymidine 
Kinase (TK) enzyme encoding gene is crucial for DNA metabolism and is deleted in genetically 
modified herpes simplex-1 and vaccinia viruses. Thus these viruses rely on expression of TK in 
highly replicating cells such as cancer cells and thrive in such cells (Choi et al, 2016).  Another 
example is E1B 55K adenoviral protein which directly interacts with P53 and degrades it by 
ubiquitination. Due to inactivation of P53, apoptosis and cell cycle arrest is prevented in 
normal cells  (Choi et al, 2016). This inactivation of P53 by EIB55K is also mediated by its 
interaction with E4orf6, another adenoviral protein. Cancer selective adenovirus is generated 
by deletion of EIB 55K as virus can only replicate in cells with mutated P53 and normal cells 
undergo apoptosis upon infection by virus. 
1.4.1 Mechanism of Action of Oncolytic Viruses 
Oncolytic viruses target cancer cells directly resulting in cell lysis and production of TAA 
induces a systemic anti-tumour immune response (Figure 1.10). The tumour cell lysis releases 
more virus progeny in the surrounding that infects neighbouring tumour cells. Some viruses 
such as herpes simplex and vaccinia virus induce disruption of vasculature which results in 
necrosis or apoptosis of neighbouring tumour cells  (Kaufman et al, 2015; Marchini et al, 
2016). The most vital stage in oncolytic virus induced tumour control is induction of a systemic 
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anti-tumour immune response in an environment that was previously tolerogenic (Workenhe 
& Mossman, 2014). The replication of virus in cancer cells leads to presentation of TAA and 
PAMPs (virus genetic material and capsid proteins) by APC such as DC and macrophages (Guo 
et al, 2014; Workenhe & Mossman, 2014). 
 
Oncolytic viruses also induce immunogenic cell death (ICD) which includes changes in the 
conformation of cell surface markers and the release of soluble factors in a timely manner to 
induce an effective anti-cancer immune response. The success of an anti-cancer therapy is 
postulated to be dependent on the induction of ICD (Kroemer et al, 2013). ICD is characterised 
by the release of DAMPS from a dying cell. The exposure of endoplasmic reticulum (ER)   
Figure 1.10 Oncolytic viruses induce death of tumour cells through local and systemic anti-tumour immune 
response, adapted from (Kaufman et al, 2015; Marchini et al, 2016).   
Oncolytic viruses are tumour selective and have multiple modes of action. OV directly target and infect cancer 
cells, resulting in their lysis.  The release of virus from dying tumour cells ensures constant supply of virus 
progeny which infects more cancer cells. Oncolytic viruses induce local and systemic cancer specific immune 
response. Oncolytic viruses directly kil l  tumour cells by lysis and indirectly induce tumour clearance by 
inducing a systemic immune response. Upon virus infection antiviral immune response is triggered which 
leads to stimulation of inflammatory cytokines and type 1 interferons. Viral antigens, TAAs, PAMPS and 
DAMPs all  stimulate APC. Antigens are cross presented to CD4 and CD8 cells and NK cells are stimulated by 
cytokines leading to a tumour specific immune response. 
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protein calreticulin on the cell surface at the pre apoptotic stage, secretion of extracellular 
adenosine triphosphate (ATP) when an apoptotic cell is undergoing blebbing and release of 
the cytokine mediator high mobility group box 1 protein (HMGB1) at the late stage of 
apoptosis are all hallmarks of ICD (Chiocca & Rabkin, 2014; Guo et al, 2014; Kroemer et al, 
2013; Workenhe & Mossman, 2014).  Release of DAMPS and PAMPs is seen by the immune 
system as 'danger' and 'eat me' signals (Figure 1.8). These signals and cytokines such as IL-12 
and TNFα stimulate the maturation of DC which go on to expand the repertoire of antigen-
specific CD4+ and CD8+ T cells (Kaufman et al, 2015; Marchini et al, 2016). Tumour cell lysis 
also results in production of tumour antigens which trigger tumour specific CD8+ T cell 
production. This activation of the adaptive immune response results in systemic tumour 
control and regression (Kaufman et al, 2015). 
1.4.1.1     Constituents of Immunogenic cell death  
The immune system has evolved to differentiate between immunogenic and non-
immunogenic cell death. ICD occurs in response to ER stress and cellular fragmentation 
(Kroemer et al, 2013). Inability of cancer immunotherapies to induce ICD or emission of ICD 
determinants can contribute to therapeutic failure. ICD is characterised by exposure of 
calreticulin, release of HMGB1 and extracellular ATP. The normal physiological role of ER, a 
cytoplasmic organelle is protein folding and storage of calcium. Certain factors such as 
mutational load of proteins, pathological damage like formation of disulphide bonds or virus 
infection lead to ER stress (Kroemer et al, 2013). Oncolytic viruses induce ER stress in the 
infected cell which leads to translocation of calreticulin on to the plasma membrane. 
Calreticulin protein is an abundant protein in the ER and is responsible for maintenance of 
homeostasis and protein chaperoning (Gardai et al, 2005; Kroemer et al, 2013). However, 
exposure of calreticulin on the cell surface leads to phagocytosis of a dying cell by interaction 
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with CD91 receptor which is mostly present on macrophages and DCs (Gardai et al, 2005; 
Kroemer et al, 2013). This cross priming leads to the production of pro-inflammatory signals 
such as TNF α and IL-6.  Depletion of the ‘eat me’ signal calreticulin results in blockage of 
induction of immunogenic cell death (Obeid et al, 2007; Panaretakis et al, 2009).  
Another constituent of ICD is extracellular ATP which is a metabolite and a 
paracrine/autocrine messenger that interacts with purinergic receptors (P2X and P2Y) 
(Kroemer et al, 2013). However, when a cell undergoes physical damage or cell membrane 
injury, ATP is released into the extracellular space and interacts with purinergic receptor 
(P2X7) on the surface of monocytes and DCs. This leads to the formation of an inflammasome 
which stimulates interleukin release, IL-1β triggers an adaptive anti-cancer immune response 
by IFN γ producing CD8+ T cells (Ghiringhelli et al, 2009; Kroemer et al, 2013; Krysko et al, 
2012). Therefore, ATP acts like a ‘find me’ signal for DC and monocytes and when ATP is 
enzymatically eliminated, the dying cell supernatant is unable to attract monocytes (Elliott et 
al, 2009).  
One of the main characteristics of ICD is release of HMGB1, a nuclear chromatin binding 
protein which has an important role in transcriptional function of proteins (Kroemer et al, 
2013; Muller et al, 2004). In the presence of cellular damage, HMGB1 is a marker of damage 
and has multiple functions. It acts as a cytokine mediator and pro-inflammatory molecule, 
binding to toll-like receptors (TLR) 2 and 4 on macrophages and DCs triggering IL-6, IL-8 and 
TNF α (Krysko et al, 2012). The importance of HMGB1 as an immunogenic molecule is 
highlighted in a study conducted by Apetoh L et al. This group used a CT29 colon 
adenocarcinoma murine model and inoculated the animals with CT29 cells devoid of HMGB1 
or co-injected with HMGB1 antibody. The absence of HMGB1 affected the ability of animals 
to reject rechallenge with CT29 live cells (Apetoh et al, 2007).  
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The ICD induction mechanism is complex and the ability of a dying cell to induce stimulatory 
anti-tumour immune response needs to be further studied. There are some factors that 
contribute to induction of ICD such as production of caspases, ER stress and stimulation of 
certain modes of programmed cell death. Oncolytic viruses are also ICD inducers as they can 
induce cancer cells to undergo either one or more of the following modes of cell death: 
necroptosis, pyroptosis, apoptosis and autophagy. A mode of cell death induced by an 
oncolytic virus depends on the type, dose of virus and origin of tissue, and also dictates 
whether the therapy will be immunogenic i.e. induce release of immunogenic cell death 
determinants or not (Guo et al, 2014).  
1.4.1.2     Oncolytic virus induced mode of cell death 
Oncolytic viruses target cancer cells through multimodal mechanisms, virus induced oncolysis 
can trigger target cells to undergo apoptosis, necroptosis, pyroptosis and/or autophagy. 
These immunogenic modes of cell death lead to morphological and structural cellular changes 
that trigger release of ICD determinants resulting in an effective cancer specific immune 
response (Figure 1.11). Apart from apoptosis all modes of cell death are considered 
inflammatory however, recent reviews have showed cells can undergo either non-
immunogenic or immunogenic forms of apoptosis and some oncolytic viruses induce an 
inflammatory form of apoptosis (Bartlett et al, 2013; Guo et al, 2014; Inoue & Tani, 2014; 
Obeid et al, 2007).  
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Cells undergoing apoptosis are characterised by chromatin condensation, DNA fragmentation 
and membrane blebbing (Elmore, 2007). Apoptosis mainly occurs through two pathways, 
extrinsic (ligand dependent) and intrinsic (mitochondrial) (Elmore, 2007; McIlwain et al, 
2013). To state briefly, binding of death receptor ligands (TNF α, FasL) to death receptors 
(TNFR, FasR) leads to caspase 8 recruitment and activation by dimerization. Activated caspase 
8 cleaves executioner caspases such as 3 and 7 which result in target cell degradation. 
Furthermore, mitochondrial stress or physical damage leads to release of cytochrome C from 
the mitochondrial pores. Cytochrome C forms an apoptosome with caspase 9 and adaptor 
Figure 1.11 Immunogenicity of key modes of cell death, adapted from (Guo et al, 2014). 
Non-immunogenic mode of death remains immunogenically silent due to retention of cell  membrane integrity 
and presence of apoptotic bodies leading to engulfment by macrophages. However, immunogenic apoptosis 
results in membrane disintegration, DNA fragmentation and exposure of calreticulin and heat shock proteins 
which are danger signals that attract DCs.  Immunogenic modes of cell  death such as necroptosis and pyroptosis 
result in expulsion of cellular components into the extracellular space resulting in production of inflammatory 
cytokines and release of DAMPs such as HMGB1 and extracellular ATP.  
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protein apoptotic protease-activating factor-1 (APAF1) (Elmore, 2007; McIlwain et al, 2013). 
This leads to cleavage and recruitment of executioner caspases resulting in apoptosis. 
Executioner caspases target proteins for proteolysis before apoptosis onset, one such protein 
is poly (ADP-ribose) polymerase (PARP) which detects and repairs DNA breaks. A hallmark of 
apoptosis is the inactivation and cleavage of PARP at the execution stage of apoptosis (Oliver 
et al, 1998). Apoptosis cell death is immunogenic as evidenced by exposure of calreticulin and 
heat shock protein (HSP) at the pre-apoptotic stage followed by release of HMGB1 at a later 
stage due to disruption of the cell membrane (Guo et al, 2014; Inoue & Tani, 2014).  
The upstream signalling pathways of apoptosis and necroptosis, a regulated form of necrosis 
are similar (De Munck et al, 2017; Linkermann & Green, 2014). Due to external stimulus or 
viral infection TNF α is produced which stimulates TNFR1 receptor. This leads to recruitment 
of adapter protein death domains that bind to procaspase 8 and recruit FLIP, a protein 
structurally similar to caspase 8 but lacks protease activity (Linkermann & Green, 2014). The 
caspase 8 and FLIP complex blocks apoptosis thus, enabling receptor-interacting 
serine/threonine-protein kinase 1 (RIPK1) recruitment (Inoue & Tani, 2014; Linkermann & 
Green, 2014). RIPK1 forms a necrosome with RIPK3 that acts as a necroptosis induction signal 
(Inoue & Tani, 2014; Linkermann & Green, 2014). Phosphorylation of mixed lineage kinase 
domain-like (MLKL) pseudokinase results in a calcium influx leading to cellular swelling and 
plasma membrane rupture resulting in release of intracellular components (Inoue & Tani, 
2014; Linkermann & Green, 2014). Cells undergoing necroptosis release cytokines and 
cytoplasmic constituents such as HMGB1 and ATP into the extracellular space (De Munck et 
al, 2017; Guo et al, 2014). 
Another mode of cell death induced by oncolytic viruses is autophagy. Autophagy is a 
lysosomal degradation pathway which is stimulated in response to nutrient deprivation, 
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metabolic stress and hypoxia (De Munck et al, 2017; Levine & Kroemer, 2008). It involves 
encapsulation of cytoplasmic components in lysosomes with double membrane walls, an 
initial step of degradation involves formation of a phagophore vesicle followed by elongation 
and fusion of membrane walls to form an autophagosome (Levine & Kroemer, 2008). 
Autolysosome forms as a result of the lysosome fusing with an autophagosome resulting in 
degradation of cellular components (Levine & Kroemer, 2008). Autophagy not only induces 
release of DAMPs such as HMGB1 and extracellular ATP from dying cells but also aids in cross 
presentation of antigen to T cells (Bartlett et al, 2013; Guo et al, 2014). 
In response to bacterial or viral infection of cells an inflammatory mode of cell death, 
pyroptosis is activated. Pyroptosis occurs as a result of activated caspase 1 which is recruited 
by a cytosolic complex known as an inflammasome (De Munck et al, 2017; Inoue & Tani, 
2014). Pro-inflammatory cytokines such as IL-1β and IL-18 are catalytically cleaved by caspase 
1 (Inoue & Tani, 2014). This leads to a pro-inflammatory response, membrane pore formation, 
cell swelling, plasma membrane lysis and release of cellular components into the extracellular 
space (De Munck et al, 2017). 
The mode of cell death induced by oncolytic viruses affects the immunogenicity of the tumour 
microenvironment (De Munck et al, 2017). Table 1.1 compares different modes of cell death 
and the ICD determinants induced.  
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1.4.2.2.1 Oncolytic viruses that induce ICD 
Oncolytic virus infection results in tumour cell lysis and release of DAMPs, PAMPs and TAAs 
which triggers ICD and induces an anti-tumour immune response (Inoue & Tani, 2014). 
Various oncolytic viruses induce either one or more forms of ICD which are evidenced by 
release of DAMPs. In this section a few examples of oncolytic virus induced ICD will be 
discussed.  
Different variants of Adenovirus induce certain modes of death and ICD determinants . 
Adenoviruses have a double stranded DNA encapsulated in an icosahedral capsid (Kaufman 
et al, 2015; Niemann & Kühnel, 2017). A conditionally replicative adenovirus controlled by the 
human telomerase reverse transcriptase (hTERT) and EIB 55K-deleted Adenovirus selectively 
induce autophagy in glioma cells (De Munck et al, 2017; Inoue & Tani, 2014). In contrast 
another variant of adenovirus encoding the CD40 ligand under control of hTERT promoter 
(Ad5/3-hTERT-hCD40L) has shown induction of apoptosis in MB49 bladder and B16 OVA 
melanoma murine models (Diaconu et al, 2012). Induction of HMGB1, extracellular ATP and 
Modes of programmed cell death and immunogenic determinants 
 Apoptosis Autophagy Necroptosis Pyroptosis 
Initiators Receptor-ligand 
interaction 
Hypoxia, Nutrient 
deprivation 
Injury, infection and 
ligand-receptor 
interaction 
Infection and release 
of DAMPs 
Signalling 
Pathway 
Extrinsic, intrinsic 
and caspase 3,7 
dependent 
Caspase 
independent, 
autophagosome 
and lysosome 
protease 
Necrosome 
formation with RIPK1 
and RIPK3 
Inflammasome 
formation and 
caspase 1 dependent 
Characteristics DNA 
fragmentations, cell  
shrinkage and 
apoptotic bodies 
Autophagic bodies Cell swelling and 
plasma membrane 
loss 
Pore formation, cell  
swelling and loss of 
plasma membrane 
Released 
DAMPs 
Calreticulin, 
HMGB1,ATP 
HMGB1,ATP ATP,HMGB1 HMGB1,ATP,IL-1β,IL-
18 
Table 1.1 Modes of programmed cell death and ICD determinants induced, adapted from (Inoue & Tani, 2014). 
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calreticulin with increase in stimulation of Th cells, TNF α, IFN γ, CD8+ T cells and macrophages 
was also shown (Diaconu et al, 2012).   
A naturally occurring ribonucleic acid (RNA) single stranded oncolytic virus, coxsackievirus B3 
(CVB3), resulted in induction of apoptosis evidenced by pre-apoptotic exposure of calreticulin 
and release of ATP and HMGB1 in non-small cell lung cancer (NSCLC) cell-lines (De Munck et 
al, 2017; Inoue & Tani, 2014; Miyamoto et al, 2012). 
Another naturally occurring virus, measles virus (MV) induced ICD in melanoma cells with 
increased expression of inflammatory cytokines (IL-8, IL-6, TNF α and HMGB1) (De Munck et 
al, 2017; Donnelly et al, 2013) and according to Munck et al. these characteristics of ICD are 
indicative of necrosis or apoptosis. 
Newcastle disease virus (NDV), an enveloped avian paramyxovirus with a double stranded 
RNA (Elankumaran et al, 2010; Kaufman et al, 2015) induced necroptosis in Glioblastoma 
Multiforme cell-lines. The ICD was evidenced by the exposure of calreticulin and release of 
HMGB1 (De Munck et al, 2017; Koks et al, 2015).  
Vaccinia virus (VV) is a double stranded DNA virus with deletion of the non-essential virus 
genes such as thymidine kinase to make it cancer specific (Goldufsky et al, 2013). Early pre-
clinical studies have demonstrated immunogenicity of VV therapy which is evidenced by 
release of extracellular ATP, HMGB1 and calreticulin (Goldufsky et al, 2013; Guo et al, 2005). 
VV induced necroptosis in ovarian cancer cells which underwent cell membrane and nucleus 
rupture (De Munck et al, 2017; Whilding et al, 2013). Immunogenicity was suggested by 
release of HMGB1 (Whilding et al, 2013). An overview of oncolytic viruses that induce ICD is 
stated in Table 1.2. 
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The tumour microenvironment is immunosuppressive and induction of multimodal types of 
cell death by oncolytic viruses results in re-priming of the cancer specific immune response. 
Understanding the full potential of oncolytic virus induced immunogenicity will provide 
increased treatment efficacy and maximise anti-cancer immune responses. 
1.4.2 Oncolytic Viruses in Clinical Development 
In the next section two oncolytic viruses that gained full approval for use in the clinic will be 
discussed followed by a detailed discussion of coxsackieviruses.  
Adenoviruses express proteins which target the cell cycle signalling proteins such as Rb and 
TP53 to prevent apoptosis (Kaufman et al, 2015). The EIB protein blocks p53 activity and 
prevents cell cycle arrest, viruses with deleted EIB protein only grow in cells lacking functional 
p53 thus limiting virus replication to cancer cells (De Munck et al, 2017). Early clinical trials 
using ONYX-015, a genetically modified Adenovirus with deleted E1B, showed poor efficacy 
and studies were halted which led to creation of another version with larger deletion of E1B 
known as H101 (Choi et al, 2016). A phase III randomised clinical trial done by Shanghai 
Sunway Biotech treated 160 head and neck cancer patients with H101 with and without pre-
treatment with chemotherapy. A response rate of 79 % with H101 in combination with 
chemotherapy as compared to 40 % response rate with chemotherapy alone was reported 
Oncolytic Virus Cancer Type Type of cell death Immunogenic markers 
hTERT-Ad Human glioma Autophagy Not Assessed 
Ad5/3-hTERT-hCD40L Murine bladder cancer 
and melanoma 
Apoptosis Calreticulin, HMGB1,ATP 
E1B deleted Ad Glioma  Autophagy Not Assessed 
CVB3 NSCLC Apoptosis Calreticulin, HMGB1,ATP 
MV Melanoma Apoptosis/Necroptosis  HMGB1,IL-8,IL-6,TNF α 
VV Ovarian Cancer Necroptosis HMGB1 
Table 1.2 Overview of mode of death and immunogenic markers induced by oncolytic viruses. 
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which led to approval of the first oncolytic virus for treatment of head and neck cancers by 
Chinese regulators in 2005 (De Munck et al, 2017; Garber, 2006).   
Another oncolytic virus that gained approval for use in the clinic is Herpes Simplex Virus (HSV). 
HSV has a double stranded DNA with 152 kb genome which is genetically modified to make it 
less virulent and more cancer specific (Eager & Nemunaitis, 2011; Goldufsky et al, 2013). 
Modifications in HSV virulent genes include, deletion of the ICP34.5 gene which blocks virus 
replication in neurones (Eager & Nemunaitis, 2011; Goldufsky et al, 2013) and deletion of the 
ICP47 gene which enables antigen presentation by inhibiting downregulation of MHC class I 
in virus infected cells (De Munck et al, 2017). This deletion has enabled placement of the 
unique short 11 gene under ICP47 immediate early promoter control which further enhances 
virus replication in tumour cells by inhibiting phosphorylation of protein kinase R (PKR), an 
antiviral response (Eager & Nemunaitis, 2011; Goldufsky et al, 2013). OncoVEXGM-CSF is a 
modified HSV with addition of GM-CSF immunomodulatory gene coding sequence which is 
controlled by the human cytomegalovirus promoter (Eager & Nemunaitis, 2011). A phase I 
clinical trial in melanoma, head and neck and breast cancer patients was safely tolerated with 
evidence of necroptosis and tumour size reduction which lead to a successful phase II clinical 
trial in malignant melanoma patients with 25.5 % overall response rate of one year (Eager & 
Nemunaitis, 2011; Hu et al, 2006; Senzer et al, 2009). OncoVEXGM-CSF was renamed T-VEC 
which was the first genetically modified oncolytic virus approved by the FDA for treatment of 
advanced melanoma in October 2015 (Greig, 2016). This was based on results from a 
randomised Phase III clinical trial which had durable response rate (DRR) as its primary end-
point (Andtbacka et al, 2015). Although T-VEC showed no significant improvement in overall 
survival, it resulted in 16.3 % DRR in T-VEC treated patients as compared to 2.1 % in GM-CSF 
treated patients (Andtbacka et al, 2015; Greig, 2016).  
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1.5 Coxsackievirus A21  
Coxsackievirus A21 (CVA21) is a positive single stranded RNA virus enclosed in an icosahedral, 
30 nm in diameter (Bradley et al, 2014) (Figure 1.12). CVA21 is naturally occurring and leads 
to mild upper respiratory tract infections in humans displaying symptoms such as head ache, 
sore throat, chills and chest congestion (Bradley et al, 2014; Zichun et al, 2012). 
 
Coxsackieviruses belong to the Enterovirus genus which is part of the Picornaviridae family. 
Enterovirus genus consists of 10 species including rhinoviruses, enteroviruses , polioviruses, 
echoviruses and coxsackieviruses (Fields, 6th Ed, 2013). Coxsackieviruses were originally 
classified into two groups based on histological lesions and pathogenicity observed in new 
born mice (Hyypiä et al, 1993; Roberts & Boyd, 1987; Xiao et al, 2005). Group A viruses 
consisted of 23 serotypes, affected skeletal muscles, caused flaccid paralysis and myositis in 
mice (Hyypiä et al, 1993; Xiao et al, 2005). Whilst group B consisted of 6 serotypes and 
resulted in spastic paralysis, myocarditis and replicated in the central nervous system of mice 
(Hyypiä et al, 1993; Xiao et al, 2005). Due to the sequence similarity coxsackieviruses were 
reclassified into enterovirus-A (CVA2-8, CVA10, 12, 14, 16), enterovirus-B (CVB1-6, CVA9) and 
Figure 1.12 Structure of CVA21, taken from (Xiao et al, 2005).   
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enterovirus-C (CVA1, 11, 13, 15, 17-22, CVA21). CVA21 belongs to enterovirus C group 
(Stanway et al, 2002; Xiao et al, 2005) (Figure 1.13).  
 
1.5.1 Life Cycle 
Coxsackieviruses carry their own protein synthesis and RNA replication machinery, a single 
polyprotein is divided into three sections. P1 encodes for viral structural proteins, viral protein 
(VP) 1-4 whilst P2 and P3 regions encode for proteins essential for genome replication and 
processing(Fields, 6th Ed, 2013). The viral protein synthesis, genome replication and virus 
encapsidation takes places in the cell cytoplasm and is summarised in Figure 1.14 with in 
depth discussion of each stage in the viral replication cycle in the following sections.  
 
 
Enterovirus 
Rhinovirus Enterovirus Poliovirus Echovirus Coxsackievirus 
Enterovirus A Enterovirus B Enterovirus C 
CVA2-8 
CVA10 
CVA12 
CVA14 
CVA16 
CVA1-6 
CVA9 
CVA1 
CVA11 
CVA13 
CVA15 
CVA17-22 
CVA21 
Figure 1.13 Enterovirus classification, adapted from (Stanway et al, 2002). 
64 
 
 
1.5.1.1    Virus Binding, internalisation and protein synthesis 
In the VP1 capsid protein there is a hydrophobic canyon which attaches to viral entry 
receptors found on host cells (Fields, 6th Ed, 2013; Rossmann et al, 2002). The ICAM-1 cell 
membrane receptor is utilised by CVA21 for viral entry leading to a conformational change 
that induces release of viral RNA into the host cell cytoplasm (Fields, 6th Ed, 2013; Rossmann 
et al, 2002; Xiao et al, 2001) (Figure 1.15).  
Figure 1.14 Picornavirus life cycle, adapted from (Fields, 6th Ed, 2013).  
Virus attaches to membrane receptors resulting in viral capsid conformational change leading to viral capsid 
uncoating and genome entry. Picornaviruses have a positive single stranded RNA strand which acts as an 
mRNA and immediate initiation of translation is undergone leading to synthesis  of a single large polyprotein 
which is processed further into viral structural and processing machiner y.  Viral polymerases synthesise a 
negative single RNA strand which is used as a template to produce multiple copies of the positive RNA strands. 
The positive single strands are used to synthesize more viral proteins. Some of the newly synthesized positive 
RNA strands undergo morphogenesis and the genome is enclosed in a capsid and the virion is released via 
host cell  lysis.  
 
65 
 
 
Once in the cytoplasm, the viral RNA is released in to the cytosol where polyprotein synthesis 
begins (Fields, 6th Ed, 2013). Infection of target cells by virus is rapid and shuts down host 
translation and transcription. For cap dependent translation initiation eukaryotic initiation 
factor (eIF) 3 together with eIF4A and eIF4G forms eIF4F complex which is recognised by the 
ribosome (Figure 1.16).  
 
  
 
 
Figure 1.15 Interaction of CVA21 with ICAM-1 receptor, taken from (Xiao et al, 2005). 
CVA21 capsid proteins, VP1 (blue), VP2 (green) and VP3 (red) form a canyon to which ICAM-1 receptor domain 
1 binds. This leads to a conformational change and virus endocytosis.  
eIF3 
eIF4G 
eI
F4
A
 
AUG UAA 
5’ 3’ 
IRES 
Figure 1.16 Translation initiation in Picornaviruses, adapted from (Fields, 6th Ed, 2013). 
In the initiation of IRES dependent protein synthesis, 40s ribosomal subunit binds to mRNA via interaction 
with eIF3. The eIF3 factor binds to eIF4G and eIF4A forming the eIF4F complex. Helicase eIF4F is recruited to 
unwind RNA secondary structures. Once the complex is in place ribosome scans the mRNA for start codon 
(AUG) and translation begins. Translation is terminated once ribosome reaches stop codon (UAA). 
 
eIF4F complex 
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However, viruses cleave eIF4G which results in eIF4F complex inactivation and inhibition of 
host protein synthesis (Firth & Brierley, 2012). The internal ribosome entry site (IRES) located 
on the 5’ end of the single stranded RNA (+ssRNA) genome initiates 40s ribosomal subunit 
binding and directs cap-independent translation initiation (Belsham & Sonenberg, 2000; Firth 
& Brierley, 2012). Host translation initiation factors eIF4A, eIF4G are hijacked by the virus and 
bind to IRES on the +ssRNA resulting in ribosome binding and protein synthesis initiation 
(Belsham & Sonenberg, 1996; Belsham & Sonenberg, 2000).  
1.5.1.2    Viral Polyprotein Processing  
The viral genome encodes a long polyprotein which is cleaved into mature viral proteases and 
polypeptides (Figure 1.17) (Fields, 6th Ed, 2013; Krausslich et al, 1988). The resulting 
polyprotein is cleaved in 3 stages, firstly 2Aprotease (pro) cleaves P1 and P2 polyprotein segments 
into structural and non-structural domains, respectively (Krausslich et al, 1988; Mutsvunguma  
et al, 2011).  Secondly precursor forms of protein are further cleaved into mature forms  and 
polymerases by 3Cpro for genome processing and RNA replication (Krausslich et al, 1988; Lin 
et al, 2009; Mutsvunguma et al, 2011). A maturation cleavage occurs at the final stage of 
replication cycle when virion is assembled, VP0 is cleaved into capsid proteins VP2 and VP4 
(Fields, 6th Ed, 2013; Krausslich et al, 1988). Virus reassembles 60 copies of VP1, VP2, VP3 
and VP4 into capsid which encapsulates the viral genome. The virion is released from the cell 
through lysis and the host cell loses its membrane integrity (Fields, 6th Ed, 2013). 
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1.5.1.3    RNA replication and synthesis 
For RNA synthesis and genome amplification of +ssRNA, production of –ssRNA is crucial 
(Fields, 6th Ed, 2013). The 3CD viral precursor polyprotein binds to cis acting replication 
element (cre) located in the coding region of viral +ssRNA (Fields, 6th Ed, 2013; Shen et al, 
2008) (Figure 1.18 (A)). This interaction triggers a conformational change allowing 3Dpolymerase 
(pol) to bind. The complex recruits viral protein genome linked (VPg) which is located at the 5’ 
end of the genome and undergoes uridylylation by 3Dpol (Paul et al, 2000; Shen et al, 2008). 
Uridylyated VPg serves as primer for RNA synthesis (Fields, 6th Ed, 2013; Gerber et al, 2001; 
Shen et al, 2008).  The 5’ end of viral genome contains a clover-leaf like structure which is the 
binding site for cellular poly r (C) binding proteins (PCBP) and 3CDpro protein forming the 
ribonucleoprotein complex (Fields, 6th Ed, 2013) (Figure 1.18 (B)). The ribonucleoprotein 
P1 P2 P3 
Structural/capsid Non-Structural 
2A
 (pro)
 
VP0 VP1 VP3 2A 2BC 3AB 3CD 
3C
 (pro)
 3C
 (pro)
 3C
 (pro)
 
VP4 VP2 
Maturation 
cleavage  
2BC 2C 
3A 3B 
3C 
(pol)
 3D
 (pol)
 
3C
 (pro)
 
Figure 1.17 Picornavirus polyprotein processing, adapted from (Lin et al, 2009; Mutsvunguma et al, 2011). 
Picornaviruses carry a single positive strand of RNA which encodes a large polyprotein. The polyprotein is cleaved 
in to P1 (structural) and P2, P3 (non-structural) domains. P1 is further cleaved by proteases to form 60 copies 
each of VP1, VP3 and VP0 to form the capsid. P2 and P3 domains are also further cleaved to giv e proteins and 
polymerase crucial for replication and RNA synthesis.  
68 
 
complex at the 5’ end of +ssRNA interacts with Poly (A) binding protein (PABP) at the 3’ end 
genome which circularises the genome (Fields, 6th Ed, 2013; Herold & Andino, 2001) (Figure 
1.16 (C)). The whole complex is transferred from 5’ end to the 3’ end and VPg-pUpU is used 
as the RNA synthesis primer (Fields, 6th Ed, 2013) (Figure 1.18 (D)). A negative strand is 
formed which serves as a template for positive strands (Fields, 6th Ed, 2013; Herold & Andino, 
2001).  
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Figure 1.18 Picornavirus model of negative RNA strand synthesis, adapted from (Fields, 6th Ed, 2013; Shen et al, 
2008) 
(A) For the assembly of picornavirus polymerase complex, 3CD domains interact with Cre region leading to 
conformational change which allows binding of 3D polymerase. (B) PCBP and 3CD domains bind to 5’ end of the 
mRNA forming the ribo-nucleoprotein complex and PABP binds to 3’ end. (C) The interaction of ribo-nucleoprotein 
complex with PABP at 3’ leads to circularisation of + mRNA strand.  (D) The 3D polymerase synthesises VPg-pUpU 
by using Cre sequence AAAAA as template and the whole complex is shifted to 3’ end of mRNA where RNA synthesis 
initiates. 
5’ 3’ Poly A 
Polymerase complex 
3D 3D 
3C 
3C 
3D
(pol)
 
VPg 
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IRES 
3CD 
PCBP 
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5’ 3’ 
IRES 
3D 3D 
3C 
3C 
3D
 (pol)
 
VPg 
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5’ 
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1.5.2 Mechanism of selective replication in cancer by CVA21 
CVA21 enters host cells via two membrane receptors, ICAM-1 and decay-accelerating factor 
(DAF) (Bradley et al, 2014). ICAM-1 is crucial for viral internalisation and induced cell lysis 
whereas DAF is a secondary co-receptor for viral entry (Bradley et al, 2014; Rossmann et al, 
2002; Shafren et al, 1997b; Xiao et al, 2001). CVA21 can infect normal cells of the body such 
as peripheral blood mononuclear lymphocytes but due to minimal levels of viral entry 
receptor ICAM-1 it does not lead to productive infection (Bradley et al, 2014). 
1.5.2.1    ICAM-1 -Physiological role  
ICAM-1 is a 76-114 kilodalton (kDa) cell surface glycoprotein which has 4 immunoglobulin G 
(IgG)-like extracellular domains and one transmembrane domain with a short cytoplasmic 
region (Lawson & Wolf, 2009; Rahman & Fazal, 2009) (Figure 1.13 (A)). ICAM-1 is expressed 
on endothelial cells, fibroblasts and leukocytes (Hopkins et al, 2004). ICAM-1 is a ligand for β2 
integrin family members, lymphocyte function associated antigen 1 (LFA 1) and macrophage-
1 antigen (MAC-1) as well as a receptor for rhinoviruses and CVA21 (Hopkins et al, 2004; 
Lawson & Wolf, 2009).  Binding of ICAM-1 to LFA-1 is important for transendothelial migration 
of immune cells into inflammatory sites (Lawson & Wolf, 2009; Schnoor & Parkos, 2008) and 
presence of chemokines trigger integrin LFA-1 expression on leukocytes which enables spread 
and firmer attachment to endothelium via ICAM-1 interaction (Lawson & Wolf, 2009; Rahman 
& Fazal, 2009), thus enabling leukocytes to roll on the endothelial lining and interact with 
selectins (Lawson & Wolf, 2009; Long, 2011; Rahman & Fazal, 2009). As a result of this 
interaction, Ca2+ influx increases leading to leaky membrane junctions and migration of 
leukocytes across the endothelium (Lawson & Wolf, 2009). 
The normal epithelial cells of the body do not express ICAM-1 under homeostatic conditions  
however, cancerous lesions such as in oral, pulmonary, and intestinal epithelial cells have 
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increased ICAM-1 expression. Induction of ICAM-1 expression is stimulated by inflammatory 
cytokines such TNF α, IL-6, IFN γ, and IL-1β (Hopkins et al, 2004). 
1.5.2.2    DAF -Physiological role 
DAF has a molecular weight of 70,000 and consists of 4 short extracellular domains held by 
glycosylphosphatidylinositol to the cell membrane (Figure 1.13 (B)), (Xiao et al, 2005). DAF is 
a regulatory membrane protein found in most cells of the body including monocytes , 
neutrophils, platelets and lymphocytes (Shafren et al, 1997b; Shibuya et al, 1992). DAF 
downregulates complement activation, prevents attack against autoantigens and protects  
host cells from damage (Shibuya et al, 1992; Varela et al, 2008).  DAF directly targets both 
classical and alternative complement pathways by targeting C3 and C5 convertases (Brodbeck 
et al, 2000; Davitz, 1987). It blocks factor B and C2 uptake by C3B and C4B fragments (Davitz, 
1987). This blocks assembly of convertases and formation of the membrane attack complex 
thus inhibiting the complementation activation cascade (Davitz, 1987). 
1.5.2.3    Role of ICAM-1 and DAF as CVA21 receptor  
Binding of CVA21 to two membrane receptors, ICAM-1 and DAF increases the likelihood of 
effective and productive viral infection (Newcombe et al, 2004). The role of ICAM-1 as a 
CVA21 attachment and entry receptor has previously been shown by Shafren et al (Shafren 
et al, 1997a). In this study, importance of ICAM-1 as a viral entry receptor was demonstrated 
by blocking CVA21 infection in HeLa cells using monoclonal ICAM-1 antibody. Additionally, 
murine cells transfected with human ICAM-1 became sensitive to CVA21 infection (Shafren et 
al, 1997a). Other studies also confirmed ICAM-1 domain 1 binds to the canyon in the VP1 
capsid region of CVA21 leading to a conformational change that results in viral entry into the 
host cell (Shafren et al, 1997a; Xiao et al, 2001). Binding to DAF does not induce viral capsid 
conformational change and hence it is unable to stimulate a lytic infection (Shafren et al, 
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1997b). DAF acts as an accessory receptor and co-facilitator for CVA21, as it binds to CVA21 
and accumulates viral particles on the cell surface (Johansson et al, 2004; Stephen Bradley, 
2014; Xiao et al, 2005). CVA21 can reversibly bind to DAF and still retain its infectious ability, 
awaiting ICAM-1 induction (Newcombe et al, 2004; Shafren et al, 1997b). Once significant 
expression of ICAM-1 is induced on the same cell or neighbouring cells by stimulatory 
cytokines, CVA21 irreversibly binds to ICAM-1 leading to lytic infection (Newcombe et al, 
2004; Shafren et al, 1997b). However, upon removal of DAF in Hela-B cells no change in viral 
binding was observed but treatment with an anti-ICAM-1 antibody greatly reduced virus 
attachment (Shafren et al, 1997b). CVA21 binds to DAF via extracellular crosslinking of the 
receptor and is endocytosed by caveolae which are invaginations in the cell membrane wall  
(Shafren, 1998). ICAM-1 mediated CVA21 endocytosis is mediated by the viral capsid protein 
1 binding to domain 1 of ICAM-1, leading to a viral capsid conformational change and entry 
into the host cell (Xiao et al, 2005). Figure 1.19 shows the ICAM-1 and DAF structural 
conformation.  
Figure 1.19 Schematic of DAF and ICAM-1 viral entry membrane receptors, adapted from (Shafren et al, 
2000). 
DAF is a 70 kDa membrane protein which is attached to the cell  surface by a glycophosphatidylinositol (GPI) 
l inkage and consists of four short consensus repeats (SCR). ICAM-1 membrane receptor is a 90 kDa 
glycoprotein with five extracellular domains and a short hydrophobic cytoplasmic domain. Domain 1 has two 
N-glycosylation linkage sites whereas domains two-five have a single glycosylation site. CVA21 enters host 
cells by binding to domain 1 of ICAM-1 and cross-linkage of DAF mediates caveolae induced endocytosis.   
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1.5.2.4    Receptor expression in neoplastic disease 
Viral entry receptors ICAM-1 and DAF are over expressed on various neoplastic tissues which 
makes CVA21 an ideal cancer specific therapy (Bradley et al, 2014). The tumour 
microenvironment promotes an increase in ICAM-1 expression on cancer cells as compared 
to normal cells of the body (Roland et al, 2007). Cytokines like TNF α, IL-1 and IFN-γ induce 
ICAM-1 expression on tumour cells and a role of TAMs in VEGF-mediated ICAM-1 stimulation 
has also been reported (Roland et al, 2007). Various malignancies such as breast cancer 
(Schroder et al, 2011), colon cancer (Maeda et al, 2002), oral cancer (Usami et al, 2013), 
nasopharyngeal cancer (Liu et al, 1999), lung cancer (Kotteas et al, 2014) and melanoma 
(Johnson et al, 1989) display increased ICAM-1 expression on tumour cells 
(https://www.proteinatlas.org/ENSG00000090339-ICAM1/pathology, assessed on 10 Dec 
17). Cancer cells over express complement regulatory proteins, such as DAF to evade damage 
by complement activation (Kiso et al, 2002; Loberg et al, 2005). High expression of the 
membrane receptor DAF was reported in head and neck cancers (Kesselring et al, 2014), 
haematological cancers (Hara et al, 1992), gastric cancer (Kiso et al, 2002), prostate cancer 
(Loberg et al, 2005) and colorectal cancer (Durrant et al, 2003). 
74 
 
 
1.5.3 Pre-clinical and clinical studies using CVA21  
CVA21 oncolytic cancer specific therapy has been tested in multiple preclinical and clinical 
studies targeting various malignancies. In preclinical studies it has been tested in melanoma, 
multiple myeloma, pancreatic cancer, prostate cancer, head and neck cancers, breast cancer 
and lung cancer (Bradley et al, 2014). In vitro CVA21 mediated oncolysis was induced in two 
melanoma cell-lines and reduction of xenograft melanoma tumours was achieved when 
CVA21 was administered via intravenous, intratumoural and intraperitoneal routes in mice 
(Au et al, 2005; Bradley et al, 2014; Shafren et al, 2004). In multiple myeloma, CVA21 
Figure 1.20 Expression of ICAM-1 membrane receptor on malignancies, adapted from The Human Protein 
Atlas (https://www.proteinatlas.org/ENSG00000090339-ICAM1/pathology, assessed on 10 Dec 17). 
 
According to summarised data of immunohistochemistry ICAM-1 staining performed on cancer tissues, 
ICAM-1 was highly expressed on melanoma, ovarian cancer, thyroid cancer, l iver cancer and lymphoma. 
High-intermediate expression of ICAM-1 membrane protein was displayed by stomach cancer, breast 
cancer, urothelial cancer and glioma.  
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underwent many replication cycles and induced cell death in vitro (Au et al, 2007), reduction 
in tumour volume was reported in vivo however some adverse effects such as hind limb 
paralysis of severe combined immunodeficiency (SCID) mice occurred (Hadac & Russell, 
2006). CVA21 induced cytotoxicity was also reported in breast cancer cell-lines whilst, CVA21 
administration in SCID mice reduced tumour burden and eradicated distant spontaneous  
breast cancer metastases (Skelding et al, 2009). In addition, Berry et al. showed sensitivity of 
prostate cancer cell-lines to CVA21 induced death and tumour regression upon CVA21 
intravenous injection in SCID and BALB/c mice (Berry et al, 2008). CVA21 therapy displayed 
lysis in pancreatic cancer cell-lines (Lincoln Smith, June 2015), with a decrease in tumour 
burden reported in a BALB/c pancreatic cancer murine model (Prof Darren Shafren, 2011). 
The efficient anti-tumor response of CVA21 in all the above studies was attributable to the 
high expression of ICAM-1 membrane receptor on the cancer cells (Bradley et al, 2014). 
The clinical studies performed using CVA21 have been summarised in Table 1.3.  
CVA21 is an ICAM-1 targeted, naturally occurring ‘common cold’ virus which has shown 
selective tumour lytic activity in multiple solid cancers.  CVA21 displays mild pathogenicity, is 
well tolerated in clinical setting with few grade 3 and 4 adverse events reported. The possible 
benefit of CVA21 oncolytic virotherapy over other oncolytic viruses is due to its small size 
which allows faster replication cycle (6 hours) in tumour cells and dissemination to distant 
metastatic sites (Shafren et al, 2004; Skelding et al, 2009). Furthermore, the lack of a 
significant neutralising antibody response and overexpression of viral entry receptors on 
neoplastic cells makes CVA21 an ideal cancer therapy (Bradley et al, 2014; Shafren et al, 2004; 
Skelding et al, 2009). 
CVA21 oncolytic virus has shown selective tumour lytic activity in multiple solid cancers.  The 
immunotherapeutic and lytic ability of CVA21 has been clearly evidenced in in-vivo cultures 
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and in vivo models of melanoma, reduction of non-injected melanoma lesions was also 
exhibited when CVA21 was administered intratumourally alone or in combination with 
immune checkpoint inhibitors. Additionally, the accessibility and superficial location of 
NMIBC allows direct intravesical administration of anti-tumour agents, such as oncolytic virus 
for direct translatability to a clinical setting.  
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Identifier Phase Condition Study, objectives and endpoints Results 
NCT00235482 
Completed 
1 Mal ignant 
melanoma  
Intratumoural  s ingle injection into the 
subcutaneous melanoma lesion. Endpoint 
was  safety assessment and tumour 
response. 
Awaiting 
NCT00636558 
Completed 
1 Melanoma, 
breast cancer 
and prostate 
cancer 
CVA21 given intravenous ly in multiple 
doses to s tage IV sol id cancer patients . 
Endpoint objectives  were evaluation of 
safety, tolerability and antivi ra l  antibody 
production. 
Awaiting 
NCT02043665 
(STORM) 
Recruiting 
1 Non-small cel l  
lung and 
bladder cancer 
CVA21 adminis tered systemica l ly in 
combination with immune checkpoint PD-1 
inhibi tor, Pembrol izumab. Endpoint 
objectives are to establish response rate 
and safety of multiple vi rus  doses . 
- 
NCT00832559 
Terminated, 
due to poor 
recruitment 
1 Head and neck 
cancer 
Intratumoural injections in head and neck 
cancer patients. Endpoint objectives  were 
safety, tolerabi l i ty, efficacy, CVA21 
antibody measurement. To also determine 
anti -tumour responses . 
- 
NCT02565992 
(CAPRA) 
Recruiting 
1 Advanced 
melanoma  
Intratumoural  injections  of CVA21 in 
combination with Pembrol izumab. 
Endpoint objectives are safety, tolerabi l i ty 
and measurement of dose l imiting 
toxici ties . 
- 
NCT02307149 
(MITCI) 
Recruiting 
1 Advanced 
melanoma  
Intratumoural  injections  of CVA21 in 
combination with Ipilimumab, inhibi tor of 
CTLA-4 immune checkpoint. Endpoint 
objectives  are response and overa l l  
surviva l . 
- 
NCT01227551 
(CALM) 
Completed 
2 Mal ignant 
melanoma  
Intratumoural injections of CVA21 in stage 
3 and 4 melanoma patients . Endpoint 
objective are response rate and immune 
mediated progress ion free surviva l . 
Immune related progression 
free surviva l  was  seen in 
38.6 % patients , 21.1 % 
displayed durable response 
rate and 11 out of 57 
patients  had serious  
adverse effects  to CVA21. 
NCT01636882 
Completed 
2 Mal ignant 
Melanoma  
This  s tudy i s  extens ion of NCT01227551 
s tudy to given CVA21 ti ll 48 weeks patients 
who benefi ted from 10 doses  earl ier. 
Endpoint is treatment efficacy beyond 18 
weeks  of CVA21 injections . 
Awaiting 
NCT02316171 
(CANON) 
Completed 
2 Non-muscle 
invas ive 
bladder cancer  
Intravesicular adminis tration of CVA21 in 
combination with low doses of Mitomycin 
C chemotherapy. Endpoint was evaluation 
of safety and tolerabi l i ty when CVA21 via  
intraves ica l  route. 
Awaiting 
NCT02824965 
Recruiting 
1 Non-small cel l  
lung cancer 
Intravenous  CVA21 adminis tration in 
combination with Pembrol izumab. 
Endpoint objectives are safety, response 
and overa l l  surviva l . 
- 
NCT00438009 
Completed 
1 Stage IV 
melanoma  
Intratumoural  adminis tration of two 
CVA21 doses. Endpoint was eva luation of 
safety and change in tumour s ize in 
injected and non-injected les ions . 
Awaiting 
Table 1.3 Summary of clinical trials using CVA21 oncolytic therapy, information taken from (https://clinicaltrials.gov/ , 
Accessed 12 Oct 2017; https://www.viralytics.com/our-pipeline/cavatak/cavataktm/, assessed on 7 Dec 17). 
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1.6 Study Objectives  
This thesis set out to test the hypothesis that bladder and pancreatic cancers have IC AM-1 
receptor expression which is a target for CVA21 oncolytic therapy. Bladder and pancreatic 
cancers will be ideal targets for CVA21 treatment induced cytolysis which will increase 
immunogenicity. In order to investigate this hypothesis, the following study objectives were 
addressed: 
 Chapter 3 – Evaluated sensitivity of bladder cancer in vitro to CVA21 induced death, 
means of selective replication in cancer cells, mode of cell death and immunogenicity 
induced by CVA21 therapy.  
 Chapter 4 – Assessed susceptibility of pancreatic cancer cell-lines in vitro to CVA21 
induced death and mechanism of viral resistance despite the presence of the viral entry 
receptor, ICAM-1.  
 Chapter 5 – Assessed therapeutic benefit of intratumoural CVA21 administration in a 
subcutaneous bladder cancer murine model. Study endpoints were reduction in tumour 
size, improvement in overall survival and establishment of a bladder in vivo model for 
further combination studies.  
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CHAPTER 2: MATERIALS AND METHODS 
2.1 Cell lines, media and supplements  
Bladder and pancreatic cancer cell lines used in this thesis are shown in Table 2.1. Media used 
for each cell-line was supplemented with 100 U/ml Penicillin (Sigma), 100 µg/ml Streptomycin 
(Sigma), 2 mM L-Glutamine (Sigma) and 10 % foetal bovine serum (Life Technologies, UK).  
The cell lines were handled in a sterile class II biosafety cabinet and incubated at 37°C in 5 % 
CO2. All cell lines were authenticated by DDC Medical with short tandem repeat (STR) profiling 
with the exception of PL45 and PANC-1 pancreatic cancer cell lines which were purchased 
from American Type Culture Collection (ATCC) and Sigma, respectively. MycoAlert™ PLUS 
Mycoplasma Detection Kit (Lonza) was used in accordance with manufacturer’s instructions 
to determine absence or presence of mycoplasma once every month. From initial thawing to 
subsequent use in experiments, cells were passaged 30 times over a period of 15 weeks.  
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Additional chemotherapeutic agents were used in this thesis and are mentioned in Table 
2.2. 
 
 
 
 
 
 
Carcinoma Cell-line Media Supplier 
 
 
 
 
Transitional cell urinary 
bladder carcinoma 
T24 McCoy’s 5a Medium Modified (Fisher) ATCC 
TCCSUP Dulbecco’s Modified Eagle’s (Sigma) ATCC 
5637 RPMI-1640 (Sigma) ATCC 
KU19-19 RPMI-1640 (Sigma) DSMZ 
RT-112 RPMI-1640 (Sigma) DSMZ 
VM-CUB 1 Dulbecco’s Modified Eagle’s (Sigma) DSMZ 
J82 Eagle’s Minimum Essential (Sigma) ATCC 
253J RPMI-1640 + Dulbecco’s Modified 
Eagle’s  
Prof M Knowles, 
Uni of Leeds 
VM-CUB-2 Dulbecco’s Modified Eagle’s (Sigma) Prof M Knowles, 
Uni of Leeds 
HCV29 RPMI-1640 (Sigma) Prof M Knowles, 
Uni of Leeds 
Mouse Bladder carcinoma MB49 Dulbecco’s Modified Eagle’s (Sigma) Prof A Loskog, 
Uppsala University, 
Sweden 
Mouse bladder cancer 
cell-line transfected with 
human ICAM-1 receptor 
MB49/ICAM-1 Dulbecco’s Modified Eagle’s (Sigma) + 
G418, Geneticin® (ThermoFisher) 
Transfected by Dr 
Guy Simpson 
 
 
 
 
Pancreatic 
Adenocarcinoma 
PL45 Dulbecco’s Modified Eagle’s (Sigma) ATCC 
PANC-1 Dulbecco’s Modified Eagle’s (Sigma) Sigma 
PSN-1 RPMI-1640 (Sigma) ATCC 
AsPC1 RPMI-1640 (Sigma) ATCC 
HPAF II Eagle’s Minimum Essential (Sigma) ATCC 
BxPC3 RPMI-1640 (Sigma) ATCC 
Capan-2 McCoy’s 5a Medium Modified (Fisher) ATCC 
Hs 766T Dulbecco’s Modified Eagle’s (Sigma) Dr Gunnel Hallden 
,Barts Cancer 
institute, London 
Chemotherapeutic Drugs Supplier Storage 
Mitomycin C from Streptomyces 
Caespitosus 
Sigma 2-8°C 
Cisplatin Hospira, UK limited Room temperature 
Mitoxantrone Sigma 4°C 
Table 2.1 Bladder and pancreatic cancer cell lines and media. 
Table 2.2 Chemotherapeutic agents used in this study. 
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2.2 Passaging, storage and culture of adherent cell lines  
Revival of frozen cells was carried out by resuspending them in cell-line specific complete 
media (Table 2.1) and centrifuging for 2 minutes at 2000 revolutions per minute (rpm). The 
supernatant was discarded and the cell pellet was resuspended in cell -line specific media. 
Cells were incubated in a 25 cm3 flask for 2 days or until they reached 80-90 % confluence. 
Cells were then split into additional flasks to bulk the original stock. Cells were incubated until  
they reached 80-90 % confluency. A confluent cell flask was washed with Hank’s Solution 
(Sigma) and adherent cells were removed from the culture surface with trypsin-EDTA solution 
(x1) (Sigma) at 37°C.  
Storage of cells in liquid nitrogen involved centrifugation and resuspension of cell pellets in 
freezing media which consisted of 50 % cell-line specific media, 40 % fetal bovine serum (Life 
Technologies, UK) and 10 % Dimethyl sulfoxide (Fisher). 1×106 cells/ml were pipetted into a 
cryovial and stored overnight at -80°C in a Mr. Frosty™ Freezing container (ThermoFisher). All 
vials were moved into liquid nitrogen containers the following day. 
2.3 Counting and Plating cells 
Viable cells were counted on the Neubauer haemocytometer. 10 µl cells were resuspended 
in 90 µl of Trypan blue vital stain (ThermoFisher) that allows identification of live cells from 
non-viable cells as dead cells take up the dye due to permeable membranes . 10 µl of the 
resuspended cells were placed on the haemocytometer grid and viable cells were counted. 
The following formula determined the cell number: 
𝐶𝑒𝑙𝑙 𝑐𝑜𝑢𝑛𝑡 / 𝑚𝑙 =
𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑒𝑙𝑙𝑠 × 𝑑𝑖𝑙𝑢𝑡𝑖𝑜𝑛 𝑓𝑎𝑐𝑡𝑜𝑟 (10) × 𝑐ℎ𝑎𝑚𝑏𝑒𝑟 𝑣𝑜𝑙𝑢𝑚𝑒 (104)
4 𝑠𝑞𝑢𝑎𝑟𝑒𝑠
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2.4 Oncolytic Virus 
The Kuykendall strain of CVA21 used as an oncolytic virus throughout this thesis is owned and 
manufactured by Viralytics Limited (Sydney, Australia) and is branded as CAVATAK™. Stock 
virus was kindly provided by Viralytics at a concentration of 7.5×107 TCID50 /ml in 2.15 ml vials 
which were stored once received at -80°C.  
2.4.1 Dilution of working virus concentration 
Plaque forming units (pfu) is the measure of infectious virus particles capable of infecting 
permissive cells, causing plaque formation that allows for virus to be titrated. Stock 7.5×107 
pfu/ml of CVA21, which was previously titrated by the manufacturer, was diluted to a working 
concentration per well of cells using the established equation (Pourianfar et al, 2012): 
𝑃𝑓𝑢 𝑝𝑒𝑟 𝑤𝑒𝑙𝑙 = 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑒𝑙𝑙𝑠 𝑝𝑒𝑟 𝑤𝑒𝑙𝑙 × 𝑚𝑢𝑙𝑡𝑖𝑝𝑙𝑖𝑐𝑖𝑡𝑦 𝑜𝑓 𝑖𝑛𝑓𝑒𝑐𝑡𝑖𝑜𝑛 (𝑀𝑂𝐼)∗ 
𝑉𝑜𝑙𝑢𝑚𝑒 𝑜𝑓 𝐶𝑉𝐴21 𝑠𝑡𝑜𝑐𝑘 𝑛𝑒𝑒𝑑𝑒𝑑 𝑝𝑒𝑟 𝑤𝑒𝑙𝑙 =
𝑝𝑓𝑢 𝑝𝑒𝑟 𝑤𝑒𝑙𝑙
7.5 × 107𝑝𝑓𝑢 𝑝𝑒𝑟 𝑚𝑙 𝐶𝑉𝐴21
  
The concentration of CVA21 that resulted in 50 % death of target cells, known as the IC 50 was 
calculated using the CalcuSyn Software (Biosoft, UK), Table 2.3. 
 
 
 
*MOI i s  a  measure of average number of vi rus particles infecting each cell.  
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2.5 Cell viability and cytotoxicity assay  
In order to assess reduction in cell survival induced by CVA21, MTS colorimetric cell -viability 
assay (CellTiter 96® Aqueous One Solution Cell Proliferation Assay-Promega) was used. MTS 
measures the cellular respiration and metabolic activity of cells which indicates the number 
of viable cells (Figure 2.1). 
 
 
 
 
 
 
 
Cancer Cell-line CVA21 MOI 
 
 
 
 
 
Bladder 
T24 11.44 
TCCSUP 1.00 
5637 1.83 
KU19-19 25.0 
RT-112 25.0 
VM-CUB 1 25.0 
253J 2.28 × 10-3 
VM-CUB-2 0.293 
HCV29 4.57 × 10-3 
J82 25.0 
 
 
 
 
Pancreatic 
PL45 10.0 
PANC-1 10.0 
PSN-1 10.0 
AsPC1 10.0 
HPAF II 10.0 
BxPC3 10.0 
Capan-2 10.0 
Hs 766T 10.0 
Figure 2.1 Conversion of MTS compound into coloured formazan product in the presence of metabolically 
active cells (Promega).  
The CellTiter 96® Aqueous One Solution contains a tetrazolium compound, [3-(4, 5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt, MTS. The MTS compound combines with 
an electron coupling reagent which in the presence of NADPH/NADH from metabolically active cells reduces to 
a coloured formazan compound. The amount of formazan compound produced is directly proportional to  the 
number of viable cells.  
Table 2.3 CVA21 MOI used in bladder and pancreatic cancer cell-line experiments. 
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Cells were counted on the Neubauer haemocytometer, 100 µl cells/well were plated in a 96-
well plate at the required seeding density and incubated overnight at 37°C to ensure an 80 % 
confluency. Cells were treated with a range of CVA21 MOIs from 0-50 and incubated for 72 
hours. As an additional control heat inactivated CVA21 was used to demonstrate that cell 
death induced was due to live virus. CVA21 was heat inactivated at 60°C for 2 hours in a water 
bath. After 72 hours 100 µl of MTS reagent diluted 1:10 in RPMI-1640 media was added to 
each well and incubated for an hour. The absorbance/optical density (OD) was measured at 
490 nm using the Variskan® Plate Reader (ThermoFisher).  
Percentage cell survival was calculated by the following equation =  
% 𝑐𝑒𝑙𝑙 𝑠𝑢𝑟𝑣𝑖𝑣𝑎𝑙 =   (
(𝑎𝑣𝑒𝑟𝑎𝑔𝑒 𝑂𝐷 𝑐𝑒𝑙𝑙𝑠 𝑤𝑖𝑡ℎ 𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡)
(𝑎𝑣𝑒𝑟𝑎𝑔𝑒 𝑂𝐷 𝑐𝑒𝑙𝑙𝑠 𝑤𝑖𝑡ℎ𝑜𝑢𝑡 𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡 )
− 𝐴𝑣𝑒𝑟𝑎𝑔𝑒 𝑂𝐷 𝑀𝑇𝑆 𝑏𝑙𝑎𝑛𝑘) × 100  
 
2.6 Flow cytometry  
Table 2.4 states the dilution factors and suppliers for all the primary and secondary antibodies 
used in flow cytometry analysis for human and mouse cell lines.  
Primary Antibodies 
 Name Supplier Dilution 
Human/ Mouse Rabbit polyclonal to Calreticulin Abcam 1:100 
Rabbit monoclonal to HSP70 Abcam 1:100 
Rabbit polyclonal to FAS Abcam 1:20 
Rabbit IgG, monoclonal -isotope control  Abcam 1:3000 
 
Human 
Anti-Human CD274 (PD-L1, B7-H1) Purified Biolegend 1:50 
Phycoerythrin (PE) Anti -human HLA-A,B,C, Clone: W6132 Biolegend 1:10 
PE Anti-human CD80, Clone 2D10 eBioscience 1:10 
PE Mouse Anti-Human CD54 BD Biosciences 1:2 
PE Mouse Anti-Human CD55 BD Biosciences 1:2 
Mouse PE Anti-mouse H-2 (clone:M1/42) Biolegend 1:50 
PE Anti-mouse CD80 (clone:16-10A1) Biolegend 1:50 
Rat Anti-Mouse CD274 (B7-H1), PE, Clone: M1H5 eBioscience 1:20 
Monoclonal Mouse Anti -Enterovirus Clone 5-D8/1 Dako 1:10 
Secondary Antibodies 
 Alexa Fluor® 488 goat anti -mouse IgG1 (y1) Invitrogen 1:200 
 Alexa Fluor® 488 goat anti -rabbit IgG Invitrogen 1:200 
Table 2.4 Primary and secondary antibodies used in flow cytometry analysis. 
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2.6.1 QuantiBRITE™ - Expression of ICAM-1 and DAF receptors on cancer cell lines  
Cells were plated in a 6-well plate at an appropriate seeding density to reach 80-90 % 
confluency and incubated overnight. The next day, cells were washed with phosphate 
buffered saline (Oxoid™ PBS tablets, ThermoFisher) and detached with StemPro® Accutase® 
Cell Dissociation Reagent (ThermoFisher). Cells were transferred to a universal tube, 
centrifuged and resuspended in PBS. 100 µl of cells were pipetted into the appropriate 
number of wells of a 96-well plate and centrifuged.  Cells were incubated for 30 minutes with 
PE Mouse Anti-Human CD54 antibody (ICAM-1, BD Biosciences) and PE Mouse Anti-Human 
CD55 antibody (DAF, BD Biosciences). PBS 0.1 % bovine serum albumin (BSA) was used as a 
negative control. The cells were then subsequently washed in PBS and the mean density of 
ICAM-1 /DAF bound per cancer cell was determined using QuantiBRITE™ PE beads (BD 
Biosciences). QuantiBRITE™ PE beads are conjugated with 4 levels of PE which are used with 
PE-labelled monoclonal antibodies to determine the antibody bound per cell using a  
MACSQuant flow cytometer with MACSQuantify software (Miltenyi Biotec) (Figure 2.2) . 
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molecules/bead
Figure 2.2 Linear Regression of QuantiBRITE™ PE molecules per beads with their means (BD Bioscience). 
In order to determine the PE/ICAM-1 molecules per cell, the geometric means of 4 bead populations were 
obtained using flow cytometry. The log10 of the fluorescence mean (Log FL2) was plotted against the log10 of PE 
molecules per bead (Log PE/bead), value provided in the kit. Linear regression was calculated using the equation 
y= mx +.c where y=log10 fluorescence mean, x =log10 PE molecules per bead. The ICAM-1 antibody bound on 
unknown sample was calculated by substituting log fluorescence mean for sample mean value. 
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2.6.2 Expression of ICAM-1 and DAF receptors after Mitomycin C treatment 
Cells were plated at a seeding density of 4×105 cells/well in a 6-well plate and incubated 
overnight. The next day cells were treated with a range of Mitomycin C concentrations from 
0-4 µg/ml and incubated for an hour. Mitomycin C was removed and 2 ml of media was added 
to both Mitomycin C treated and untreated wells. Cells were incubated for 24, 48 and 72 
hours, and at specific time point cells were harvested using StemPro® Accutase® Cell 
Dissociation Reagent (ThermoFisher) and centrifuged at 1500 rpm for 3 minutes.  100 µl of 
cells resuspended in PBS were pipetted into the appropriate number of wells of a 96-well 
plate.  
The LIVE/DEAD® Fixable Violet Dead Cell Stain Kit (Life Technologies) was used to discriminate 
the live cells from the dead cells. The dye binds to free amines both inside and on the cell 
surface. The damaged cell surface of dead cells allows the dye to penetrate and bind to 
amines on the surface and inside resulting in a stronger fluorescence signal as compared to 
live cells where dye only binds to cell surface amines due to an intact cell membrane. Cells 
were incubated for 20 minutes in ViViD live dead stain (diluted 1:20 in water) followed by a 
wash with PBS. The plate was centrifuged, 40 µl of primary PE Mouse Anti-Human CD54 
(ICAM-1) antibody and PE Mouse Anti-Human CD55 (DAF) antibody diluted in PBS 
supplemented with 0.1 % BSA was added and incubated for 30 minutes. Following incubation, 
cells were washed and expression of ICAM-1 and DAF post Mitomycin C treatment was 
analysed using a MACSQuant flow cytometer. For further experiments in which Mitomycin C 
was used, a cytostatic dose of 0.50 µg/ml was used to treat the cells, further discussed in 
Chapter 3 (Section 3.3.4).  
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2.6.3 Immunogenic cell death determinants  
Cells were plated in 6-well plates at a seeding density of 4×105 cells/well and incubated 
overnight. Cells were treated with 0.50 µg/ml of Mitomycin C for an hour, the Mitomycin C -
only control wells were replaced with media. CVA21 alone and combination wells were 
treated with CVA21 and incubated for 24, 48 and 72 hours. As a positive control for ICD 
induction cells were treated with 1 µM Mitoxantrone (MTX, Sigma) (Angelova et al, 2014; 
Hodge et al, 2013). As an additional control, cells were treated with heat inactivated virus to 
show induction of death and expression of ICD markers was due to live virus infection (Section 
2.5). The cells were washed with PBS at specific time points and dissociated with accutase. 
Cells were centrifuged and resuspended in PBS, 100 µl of cells were placed in a 96-well plate. 
The supernatant was centrifuged, transferred to a 1.5 ml eppendorf and stored at -80°C for 
extracellular ATP assay and HMGB1 ELISA (IBL international) (Section 2.10.3 and 2.13).  Cells 
were incubated for an hour with Rabbit IgG Isotype control (Abcam), Rabbit Anti -Human 
Calreticulin antibody (Abcam), Rabbit Anti-Human HSP70 (Abcam), Rabbit Anti- Human FAS 
(Abcam), Mouse Anti-Human CD274/PD-L1 PE (eBioscience), Mouse Anti-Human Leukocyte 
Antigen (HLA) PE (Biolegend) and Armenian Hamster Anti-Human CD80 PE (eBioscience) 
antibody, see Table 2.4 for antibody dilutions. After washing the cells, for non-labelled mouse 
and rabbit antibodies, the relevant Goat Anti-Mouse IgG1 Alexa Fluor® 488 (Life Technologies) 
and Goat Anti-Rabbit IgG Alexa Fluor® 488 (Life Technologies) secondary antibodies were 
added for 30 minutes. Following washing in PBS, cells were analysed by flow cytometry using 
the MACSQuant Analyzer and MACSQuantify software (Miltenyi Biotechnology). 
2.6.4 Annexin V-PE  
Three of the six bladder cancer cell lines, T24, TCCSUP, 5637 which were susceptible to CVA21 
induced cytotoxicity were plated in 6-well plates and incubated overnight at 37°C. Cells were 
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treated with 0.50 µg/ml of Mitomycin C (Sigma Aldrich) for an hour. After an hour, CVA21-
only and combination wells were treated with CVA21 for 24, 48, and 72 hours. Untreated 
negative control and Mitomycin C treated cells were incubated for 24, 48 and 72 hours with 
media. At specific time-points cells were dissociated using accutase and centrifuged at 1500 
rpm for 3 minutes. 100 µl of cells were resuspended in 1× Binding Buffer (provided in the 
Annexin V 556419-BD Biosciences Kit) and pipetted into 96-well plates. 5 µl each of 7-
aminoactinomycin D (7-AAD) and Annexin V fluorescein isothiocyanate (FITC) was added to 
the wells for 15 minutes and subsequently analysed by flow cytometry. 
2.7 Immunofluorescence  
2.7.1 Enterovirus staining for presence/ internalisation of CVA21  
Immunofluorescent staining for enterovirus capsid protein VP1 was applied to confirm virus 
presence and localisation inside bladder and pancreatic cancer cell lines. Cells were plated in 
Falcon® 8-Well Culture Slides (Corning) at an appropriate seeding density and incubated 
overnight. Each bladder cancer cell-line was treated with its specific IC50 dose of CVA21 as 
stated in Table 2.3 and incubated for 24 hours. Bladder cancer cell lines that were resistant 
to virus induced death were treated with CVA21 MOI of 25. For pancreatic cancer cell lines, 
where the resistance to CVA21 was investigated a standard MOI of 10 was used.  
Wheat Germ Agglutinin (WGA), Alexa Fluor® 594 conjugate (Molecular Probes 7.5 µg/ml) is a 
cell membrane stain which binds to the sialic acid on the cell membrane. WGA stain was 
added to each relevant chamber and incubated for 15 minutes on ice followed by one PBS 
wash. Cold 4 % formaldehyde (Sigma) was added for 15 minutes at room temperature to fix 
the cells. Chambers were rinsed with PBS and 0.2 % Triton X-100 (Sigma) was added for 15 
minutes to permeabilise cells. Cells were incubated with monoclonal mouse Anti-Enterovirus  
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antibody (Dako, 1:10) for 30 minutes at room temperature. Chambers were rinsed with PBS 
twice and incubated with Goat Anti-Mouse IgG2a, Alexa Fluor® 488 secondary antibody 
(1:200) and TO-PRO®-3 nuclear stain (1:400) for an hour at room temperature. Chambers  
were rinsed with PBS and removed using the chamber separation tool provided with the 
slides. The glass slide was mounted with Vectashield Hardset mounting medium (Vector 
Laboratories). Cells were imaged using a Nikon A1M confocal microscope with NIS elements 
acquisition software (Nikon, UK). 
2.7.2 Immunofluorescence detection of CVA21 cell membrane binding 
In order to confirm virus was binding to the cell surface, cells were treated with virus at 4°C. 
Virus binding by confocal analysis was conducted as described previously (Berryman et al, 
2005). Cells were plated on chamber slides and left for 24 hours in the incubator. The next 
day, chamber slides were placed on ice and treated with CVA21 MOI of 25 and 50 at 4°C. Cells 
were incubated with CVA21 for 5 and 10 minutes. At specific time points cells were washed 
with cold media and incubated with blocking agent, PBS in 10 % goat serum, for 30 minutes. 
Cells were then washed with cold medium and incubated for a further 30 minutes at 4°C with 
monoclonal mouse Anti-Enterovirus antibody. Cells were washed and incubated with Goat 
Anti-Mouse IgG2a Alexa Flour A488 (1:200) for an hour at 4°C. Cells were fixed with cold 4 % 
paraformaldehyde before being mounted with hardset Vectashield with 4', 6-diamidino-2-
phenylindole (DAPI, Vector Laboratories). Cells were imaged using Nikon A1M confocal 
microscope with NIS elements acquisition software (Nikon, UK).  
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2.8 Western Blotting  
For western blotting, 4×105 cells/well were plated in 6-well plates and incubated over-night. 
The next day cells were treated with Mitomycin C for an hour, CVA21 alone, or in combination 
with Mitomycin C for 24 to 72 hours.  At specific time points, the cells were washed with PBS 
and lysed using 300-500 µl of Radioimmunoprecipitation assay (RIPA) lysis buffer 
(ThermoFisher) and Halt™ Protease and Phosphatase Inhibitor Cocktail (ThermoFisher). Cells 
were placed on ice for 5 minutes and then sonicated for 15 seconds, three times. After 
sonication cells were centrifuged at 4°C 13,000 rpm for 15 minutes. Cell lysates were pipetted 
into new labelled 1.5 ml eppendorfs, their protein content was measured using the 
bicinochoninic acid (BCA) Protein Assay Kit (Thermo Fisher), as per the manufacturer’s 
instructions. Lysates were stored at -80°C. Lysates were diluted in RIPA buffer to make up 20-
30 µg/ml of total protein concentration, 10 µl of NuPAGE® LDS Sample Buffer (4×, 
ThermoFisher) and 4 µl of NuPAGE® Sample Reducing Agent (10×, ThermoFisher) was added 
to the samples before heating the samples at 95°C for 5 minutes. 40 µl of samples were loaded 
onto a 4-12 % Bis Tris protein gel, 1.0 mm, 10 well (NuPAGE™ Novex™) and 3 µl of BLUeye 
Pre-Stained Protein Ladder (10-245 kDa, Geneflow) was loaded. Glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH), a housekeeping gene constitutively expressed in cells, was used as 
a loading control to ensure equivalent protein was loaded for all samples. Gels were run at 
120 Voltage for an hour in NuPAGE® 3-(N-morpholino) propansulfonic acid (MOPS) Sodium 
Dodecyl Sulfate (SDS) Running Buffer (20×, Life Technologies). Gels were transferred at 20 
voltage for 7 minutes using iBlot® Gel Transfer device (ThermoFisher Scientific). Membranes  
were blocked in 5 % non-fat milk in Tris Buffered Saline (TBS, Sigma) with 0.1 % Tween-20 
(ThermoFisher) for an hour. Membranes were incubated with primary antibody overnight at 
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4°C (Table 2.5). After 24 hours, the membranes were washed in TBS 0.1 % Tween for 5 
minutes, three times. The membranes were incubated for one hour with secondary 
antibodies, specific for each primary antibody as stated in Table 2.5. Membranes were 
washed with TBS 0.1 % tween for 5 minutes, three times. The blot was then covered in the 
SuperSignal® West Pico Chemiluminescent substrate (Life Technologies, UK) for 3 minutes 
before protein bands were visualised using the ChemiDoc-It2 imager (UVP, UK).  
All membranes were stripped for 10 minutes using 20 ml of Restore™ Western Blot Stripping 
Buffer (ThermoFisher Scientific) and blocked for one hour with non-fat milk with 5 % TBS 0.1 
% tween-20. Membranes were incubated overnight at 4°C with purified mouse GAPDH clone 
2D9 monoclonal antibody (Insight Biotechnology) to detect GAPDH. Membranes were 
washed for 5 minutes, three times with TBS 0.1 % tween and incubated for an hour with goat 
anti-mouse IgG Horseradish Peroxidase (HRP) linked, Insight Biotechnology). Membranes  
were washed and bands were detected as previously described above.        
 
Primary Antibody Secondary Antibody Positive Control 
Rabbit PARP (Cell Signalling) 
1:1000 
Anti-Rabbit IgG 
Antibody 
(Cell Signalling) 1:2000 
Jurkat Cells extracts treated with 
25 µM Etoposide for 5 hours  
(Cell Signalling) 
Rabbit Anti-RIP3 (Abcam) 2.5 µg/ml Donkey Anti –Rabbit 
IgG (Fitzgerald) 1:5000 
3T3 cells  
Purified Mouse Anti-RIP (BD biosciences) 1:1000  
Goat anti-mouse IgG 
(Origene) 1:1000 
 
 
3T3 cells  
Mouse Monoclonal Anti-GAPDH 
(OriGene) 1:2000 
- 
Mouse Monoclonal ICAM-1 (Santa Cruz) 
1:250 
- 
Table 2.5 Primary and secondary antibodies used in western blotting. 
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2.9 Immunohistochemistry 
2.9.1 Sectioning of Paraffin Blocks 
Four micron sections of paraffin embedded tissue blocks were cut using the Leica RM2125RT 
microtome. The sections were floated in a water bath at 42°C to remove any wrinkles and to 
flatten the section. Tissues were then mounted onto charged slides (Flex IHC microscope 
slide) and placed on a drying bench (Barnstead Electro-thermal) at 60°C for at least an hour. 
2.9.2 Enzymatic Staining  
The slides were deparaffinised in 3 changes of xylene (VWR), before being rehydrated in two 
containers of 100 % ethanol (ThermoFisher). Slides were placed in methanol supplemented 
with 0.3 % hydrogen peroxide (H2O2) for 20 minutes to block endogenous peroxidase activity. 
Tissue slides were further rehydrated in 100 %, 70 %, 50 % ethanol before completing the 
rehydration process by washing the sections in distilled water. Before antibody staining can 
be performed the cross-links formed by formalin fixation must be removed. Thus antigen 
unmasking was performed using pre-boiled citrate buffer at pH 6. Slides were placed in the 
citrate buffer and heated in a microwave for 12 minutes. The slides were subsequently 
allowed to cool before being washed in distilled water for 3 minutes followed by 2 washes in 
PBS. A DAKO pen (Vector Laboratories, ImmEdge Hydrophobic Barrier Pen) was used to draw 
around the tissues on the slides and they were laid in a moist chamber. 2.5 % normal horse 
serum (RTU Vectastain Universal Elite ABC Kit) was used to block non-specific binding and 
incubated for 15 minutes. The excess horse serum was knocked off and the 
Streptavidin/Biotin blocking kit (Vector Laboratories) was applied to the tissues to block all 
endogenous biotin, biotin receptors, and avidin binding sites present in the tissues . The 
appropriate primary antibody diluted in PBS 1 % BSA was added to each section (Table 2.6) 
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whilst the negative control tissue was incubated with PBS 1 % BSA (Sigma) alone. Slides were 
left in the moist chamber overnight. Slides were then washed 3 times in PBS and treated with 
a prediluted universal secondary antibody (Vectastain Elite ABC Kit R.T.U, Vector 
Laboratories) for 30 minutes followed by a further 30 minutes incubation with stabilized ABC 
reagent. The slides were washed in PBS and 3, 3’-Diaminobenzidine (DAB) Peroxidase 
substrate solution (Vector Laboratories) was added to each section and left for 4 minutes. The 
slides were washed in distilled water for 5 minutes. Sections were counter-stained with 
haematoxylin (Vector Laboratories) for 45 seconds. The slides were left under running tap 
water for 5 minutes. Sections were dehydrated by dipping in 50 %, 70 %, 100 %, 100 % ethanol 
and 3 changes of xylene. The slides were left to dry in a fume hood for 60 minutes before 
mounting the sections with coverslips using permanent mounting medium (VectaMount, 
Vector Laboratories).  
 
 
 
2.10 Enzyme-linked immunosorbent assay (ELISA) 
2.10.1 Peripheral Blood Mononuclear Cell (PBMC) Isolation 
Blood was collected in Ethylenediaminetetraacetic Acid (EDTA) treated tubes (BD), 10 ml of 
blood was diluted in 15 mls of Hanks’ Balanced Salt Solution (Sigma) and layered on to 15 mls 
of Histopaque (Sigma) and centrifuged at 690 g for 25 minutes. The white blood cell layer was 
collected and pipetted into a 50 ml falcon tube containing 30 ml of Hanks’ Balanced Salt 
Primary Antibody Dilution  Positive Control Secondary Ab 
Rabbit Monoclonal PD-L1 antibody 
(Cell Signalling) 
1:100 Mouse Thymus  
Anti-Rabbit IgG 
(Vector Laboratories) Anti-Indoleamine 2, 3 dioxygenase antibody 
(Abcam) 
1:25 Mouse Spleen 
Anti-galectin 9 antibody  
(Abcam) 
1:500 Mouse Spleen 
Table 2.6 Primary and secondary antibodies used for immunohistochemistry, their positive controls and 
dilution factors. 
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Solution (Sigma). The tube was centrifuged at 690 g for 10 minutes. The cell pellet was 
resuspended in 10 mls of red blood cell (RBC) lysis buffer (Qiagen), incubated for 10 minutes 
after which 40 mls of Hanks was added. Cells were centrifuged at 690 g for 5 minutes. The 
resulting pellet of white blood cells was resuspended in media and cells were counted.  
2.10.2 Human Interferon Beta ELISA 
To assess the induction of an anti-viral interferon beta (IFNβ) response in cell lines post virus 
treatment, VeriKine Human IFN Beta ELISA kit (PBL Assay Science) was used. The kit was used 
according to the instructions provided by the manufacturer. The assay utilis es a sandwich 
ELISA technique to quantify the level of IFNβ produced in the cell supernatant. Cells were 
treated with Mitomycin C, CVA21 and a combination for 24 to 72 hours. The supernatant was 
collected at specific time intervals.  50 µl of samples, standards and blank were added to 50 
µl sample diluent in a 96-well plate and incubated for an hour. The plate was washed 3 times 
with wash buffer before 100 µl of diluted antibody solution was added and the plate was 
incubated for a further hour. After 3 washes the plate was incubated with 100 µl of HRP 
solution and incubated for an hour followed by washes. 100 µl of Tetramethylbenzidine (TMB) 
substrate was added and incubated for 15 minutes in the dark before 100 µl of stop solution 
was added and the plate was analysed at 450 nm on the Variskan® Plate Reader 
(ThermoFisher).  
2.10.3 HMGB1 ELISA 
An HMGB1 ELISA (Sandwich-enzyme immunoassay, IBL International) was used for the 
quantitative determination of HMGB1 in supernatants stored from an experiment performed 
earlier (Section 2.6.3). The supernatants together with HMGB1 standards were added to the 
appropriate wells of a microtitre plate coated with purified anti-HMGB1 antibody. The plate 
was incubated overnight and washed. The next day enzyme conjugate was added for 2 hours  
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followed by a washing step. The plate was incubated with a colour substrate solution for 30 
minutes at room temperature and stop solution was added. The HMGB1 concentration was 
determined by measuring the OD values at 450 nm using a Variskan® Flash plate reader 
(Thermo Scientific, UK). 
2.11 Caspase Glo® 3/7 Assay 
Caspase Glo® 3/7 assay (Promega) (Figure 2.3) was used to evaluate caspase 3 and 7 activity 
post CVA21 infection. T24, TCCSUP and 5637 bladder cancer cell lines were plated at 1×104 
cells/well in a 96-well plate and incubated overnight. Cells were treated with Mitomycin C, 
CVA21 or a combination of the two treatments. At specific time-points, 100 µl of the Caspase 
Glo® reagent was added to each well. Cells were incubated for 30 minutes and luminescence 
was measured by the Variskan® Flash plate reader (Thermo Scientific, UK). 
 
Figure 2.3 Caspase Glo® 3/7 luminescence assay quantifies the expression of caspase 3/7 which are key 
effector enzymes in apoptosis (Promega).  
The Caspase Glo® 3/7 assay provides a substrate for caspase 3/7 consisting of the DEVD tetrapeptide sequence 
which leads to cell lysis, caspase release and production of luminescence produced by luciferase upon cleavage 
by caspase. The amount of luminescence is directly proportional to the caspase activity in the sample. 
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2.12 Apoptosis and Necroptosis Inhibitors 
A caspase inhibitor Z-VAD-FMK (Promega) was used to inhibit apoptosis, it irreversibly binds 
to the catalytic site of caspase enzymes. An inhibitor of necroptosis, Necrostatin-1 (Sigma) 
was also used, it inhibits RIP 1 protein which is crucial for necrosome formation. Cells were 
plated in a 96-well plate to reach 80-90 % confluency and treated with Necrostatin-1 (30 µM) 
for 45 minutes. Necrostatin-1 was pipetted off and cells were treated with Mitomycin C for 
an hour. Mitomycin C was replaced with media for untreated and Mitomycin C -only wells, 
CVA21 was added to combination and CVA21-only wells for 2 hours. After two hours, the 
Necrostatin-1 treated cells and untreated negative control cells were incubated for 24, 48, 72 
hours with media whereas for Z-VAD-FMK cells were treated with 20 mM of Z-VAD-FMK for 
24, 48 and 72 hours.  At specific time-points, 100 µl of MTS reagent was added to the relevant 
plates and incubated for an hour after which absorbance was measured at 490 nm using the 
Variskan® Flash plate reader (Thermo Scientific, UK). 
2.13 Extracellular ATP 
Two separate kits were used to determine the extracellular ATP concentration in the 
supernatant of cells treated with virus, Mitomycin C or a combination of these treatments . 
The extracellular ATP was quantified using Cell-Titer Glo® Luminescent assay (Promega) and 
ATP determination kit (Molecular Probes). Both kits offer a bioluminescent assay. In the 
presence of Mg+, ATP and oxygen the light emitting compound, firefly luciferin is catalysed by 
luciferase enzyme to generate a luminescent signal (Crouch et al, 1993), Figure 2.4. The assay 
was conducted as specified by the manufacturer’s protocol. In summary, cells were seeded 
at 1×104 cells/well on a 96-well opaque plate and incubated overnight to reach 80-90 % 
confluency. Cells were treated with CVA21 IC50 specific for each cell-line, Table 2.3. CVA21 
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was either added alone or in combination with 0.50 µg/ml Mitomycin C. At 24, 48 and 72 
hours the plate was equilibrated to room temperate, 100 µl of master mix with firefly luciferin 
and luciferase enzyme reconstituted as stated by the manufacturer was added to each well. 
The plate was shaken for 2 minutes and incubated at room temperature for 10 minutes  
followed by luminescence measure on the plate reader.  
 
 
 
 
 
 
 
2.14 Virus Quantification - TCID50 One Step Growth Curve  
2.14.1 Experimental Setup and Sample Preparation  
T24, TCCSUP, 5637 and RT-112 bladder cancer cell lines were plated at seeding density of 
4×105 cells/well in a 6-well plate and incubated overnight. Cells were treated with 100 µl 
Mitomycin C for an hour. Combination and CVA21-only wells were treated with their cell-line 
specific CVA21 IC50 (Table 2.3, Section 2.4.1) for 5 hours. After 5 hours, cell supernatant was 
discarded and replaced with fresh media. After 24, 48 and 72 hours supernatants were 
collected for extracellular virus quantification. 
2.14.2 Determination of the CVA21 replication using SKMEL-28 as a host cell line  
SK-MEL-28 human melanoma cells were plated at a seeding density of 1×104 cells/well in a 
96-well plate. 1:10 dilutions of the intracellular and extracellular virus sample was made in 
Figure 2.4 Basic principle behind luciferase based ATP quantification. 
Extracellular ATP is measured by the luciferin-luciferase bioluminescence reaction. Firefly luciferase is 
oxidized to oxyluciferin in the presence of ATP and oxygen, resulting in the generation of l ight. The amount 
of luminescence is proportional to the quantity of ATP production.  
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working media up to a 1×10-14 dilution.  SK-MEL-28 cells were treated with 100 µl of each virus 
dilution, or with working media for a non-infected control.  After 72 hours, wells were marked 
positive if cytopathic effect (CPE) was observed using a light microscope.  The number of 
positive and negative wells was recorded for each dilution and used to calculate the CVA21 
titre (TCID50/ml) in each sample, according to the Spearman and Karber method (Hierholzer, 
1996).  The algorithm used for TCID50/ml calculation (Ramakrishnan, 2016): 
𝑙𝑜𝑔10 50% 𝑒𝑛𝑑 𝑝𝑜𝑖𝑛𝑡 𝑑𝑖𝑙𝑢𝑡𝑖𝑜𝑛 =  − (𝑥0 −  𝑑/2 +  𝑑 ∑ 𝑟𝑖/𝑛𝑖) 
𝑥0 =  log10 of the reciprocal of the highest dilution (lowest concentration) at which all wells 
are positive/all cells viable. 
𝑑 =  log10 of dilution factor. 
𝑛𝑖 =  no. of replicates used in each individual dilution. 
𝑟𝑖 = no. of positive wells. 
 
2.15 Molecular Techniques 
2.15.1 RNA extraction 
Total RNA was extracted from cell lines using the RNeasy® Plus Mini Kit (Qiagen, UK), 
according to the manufacturer’s instructions.  In summary, cells were lysed and homogenised 
using β-mercaptoethanol (Sigma, UK) diluted 1:100 in Buffer RLT Plus for 5 minutes at room 
temperature.  The lysate was then passed through a genomic DNA (gDNA) eliminator spin and 
70 % ethanol (Fisher Scientific, UK) was added to provide appropriate binding conditions for 
the RNA, before transferring the sample to an RNeasy spin column.  Contaminants were 
washed away using specific buffers, leaving the RNA bound to the silica membrane of the 
column.  The RNA was eluted with 14 µl RNase-free water and the concentration (ng/µL) was 
analysed using the Nanodrop® ND-1000 Spectrophotometer (Labtech International, UK).  RNA 
samples were used immediately for cDNA synthesis or stored at -80°C. 
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2.15.2 Complementary DNA (cDNA) synthesis 
For cDNA synthesis the Cloned AMV First-Strand cDNA Synthesis Kit (Life Technologies) was 
used according to the manufacturer’s instructions. For each reaction 1000 ng of cDNA was 
synthesised. 10 µl of the master mix (Table 2.7) was added to each sample to give a total 
reaction volume of 20 µl. The reaction tubes were transferred to a pre-heated Veriti 96-well 
Thermal Cycler (Applied Biosystems, UK) at 50°C for 45 minutes and the reaction was 
terminated by incubating at 80°C for 10 minutes.  Assuming the cDNA synthesis reaction was 
100 % efficient, 1000 ng of cDNA was made in 20 µl volume. Therefore, 50 ng/µl of cDNA was 
made which was further diluted in RNase free water to give 5 ng/µl of cDNA. Samples were 
stored at -20°C. 
 
 
 
 
 
 
2.15.3 Real-Time/Conventional One –Step Polymerase Chain Reaction (PCR) 
The SuperScript® III One-Step RT-PCR System with Platinum® Taq High Fidelity (Invitrogen) 
was also used for one step cDNA synthesis and PCR reaction. The combination of SuperScript® 
III Reverse Transcriptase and Platinum® Taq DNA Polymerase provided better PCR yield 
making longer DNA templates easy to amplify. All the primers were designed using the 
Primer-BLAST primer designing tool (https://www.ncbi.nlm.nih.gov/tools/primer-blast, 
accessed on 5 May 2017).  A master mix consisting of 2× reaction mix, 10 µM of sense and 
anti-sense primers (Table 2.8), 1000 ng of template RNA and superscript™ III RT/Platinum® 
cDNA Synthesis 
4µl 5× cDNA Synthesis Buffer 
1µl 0.1 M DTT 
2 µl 10mM dNTP Mix 
1 µl Oligo (dT)20 (50µM) 
1 µl RNaseOUT™ (40U/µL) 
1 µl Cloned AMV RT (15U/µL) 
Table 2.7 cDNA synthesis master mix.  
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Taq was added. The total volume was made up 50 µl with RNase free water and reaction tubes 
were placed in the thermal cycler. The cycler conditions were 55°C for 30 minutes to denature 
the RNA, disrupt the secondary structure and start cDNA synthesis followed by 40 cycles at 
94°C for 15 seconds (denature) , 60-65°C for 30 seconds (anneal) and 68°C for 2 minutes 
(extend). The final extension step of the reaction was at 68°C for 5 minutes. Samples were 
stored at -20°C. This kit was used for PCR products that were sequenced at Cambridge 
University, Biochemistry Department. Some PCR products were further purified (Section 
2.15.4) and sequenced. Sequenced data was received via email and sequence alignment was 
performed using MEGA6, BioEdit Sequence Alignment Editor and DNA Baser- Base Assembler 
softwares. 
 
2.15.4 PCR Purification 
The QIAquick® PCR Purification Kit (Qiagen) was used according to the manufacturer’s  
instructions. Buffer PB was added to facilitate DNA binding to the column and centrifuged at 
13000 rpm for 30 seconds. The QIAquick column was washed with buffer PE, centrifuged and 
DNA was eluted by adding 50 µl of Buffer EB to the column. The column was centrifuged and 
eluted DNA was collected. The quality and quantity of DNA was measured using the Nanodrop 
Spectrophotometer ND1000 .The purified PCR product was sequenced by Sanger sequencing 
at Cambridge University, Biochemistry Department. 
Gene NCBI Reference  Forward Primer Reverse Primer 
ICAM-1 (PCR)  
NM_000201.2 
TTCCGGAGGGGAAGGCGCGAG CTCCTTCCTCTTGGCTTAGTC 
 
ICAM-1 (sequencing) 
GCCAATTTCTCGTGCCGC CCAATGTGCCAGGATTGG 
- GTGCTGCATGTCACCAGC 
CCGCACTCCTGGTCCTGC CCCAACAACTTGGGCTGG 
Table 2.8 The forward and reverse ICAM-1 primers used for PCR reaction and sent for sequencing of the 
ICAM-1 gene. 
 
The ICAM-1 gene consists of 3249 base pairs, it was not possible to sequence the whole gene using one pair of 
primers. Therefore, multiple primers had to be designed to sequence the whole ICAM-1 gene.  
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2.15.5 Quantitative Polymerase Chain Reaction (qPCR)  
For qPCR, the SYBR® Green JumpStart™ Taq ReadyMix™ (Sigma) kit was used and reaction 
was performed using the Stratagene Mx3005P qPCR machine (Agilent Technologies). SYBR 
green is a fluorescent dye that binds to DNA double strand and the amount of fluorescence is 
proportional to the DNA amplification. A PCR component master mix was made with 12.5 µl 
of SYBR Green Jumpstart Taq Ready Mix, 0.25 µl of ROX reference dye, 2 µl cDNA, 5.25 µl of 
RNase free water and 5 µl of 10 µM sense and anti-sense primers were added to give a total 
reaction volume of 25 µl PCR reaction per sample (Table 2.9). Beta Actin (β-actin) 
housekeeping gene was used for each sample. Samples were added to a 96-well PCR plate 
which was centrifuged for 1 minute at 2000 rpm to remove any bubbles. The plate was placed 
in the cycler with conditions of 95°C for 10 minutes (1 cycle) and 40 cycles at 95°C for 30 
seconds, 60°C for 1 minute and 72°C for 1 minute.  
The cycle threshold (Ct) values are defined as the number of cycles needed by the fluorescent 
signal to cross the background. The Ct values for each sample were calculated by the MxPro 
software (Agilent Technologies). A dissociation melting curve was also generated by the 
software which displayed a single peak for each sample.  
 
 
 
2.16 Cell Sorting 
The KU19-19 bladder cancer cell-line displayed a dual ICAM-1 population which was 
separated into ICAM-1 positive and negative populations using anti-PE Microbeads (Miltenyi 
Biotech). The principle behind this process is separation of cells with a surface marker probed 
Gene Forward Primer Reverse Primer 
Β-Actin ATGTACCCTGGCATTGCCG GACTCGTCATACTCCTGCTTG 
ICAM-1 CCATCTACAGCTTTCCGGCG TCAGCGTCACCTTGGCTCTA 
Table 2.9 Forward and reverse ICAM-1 and β-Actin primers used for qPCR reaction. 
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with a PE labelled antibody, in this case, ICAM-1 antibody (BD). The antibody labelled cells are 
loaded on a MACS® column which retains the labelled cells (LS column magnetic separation) 
and the unlabelled cells are passed in the flow through. The labelled cells can be collected 
from the LS column and this is known as positive selection. The unlabelled cells were passed 
through an LD column to make sure only a pure unlabelled population of cells flows through 
and this is known as negative selection, Figure 2.5 shows the workflow.  
For bead separation, five 175 cm3 flasks of confluent KU19-19 cells were prepared and cells 
were dissociated with accutase. Cells were centrifuged and counted.  MACs Buffer and Anti -
PE Micro beads (Miltenyi Biotec) were added to the cell pellet and incubated for 15 minutes  
at 2-8°C. Cells were washed with MACS buffer and centrifuged at 300×g for 10 minutes. The 
cell pellet was resuspended in MACs buffer and pipetted onto LS columns for positive 
selection and KU19-19 ICAM-1 positive cells were collected from the column. The flow-
through from the LS columns (containing ICAM-1 negative cells) was collected and run 
through an LD depletion column for negative selection. 
Whole, positive and negative ICAM-1 KU19-19 populations were stained for ICAM-1 and 
analysed using flow cytometry. Once the population purity was confirmed the unsorted, 
ICAM-1 positive and negative KU19-19 cell populations were plated in 96-well plates and 
incubated overnight. The cells were treated with 0.50 µg/ml of Mitomycin C alone, CVA21 
MOI of 25 alone and in combination. Cell viability analysis by MTS and ICAM-1 quantification 
assays using flow cytometry were performed.  
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2.17 Animal work 
2.17.1 Animals and their welfare  
C57BL/6 inbred male and female mice, 41 to 49 weeks old were obtained from Envigo. All 
mice were habituated for a week in the animal facility at the University of Surrey as per the 
Home Office regulations. Four mice were housed per cage which was maintained at room 
temperature (20-24°C) and 55 % +/- 10 % humidity with a supply of food and autoclaved 
water. All the in vivo experiments performed for this were approved by UK Home Office and 
University of Surrey Animal Welfare and Ethical Review Body (AWERB). Animals were checked 
Figure 2.5 Work-flow of PE microbead assay used for KU19-19 cell population separation. 
Whole KU19-19 cell  population was added to the LS MACs ® separation column and ICAM-1 negative KU19-
19 cell  population was collected from the flow through. KU19-19 ICAM-1 positive cells labelled with PE 
antibody retained in the LS columns were col lected. In order to further purify the KU19-19 ICAM-1 negative 
population the cells were run through an LD depletion column which retained any leftover ICAM-1 positive 
cells and the ICAM-1 negative pure population was collected through the flow through.  
KU19-19 whole cell population was labelled with PE ICAM-1 antibody 
and Anti-PE MicroBeads. 
Magnetically labelled PE ICAM-1 positive cells were retained in the 
column and flow through of ICAM-1 negative cells was collected. 
Flow through passed through an LD column and the PE unlabelled 
ICAM-1 negative fraction was collected. 
Positive Selection 
Depletion 
105 
 
daily by the experimenter and animal welfare team for visible signs of pain, using the mouse 
grimace scale which is a coding system for detection of pain by visible facial expressions 
(Langford et al, 2010). The tumours on mouse flank were measured using vernier callipers 
according to the animal welfare regulations stated by P. Workman et al. (Workman et al, 
2010). All animals were euthanised by schedule 1, administration of carbon dioxide followed 
by confirmation of death by cessation of circulation and breathing.   
2.17.2 Sample storage and downstream applications 
Tumours were harvested from the mice, half of it was placed in formalin and stored at room 
temperature for paraffin embedding and the other half was stored in RNALater (Sigma) at -
80°C for RNA extraction.  
2.17.3 Optimisation of murine bladder cancer model to determine therapeutic benefit of 
CVA21 oncolytic virotherapy 
 
A murine bladder cancer subcutaneous model was optimised to evaluate the therapeutic 
benefit of CVA21 therapy and study possible combinational approaches with immune -
modulatory agents.  
2.17.3.1 Optimisation of Mouse Gender 
MB49 wild-type and MB49 cell-line transfected with human ICAM-1 by Dr Guy Simpson were 
used in the in vivo experiments. MB49 urothelial carcinoma cell-line is derived from a C57BL/6 
male mice in which tumours developed after exposure of primary bladder epithelial cell 
explants to 7, 12-Dimethylbenz[a]anthracene (DMBA) for 24 hours (Summerhayes & Franks, 
1979). In order to determine the best model to use for MB49 cells, 6 female mice were 
subcutaneously injected with 1×106 MB49/ICAM-1 cells and tumour growth was monitored 
over 16 days or until the tumour volume reached close to the maximum limit of 1.5 cm 
assigned by the Home Office. 
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2.17.3.2 Optimisation of MB49 Wild-type and MB49/ICAM-1 cell lines 
The rate of tumour growth was optimised by varying the number of cells injected. In addition 
the MB49/ICAM-1 cell-line has a high risk of being rejected by the mouse immune system due 
to transfection of human ICAM-1. To confirm that the mouse immune system does not reject 
the transfected cell-line and to optimise the tumour growth, C57BL/6 mice were 
subcutaneously administered with MB49 wild type and ICAM-1 cells in two dilutions (Table 
2.10. 
Tumour Cells Cells/mouse Number of Mice 
MB49 wild type 1×106 6 
MB49 wild type 1×104 6 
MB49/ICAM-1 1×106 6 
MB49/ICAM-1 1×104 6 
 
2.17.3.3 Treatment with CVA21  
Once the model had been optimised, as explained in section 2.17.3.2, the animals were 
treated with 2 different concentrations of CVA21 oncolytic virus , 3 doses. The end point of 
the experiment was improved overall survival and reduction in tumour volume. A total of 24 
male mice were used for this experiment. Four groups consisting of 8 mice each treated with 
PBS control, 1.88×106 pfu/ml and 3.75×106 pfu/ml of CVA21 with three doses of virus every 2 
days (Figure 2.6).  CVA21 was diluted in PBS to give a total volume of 50 µl which was injected 
intra-tumourally per mouse.  
Table 2.10 Tumour cells injected to optimise tumour growth rate.  
Figure 2.6 Schematic diagram shows the injection days for MB49/ICAM-1 bladder cancer in vivo  
model treated with CVA21. 
Day -7 Day 0 Day 2 Day 5 
Subcutaneous injection of 7×105 MB49/ICAM-1 cells/mouse 
Intratumoural injection of CVA21 1.88×106 pfu/ml, CVA21 3.75×106 
pfu/ml and 100 µl of PBS in control mice. 
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2.17.4 Evaluation of tumour protection in the murine bladder cancer vaccination Model  
In order to evaluate the protection of mice from tumour and identify which immune cell 
subset is involved in tumour rejection after CVA21 treatment, we used the MB49 bladder 
cancer vaccination model. 
2.17.4.1 Production of MB49/ICAM-1 CVA21 treated cell lysates 
MB49/ICAM-1 cells were plated in a 6 well plate at 1×106 cells/well and incubated overnight. 
Cells were left untreated and treated with IC50 CVA21 MOI of 6.25. Following incubation for 
24 hours, cells were harvested and centrifuged. Cells were counted, untreated and CVA21 
treated cells were diluted to give equal seeding densities. The cell suspens e underwent 10 
seconds of sonication three times. The cell lysates were centrifuged and transferred to fresh 
eppendorfs and stored at -80°C. 
2.17.4.2 Tumour cells and tumour transplantation/injection 
In order to vaccinate mice, CVA21 treated MB49 cell lysates were generated which were used 
in a gold-standard vaccination model for studying immunogenicity of the therapy.  For the 
subcutaneous flank model, a 1 cm patch on the back of the mice was shaved and they were 
placed in a chamber connected to isoflurane for anaesthetization. Lysates were injected 
subcutaneously in the right flank of the animal on day -7 and after a week live MB49 cells 
were injected in the opposite flank. After each inject animals were laid back in their cages and 
observed till they recovered from anaesthesia. 15 minutes post-anaesthesia animals were 
checked again for obvious signs of pain or distress. 
2.17.4.3 Role of immune cell subsets in tumour protection 
To determine which immune cell subsets played a role in CVA21 mediated tumour rejection, 
MB49/ICAM-1 CVA21 treated and untreated cell lysates were subcutaneously injected in 
C57BL mice on day -7 (Figure 2.7). CD8, CD4, NK depleting antibodies were administered 
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intraperitoneally on day -2 followed by tumour challenge by MB49 wild-type cells on day 0. 
Another 5 doses of depleting antibodies was administered approximately every two days. 
Tumour measurements were performed and mice were euthanized if tumour size exceeded 
4.5 cm. Efficiency of the immune cell subset depletion was measured using flow cytometry. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Day -7 Day -2 Day 0 Day +2 Day +5 Day +7 Day +9 Day +12 
Subcutaneous MB49ICAM-1 Lysates -/+ CVA21 
IP.  CD8, CD4, NK depleting antibodies and isotype/PBS control 
Subcutaneous live MB49 Wildtype cells/tumour challenge 
Figure 2.7 Schematic diagram shows the injection days for MB49/ICAM-1 bladder cancer in vivo model treated 
with CVA21 followed by tumour rechallenge and immune cell depleting antibody administration. 
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2.18 Statistical analysis  
GraphPad Prism 6 software was used to analyse the data obtained and generate graphs. For 
all in vitro bladder cancer and pancreatic cancer cell-line experiments comparing different 
treatment groups (untreated, Mitomycin C, CVA21 combination) two-way analysis of variance 
(ANOVA) with Bonferroni correction was used. In in vivo studies comparing data from 
different groups Two-way ANOVA was also used. One-way ANOVA with Bonferroni correction 
was conducted for analysis of IFNβ ELISA and expression of ICD markers with heat inactivated 
virus treatment results. Results are displayed as (+/-) standard error bars obtained from the 
means of each group, a P value of P<0.05 was considered statistically significant. The following 
symbols are used in figures and diagrams to denote significance levels: *p<0.05, **p<0.01, 
***p<0.001 and ****p<0.0001. 
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CHAPTER 3: EVALUATION OF COXSACKIE A21 ONCOLYTIC VIRUS AS 
A THERAPEUTIC AGENT FOR BLADDER CANCER 
 
3.1 Introduction 
The world health organisation estimates that bladder cancer incidence and related deaths will 
nearly double in the near future (Ferlay et al, 2015; Sanli et al, 2017). Over the past 30 years 
only three drugs have been approved by the European Medicines Agency or FDA; BCG, 
Thiotepa and Valrubicin for the treatment of NMIBC and the lack of therapeutic effect 
provided by them highlights an unmet need for new therapies to tackle this disease (Kamat 
et al, 2016). The standard of care for NMIBC, particularly CIS is adjuvant BCG immunotherapy 
which delays cancer progression by 37 % compared to treatments without BCG therapy 
(Lamm et al, 2000; Sanli et al, 2017). However, 30-45 % of patients are deemed BCG failures 
as they are intolerant, refractory, unresponsive or relapse 6 months post-BCG therapy (Kamat 
et al, 2016). Adverse side-effects such as cystitis and flu-like symptoms result in 20 % of 
patients becoming intolerant to BCG instillations whilst in 50 % of the complete responders 
cancer recurs (Askeland et al, 2012; Fuge et al, 2015). An understanding of BCG mechanism 
of action and limitations is important for development of new and improved bladder cancer 
immunotherapies. The mode of action of BCG is not fully characterised but it is known that 
once mycobacterium is internalised by both normal and neoplastic bladder cells a cytokine 
storm is induced (Askeland et al, 2012). The detection of cytokines such as IL-2, IL-10, 1L-12, 
etc. and TNFα, GM-CSF and IFN γ in the urine of BCG treated patients is evidence of a robust 
immune response generation (Askeland et al, 2012; de Reijke et al, 1996; Redelman-Sidi et al, 
2014). BCG antigens are presented by APC which stimulates CD4+ T and cytotoxic CD8+ T cells, 
generating a robust immune response (Askeland et al, 2012; Saint et al, 2002) . This 
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immunotherapy results in direct killing of tumour cells  and production of soluble molecules 
such as TRAIL (Luo et al, 2011; Redelman-Sidi et al, 2014). It has been shown that a Th1 
response dominates and is associated with BCG therapeutic benefit where a Th2 response (IL-
10) corresponds with failure of BCG (Fuge et al, 2015; Luo et al, 2011). Therefore, Th1 inducing 
cytokines have been administered to increase BCG treatment efficacy such as IL-2, IL-12, IFN 
α and GM-CSF (Fuge et al, 2015; Luo et al, 2011). The results from cytokine monotherapy have 
not shown great therapeutic benefit however, combination with BCG has shown 
enhancement in Th1 response (Luo et al, 2011). Also, inhibitory regulatory interactions such 
as expression of PD-L1 immune checkpoint ligand on high grade bladder cancer appears to 
prevent recognition and destruction of cancer cells by T cells (Fuge et al, 2015). Studies are 
being performed to identify the therapeutic benefit of inhibiting PD-L1 and PD-1 interaction 
in bladder cancer (Fuge et al, 2015). However, given the immune-mediated beneficial effect 
of BCG, using immunotherapy for NMIBC treatment is a proven approach with the aim to 
overcome some of the problems associated with BCG therapy.  
Apart from BCG immunotherapy already displaying success in a small percentage of NMIBC 
patients, the isolated multiple epithelium layers of bladder make the anatomy of the bladder 
ideally suited for cancer-targeted therapy as it limits systemic cytotoxic effects and its 
enclosed hollow structure ensures maximum exposure to treatment agents. The intravesical 
route of delivery and ease of monitoring by cystoscopy and biopsy make it an excellent model 
for studying the mechanism and delivery of anti-cancer agents (Fuge et al, 2015; Potts et al, 
2012). Due to the clinical burden and high toxicity, bladder cancer treatment is expensive. 
Bladder cancer has the highest lifetime cost per patient amongst all cancers due to a high rate 
of recurrence, longer overall patient survival and requirement for life long cystoscopic 
surveillance (Barocas et al, 2012; Svatek et al, 2014). New treatments with better efficacy, 
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low toxicity and less side effects are required so they can provide better quality of li fe, low 
cancer progression rate, reduce the risk of recurrence and improved overall survival. 
Oncolytic viruses are biological agents which can easily be delivered to the bladder by a 
catheter and to date have shown promising therapeutic benefit clinically in melanoma and 
head and neck cancers by intratumoural injections (Goldufsky et al, 2013). Various oncolytic 
viruses such as HSV, adenovirus, reovirus and vaccinia virus have already shown therapeutic 
benefits when used pre-clinically and clinically to treat bladder cancer (Delwar et al, 2016; 
Potts et al, 2012). Oncolytic viruses target tumours by two main mechanisms, firstly by direct 
cytolytic effect and secondly by induction of a systemic anti-cancer immune response 
(Farkona et al, 2016). Various hallmarks of cancers explained by Weinberg (Hanahan & 
Weinberg, 2000; Hanahan & Weinberg, 2011) such as defective apoptosis signalling 
pathways, uncontrolled proliferation and inactive growth suppression are utilised by 
oncolytic viruses for selective replication in cancer cells (Farkona et al, 2016). Oncolytic 
viruses such as herpes simplex and adenovirus can be genetically modified to insert 
promotors to limit their infection and replication to cancer cells or naturally occuring viruses 
such as measles virus target cancer cells due to an overexpressed viral entry receptor (Choi et 
al, 2016). 
Another naturally occurring virus that exploits overexpressed membrane receptors on cancer 
cells for entry is CVA21. CVA21 is a picornavirus, 28 nm in size, non-enveloped and consisting 
of a single-stranded positive RNA genome enclosed in an icosahedral capsid (Bradley et al, 
2014; Xiao et al, 2005).  CVA21 provides localised anti-cancer therapy as it targets ICAM-1 and 
DAF membrane receptors for cell entry and both membrane receptors are frequently 
overexpressed in cancer cells as compared to normal cells (Bradley et al, 2014). For 
internalisation of CVA21 into a cancer cell, viral capsid conformational change is essential 
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which only occurs when CVA21 attaches to the ICAM-1 receptor, however, DAF cannot induce 
capsid structural changes (Shafren et al, 1997b). Therefore, the expression of ICAM-1 leads to 
CVA21 lytic infection whereas DAF acts as co-facilitator by accumulating CVA21 on the cell 
surface (Shafren et al, 1997b). ICAM-1 is overexpressed in breast cancer, prostate cancer, 
melanoma, multiple myeloma and lung cancer (Figure 1.20), and CVA21 oncolytic 
immunotherapy has already shown tumour suppressive benefits in these malignancies 
(Bradley et al, 2014). Bladder cancer is an ideal model for CVA21 oncolytic immunotherapy as 
bladder cancer cells display high to intermediate ICAM-1 cytoplasmic and membrane 
expression which can be exploited by CVA21 for entry (Figure 1.20). As CVA21 is a naturally 
occurring virus it induces only mild side effects such as flu-like symptoms whilst its small size 
enables it to spread in the tumour microenvironment. (https://www.viralytics.com/our-
pipeline/cavatak/cavataktm/, assessed on 7 Dec 17). 
Our approach to studying CVA21 as an oncolytic immunotherapy for bladder cancer   
consisted firstly, of determining susceptibility of ten bladder carcinoma cell -lines to varying 
concentrations of CVA21. It was further evaluated whether sensitivity to CVA21-induced 
death correlated to the expression of the viral receptor, ICAM-1 on the cancer cell membrane. 
Whilst upregulation of ICAM-1 on endothelial cells using cytotoxic agents such as Cisplatin 
and/or 5-Fluorouracil has been previously demonstrated (Gelbard et al, 2006; Yu et al, 2008), 
this study tested the effects of a commonly used chemotherapeutic agent for bladder cancer, 
Mitomycin C,  on ICAM-1 expression by bladder cancer cell lines. We hypothesized that pre-
treatment with a non-cytotoxic low dose of Mitomycin C would increase ICAM-1 expression 
on bladder cancer cell-lines, facilitating increased viral entry, leading to enhanced cancer-
specific cytolytic damage. 
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As an immunotherapy, CVA21 relies on the activation of a cancer specific innate and adaptive 
immune response. The immunogenicity of a therapy is characterised by the release of 
immunogenic cell death markers, such as the ‘eat me’ signal calreticulin, the ‘find me’ 
molecule extracellular ATP and the cytokine mediator HMGB1. All these signals stimulate the 
maturation of APC which present tumour antigens to T cells generating an adaptive anti -
tumour immune response. These DAMPS are thought to be the optimal way to trigger 
activation of the immune system against cancer, ultimately resulting in long-term success of 
virotherapy (Kaufman et al, 2015). The second part of this chapter investigated in detail the 
mode of cell death induced by CVA21 in bladder cancer cell-lines and whether this was 
immunogenic.  As the gold-standard approach to evaluate the ability of a specific stimulus to 
cause bona fide ICD relies on vaccination assays, a murine cancer model was developed using 
the mouse urothelial carcinoma cell line MB49 transfected with human ICAM-1. This model 
was setup in collaboration with Dr Guy Simpson. 
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3.2 Objectives 
The objectives of this chapter were to evaluate CVA21 as an oncolytic virus for the treatment 
of human bladder cancer by determining the susceptibility of bladder cancer cell lines to 
CVA21, the ability to enhance oncolysis by modulating expression of ICAM-1 by non-cytotoxic, 
low dose of Mitomycin C treatment and to trigger immunogenic cell death in treated cell lines.  
The objectives were addressed as follows:  
 CellTiter 96® Aqueous One Solution Cell Proliferation Assay (MTS) was used to determine 
viability post virus treatment in ten bladder cancer cell-lines and virus presence was 
confirmed by immunofluorescent staining and confocal analysis. 
 The cell surface density of viral entry receptors was quantified using flow cytometry with 
QuantiBRITE PE beads (BD Bioscience). 
 The effect of Mitomycin C on ICAM-1 membrane receptor expression was analysed by 
flow cytometry. TCID50 virus quantification assay was used to determine infectious titer 
of CVA21 in cells pre-treated with Mitomycin C.  
 To determine the mode of cell death induced by CVA21 treatment, three bladder cancer 
cell-lines susceptible to virus induced death were analysed for markers indicative of 
apoptosis or necrosis (Annexin V detection (ThermoFisher), LIVE/DEAD Fixable Violet 
Dead stain (ThermoFisher), Caspase-Glo® 3/7 assay (Promega), Caspase Inhibitor Z-VAD-
FMK (Promega), Necrostatin-1 (Sigma) and western blotting for whole/cleaved PARP, RIP1 
and RIP3 expression). 
 To determine the immunogenic potential of CVA21 treatment, calreticulin, HSP70, FAS, 
CD80 and MHC Class II expression were analysed by flow cytometry. HMGB1 release was 
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determined by ELISA (IBL International) and Cell-Titer Glo® Luminescent assay (Promega) 
was performed for extracellular ATP quantification. 
 Immunogenicity of MB49 ICAM-1 cells treated with CVA21 was confirmed in vivo using a 
syngeneic murine model. 
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3.3 Results 
3.3.1 Susceptibility of Bladder Cancer cell-lines to CVA21 induced death  
In order to assess CVA21 as a treatment for bladder cancer, a panel of 10 bladder cancer cell-
lines were treated with CVA21. Bladder cancer cell-lines VM-CUB-2, 253J, HCV29, T24, J82, 
TCCSUP, 5637, KU19-19, VM-CUB 1 and RT-112 were treated with CVA21 at a MOI between 
0 and 50. CellTiter 96® Aqueous One Solution Cell Proliferation Assay (MTS) was used to 
quantify percentage survival of cells 72 hours post virus treatment (Section 2.5). 
CVA21 induced death varied amongst the panel of 10 bladder cancer cell-lines (Figure 3.1). 
Six of the ten cell-lines showed reduction in cell viability with increasing CVA21 MOI. At the 
highest CVA21 MOI of 50, less than 30 % of cells survived in the T24, TCCSUP and 5637 cell-
lines whereas no cells survived in VM-CUB-2, 253J and HCV29 cell-lines when treated with 
CVA21 at a MOI of 0.78. In contrast, KU19-19 and J82 cells had approximately 80 % viable cells 
when treated with CVA21 MOI of 50. RT-112 and VM-CUB 1 were completely resistant to virus 
induced death as 100 % of cells survived at CVA21 MOI of 50.  The IC50 for VM-CUB-2, 253J, 
HCV29, T24, TCCSUP and 5637 bladder cell-lines was obtained using the CalcuSyn software 
(Table 2.3).  
To confirm virus infection and localisation inside cells, immunofluorescent staining for viral 
protein by confocal analysis was done (Figure 3.1). Cells were pre-treated with CVA21 at IC50 
values for cell-lines sensitive to CVA21 induced death. Since no IC50 was obtained for J82, 
KU19-19, RT-112 and VM-CUB 1, a MOI of 25 was used. After 24 hours cells were stained for 
the presence of viral capsid protein 1 (green), WGA membrane stain (red), TO-PR0-3 nuclear 
stain (blue), fixed and fluorescence was detected using the confocal microscope (Section 
2.7.1). CVA21 was found to be localised in the cell cytoplasm of VM-CUB-2, 253J, HCV29, T24, 
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J82, TCCSUP, 5637, KU19-19 cell-lines. No viral protein was present in VM-CUB 1 and RT-112. 
Cell-lines resistant to CVA21 induced death, except KU19-19, had no positive viral staining.  
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Figure 3.1 CVA21 treatment induced death in six out of ten bladder cancer cell-lines.  
 
The percentage cell survival of bladder cancer cell-lines treated with increasing doses of CVA21 was determined by MTS assay 
72 hours post virus infection. Six of the ten bladder cancer cell -l ines were sensitive to CVA21 induced death and showed 
reduction in cell  viability with increasing CVA21 MOI. KU19-19, VM-CUB 1, J82 and RT-112 bladder cancer cell -l ines were 
resistant to CVA21 induced death with increasing concentration of virus. Graphs represent pooled data from two independent 
experiments.  
For immunofluorescent viral staining, bladder cancer cells were treated with CVA21 for 24 hours, at CVA21 IC 50 value for VM-
CUB-2, 253J, HCV29, T24, TCCSUP, 5637 and CVA21 MOI 25 for KU19 -19, RT-112 and VM-CUB 1.CVA21 (green-Alexa Fluor 
488) was localised around the nucleus (Blue-TOPRO®-3), cell  membrane shown in red (WGA-Alexa Fluor® 594). CVA21 
localisation in the cell  cytoplasm was seen in VM-CUB-2, 253J, HCV29, T24, TCCSUP, 5637 and KU19-19 cells, no virus was 
seen inside VM-CUB 1 and RT-112 cells. The cell -l ines resistant to virus induced cytotoxicity lacked viral positivity. 
Magnification × 40. 
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3.3.1.1 Evaluation of cell viability after heat inactivated virus treatment 
As an additional control T24 and 5637 bladder cancer cell-lines were treated with heat 
inactivated virus (Section 2.5) to demonstrate that only live virus induced cell death. T24 and 
5637 cells were plated and treated with live and heat inactivated virus MOI 0 to 50. After 72 
hours incubation with virus, cell viability assay (MTS) was performed. Both T24 and 5637 
bladder cancer cell-lines were sensitive to live CVA21 induced death and displayed reduction 
in cell viability with increasing CVA21 concentration (Figure 3.2). Heat inactivated virus 
showed no effect, approximately 100 % cells survived even with increasing heat inactivated 
CVA21 concentration.  
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Figure 3.2 Heat Inactivated CVA21 had no effect on cell viability of bladder cancer cell-lines. 
 
As an additional control to show that reduction in cell  viability was due to l ive CVA21, T24 and 5637 bladder 
cancer cell -l ines were treated with heat inactivated CVA21. T24 and 5637 cells were treated with increasing 
concentration of l ive and heat inactivated CVA21 at MOI 0 to 50. MTS cell viability assay was performed 72 hours 
after CVA21 treatment. Live CVA21 displayed reduction in cell  viability with increasing CVA21 concentration in 
both T24 and 5637 cell -l ines whilst, heat inactivated virus failed to show any effect. Graphs represent data from 
one experiment. 
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3.3.2 Absence of Interferon β expression in all bladder cancer cell-lines, except J82 post 
CVA21 treatment  
 
The presence of virus inside cells in the absence of virus induced cell death could indicate the 
activity of an antiviral immune response which shuts down virus replication machinery. The 
J82 cell-line was resistant to virus induced death however viral capsid protein was detected 
in the cell cytoplasm (Figure 3.1). Therefore, the production of the antiviral cytokine, IFNβ 
was investigated by sandwich ELISA (Section 2.10.2). 
Bladder cancer cells and PBMC were pre-treated with CVA21 for 24 hours and supernatant 
was collected for IFNβ ELISA assay. PBMC was used as positive control All of the untreated 
cell-lines produced a base-line level of IFNβ and showed no significant increase in IFNβ post 
CVA21 treatment, with the exception of J82 (Figure 3.3). J82 and PBMC showed significant 
increase in IFNβ expression after CVA21 treatment. Stimulation of IFNβ production could 
explain why J82 was resistant to CVA21 induced death despite the presence of CVA21 capsid 
proteins in the cell. 
Figure 3.3 Interferon Beta anti-viral response was absent in all bladder cancer cell-lines except J82. 
 
All  bladder cancer cell -l ines were treated with CVA21 for 24 hours and supernatant was harvested. The 
expression of the IFNβ antiviral cytokine was determined by sandwich ELISA.  All  cell -l ines displayed a 
lack of IFNβ secretion after CVA21 treatment except J82 which showed a significant increase in IFNβ 
post CVA21 treatment. PBMC was used as a positive control and showed a significant increase in IFNβ 
production. Graphs represent pooled data from two independent experiments and one-way ANOVA 
statistical analysis was performed *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. 
* 
**
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3.3.3 Variable expression of viral entry receptors on bladder cancer cell-lines 
Previously Darren Shafren’s group highlighted the importance of ICAM-1 and DAF membrane 
receptors for CVA21 endocytosis (Shafren et al, 1997b). In order to investigate the role of 
ICAM-1  and DAF in CVA21 induced cytotoxicity in bladder cancer cell-lines, the cell surface 
density of ICAM-1 and DAF was quantified using QuantiBRITE™ PE beads and analysed by flow 
cytometry (Section 2.6.1). VM-CUB-2, 253J and HCV29 showed the highest expression of 
ICAM-1 with above 500,000 ICAM-1 molecules bound per cell (Figure 3.4 (A, B)). T24, J82, and 
TCCSUP showed medium expression of ICAM-1 at 50,000 ICAM-1 molecules bound per cell. 
The lowest expression of ICAM-1 was seen in 5637, KU19-19, VM-CUB 1 and RT-112 cell-lines. 
A correlation between ICAM-1 expression levels and susceptibility to virus induced death was 
observed, with cell-lines displaying the highest expression of ICAM-1 most sensitive to virus 
induced death (Figure 3.4 (C)). In contrast whilst DAF was highly expressed (>500,000 
molecules bound per cell) on VM-CUB-2, HCV29, T24 and J82 bladder cancer cell-lines no 
correlation to CVA21 induced cytotoxicity was observed.  
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C 
Figure 3.4 Bladder cancer cell-lines display differing levels of ICAM-1 and DAF membrane receptor expression. 
 
(A) PE labelled anti -ICAM-1 and anti-DAF antibodies were used with QuantiBRITE™ PE beads to quantify the ICAM-1 and 
DAF molecules bound per cell  on all  bladder cancer cell-lines. VM-CUB-1, 253J and HCV29 cell -l ines displayed the highest 
ICAM-1 expression, followed by intermediate ICAM-1 expression on T24, J82, TCCSUP and low ICAM-1 expression on 
KU19-19, VM-CUB 1 and RT-112. DAF was highly expressed on all  cell  l ines. Graphs represent pooled data from two 
independent experiments. 
(B) The mean fluorescence intensity of receptors (grey peak) is displayed as histograms against their unstained negative 
control (black peak).  
(C) Correlation between ICAM-1 expression level and percentage cell viability was compared for CVA21 MOI 0.75 (low), 
6.25 (medium) and 50 (high). Cell-l ines with the highest ICAM-1 expression were most sensitive to CVA21 induced death. 
  
 
 
126 
 
3.3.3.1 ICAM-1 positive population displays CVA21 induced sensitivity after KU19-19 
ICAM-1 whole population sorting 
 
KU19-19 cells were resistant to CVA21 induced death but virus protein was detected by 
immunofluorescent staining and confocal analysis inside KU19-19 cells (Figure 3.1). The anti-
viral IFNβ response was absent post CVA21 treatment in these cells (Figure 3.3) and the ICAM-
1 viral entry receptor was expressed on the cells (Figure 3.4). Flow cytometric analysis of 
ICAM-1 expression on KU19-19 cells showed a double peak signifying an ICAM-1 positive and 
negative population (Figure 3.4 (B)).  To prove the importance of ICAM-1 receptor for viral 
entry the KU19-19 ICAM-1 whole population was sorted into ICAM-1 positive and ICAM-1 
negative cells by PE bead sorting (Section 2.16, Figure 3.5). The ICAM-1 unsorted, positive and 
negative cell populations were treated with a range of CVA21 MOIs from 0-50, and cell 
viability was quantified using MTS assay and Annexin V staining. 
KU19-19 ICAM-1 positive cells were sensitive to CVA21 induced death whereas KU19-19 
ICAM-1 negative cells and the whole unsorted population were resistant to CVA21 induced 
death. These findings were confirmed by Annexin staining where approximately 70 % KU19-
19 ICAM-1 positive cells underwent apoptosis compared to < 10 % apoptotic KU19-19 ICAM-
1 negative cells (Figure 3.5 (C)). The KU19-19 whole cell population displayed some cytotoxic 
effect of CVA21 as 30 % cells succumbed to apoptosis as compared to approximately 5 % in 
the untreated control. These findings highlight the importance of ICAM-1 for viral entry in 
bladder cancer cells. 
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Figure 3.5 KU19-19 ICAM-1 positive population succumbed to CVA21 induced death compared to KU19-19 
ICAM-1 unsorted and negative populations. 
  
KU19-19 whole cell population was sorted into ICAM-1 positive and negative populations by PE bead sorting. 
Cells were treated with MOI 0 – 50 of CVA21 and cell  viability was quantified using MTS assay and Annexin V 
staining. Graphs represent data from one experiment. 
(A) Histograms display dual peak for ICAM-1 expression of unsorted KU19-19 cells signifying presence of two 
ICAM-1 populations (green box). Flow cytometry confirmed the selection of KU19 -19 ICAM-1 positive (blue box) 
and negative populations (purple box) following magnetic cell  sorting.  
(B) KU19-19 ICAM-1 positive cells were sensitive to CVA21 induced death as displayed by a reduction in the 
percentage cell  survival after incubation with CVA21 of 1.56-50 MOI. ICAM-1 whole population and ICAM-1 
negative population were resistant to virus induced death with approximately 100 % cell -survival.  
(C) KU19-19 ICAM-1 positive population displayed the highest percentage of cells undergoing apoptosis after 
CVA21 treatment followed by approximately 35 % apoptosis seen in the whole KU19 -19 cell  population and less 
than 10 % in the ICAM-1 negative population. 
 
 
0
.0
0
0
.7
5
1
.5
6
3
.1
2
6
.2
5
1
2
.5
0
2
5
.0
0
5
0
.0
0
0
2 0
4 0
6 0
8 0
1 0 0
1 2 0
1 4 0
K U 1 9 -1 9
C V A 2 1  M O I
P
e
r
c
e
n
ta
g
e
 S
u
r
v
iv
a
l 
(%
)
W h o le  P o p u la t io n
P o s itiv e  P o p u la tio n
N e g a tiv e  P o p u la tio n
A 
B 
W
h
o
le
 P
o
p
u
la
t i
o
n
P
o
s i
t i
v e
 P
o
p
u
la
t i
o
n
N
e g
a t
iv
e  
P
o
p
u
la
t i
o
n
0
1 0
2 0
3 0
4 0
5 0
6 0
7 0
8 0
9 0
1 0 0
T
o
ta
l 
P
e
rc
e
n
ta
g
e
 A
p
o
p
to
s
is
(%
)
U n tre a ted
C V A 2 1
C 
ICAM-1  ICAM-1  ICAM-1  
Whole population
  
Positive population
  
Negative population
  
128 
 
3.3.4 ICAM-1 membrane receptor upregulation after treatment with Mitomycin C 
Preliminary work done by the Pandha group showed radiation upregulates the expression of 
ICAM-1 cell surface receptor on bladder cancer cell-lines (GR Simpson, 2013). Radiation is not 
a common treatment for NMIBC. Therefore, the commonly used chemotherapy, Mitomycin 
C, was used to treat six bladder cancer cell lines to determine any effects on ICAM-1 receptor 
expression. T24, TCCSUP, 5637, KU19-19, VM-CUB 1 and RT-112 bladder cancer cell-lines 
were treated with 0-4 µg/ml Mitomycin C for an hour followed by incubation in growth media. 
Cells were harvested at 24, 48 and 72 hours, and expression of the ICAM-1 receptor was 
analysed by flow cytometry. An upregulation in expression of ICAM-1 was seen with 
increasing concentration of Mitomycin C over a period of 24, 48 and 72 hours (Figure 3.6). At 
low doses of Mitomycin C (up to 0.50 µg/ml) an increase in ICAM-1 expression was observed 
on all bladder cancer cell-lines, except TCCSUP. Doses of Mitomycin C of 1.00 µg/ml or higher, 
resulted in cell cytotoxicity in all cell lines tested (Figure 3.6).  Thus, there was a window of 
Mitomycin C concentration where ICAM-1 surface expression increased but minimal cell 
death was observed. Based on these results, a concentration of 0.50 µg/ml of Mitomycin C 
was selected for all subsequent experiments.  
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Figure 3.6 Upregulation of ICAM-1 receptor expression with increasing Mitomycin C concentration on bladder 
cancer cell-lines. 
 
Bladder cancer cell-l ines were treated with 0-4 µg/ml of Mitomycin C for an hour and cells were incubated for 24-
72 hours in media. Cells were harvested and incubated with ViViD live/dead followed by ICAM-1 receptor staining. 
ICAM-1 expression and percentage of viable cells were determined by flow cytometry. 
(A) T24, 5637, KU19-19, VM-CUB 1 bladder cancer cell -l ines showed an upregulation in expression of ICAM-1 
membrane with increasing concentration of Mitomycin C over time.  ICAM-1 was not upregulated in TCCSUP and 
minimal increase was seen in RT-112 cell-l ine after Mitomycin C treatment. (B) In all  bladder cancer cell -lines 
reduction in the number of viable cells was detected when cells were treated with 1.00 to 4.00 µg/ml of Mitomycin 
C. Data represents averaged results from two independent experiments  and two-way ANOVA statistical analysis was 
performed. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. 
A B 
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3.3.4.1 Mitomycin C does not facilitate CVA21- induced death in resistant cell-lines 
KU19-19, VM-CUB 1 and RT-112 are three bladder cancer cell-lines resistant to CVA21 induced 
death. We investigated whether Mitomycin C treatment could upregulate ICAM-1 expression 
on these cells and make them sensitive to virus-induced death. KU19-19, VM-CUB 1 and RT-
112 cell-lines were pre-treated with a low, non-cytotoxic dose of 0.50 µg/ml Mitomycin C for 
an hour. Mitomycin C was replaced by CVA21 and incubated for 72 hours. Cell viability was 
quantified with CVA21- alone and in combination with Mitomycin C.  
The KU19-19 cell-line showed enhanced reduction in percentage cell survival when treated 
with Mitomycin C in combination with CVA21 highlighting the importance of Mitomycin C 
induced ICAM-1 upregulation seen in Figure 3.6. Approximately 80 % of the KU19-19 cells 
survived with CVA21 alone at an MOI of 50, 60 % with Mitomycin C alone and only 40 % with 
combination treatment (Figure 3.7 (A)). VM-CUB 1 only showed a small increase in ICAM-1 
expression after Mitomycin C treatment (Figure 3.6) thus displayed approximately <10 % 
increase in CVA21 induced cytotoxicity with combination treatment. The RT-112 cell-line 
which showed no significant increase in ICAM-1 expression after Mitomycin C treatment also 
failed to display enhanced reduction in cell viability with CVA21 and Mitomycin C combination 
as no change in cell viability was reported (Figure 3.7 (A)). These results highlighted that an 
intermediate expression of ICAM-1 is required for enhanced reduction in cell viability 
followed by Mitomycin C pre-treatment combined with CVA21.  
To further demonstrate that a certain threshold of ICAM-1 is required in order to see 
enhanced reduction in cell survival with Mitomycin C, we treated KU19-19 unsorted, ICAM-1 
-positive and negative sorted populations with Mitomycin C. ICAM-1 expression was 
unchanged in all three KU19-19 ICAM-1 populations after Mitomycin C treatment (Figure 3.7 
(B)) and cells did not succumb to CVA21 induced death (Figure 3.7 (C)). These results reiterate 
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that a minimum level of ICAM-1 expression is required for CVA21 induced cytotoxicity and 
synergistic effect induced by Mitomycin C. 
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Figure 3.7 No change observed in cell viability of KU19-19 (unsorted population, ICAM-1 positive and 
negative populations), VM-CUB 1 and RT-112 cell-lines to virus induced death after Mitomycin C treatment. 
 
KU19-19, VM-CUB 1 and RT-112 cell-l ines were treated with Mitomycin C for an hour and incubated with virus  
alone or in combination for 72 hours.  Cell viability was measured using MTS assay. KU19-19 whole cell 
population was further sorted into ICAM-1 positive and negative populations which were treated with 
Mitomycin C -alone and in combination with CVA21.  ICAM-1 expression for each population post Mitomycin 
C treatment was quantified using flow cytometry and cell  viability was measured by MTS. Graphs represent 
pooled data from one experiment. 
(A) KU19-19 cell-l ine showed a slight reduction in percentage survival after combination treatment with 
approximately 30 % viable cells in combination treated cells compared to 80 % with virus alone, VM-CUB 1  
displayed about 10 % increase in cell  death with combination treatment as c ompared to CVA21 and Mitomycin 
C –alone. However, RT-112 cell -l ine showed no reduction in cell  viability with combination or single agent 
treatment. In all  three cell -l ines Mitomycin C alone induced 20-40 % cell death. (B) In all  three KU19-19 ICAM-
1 populations no increase in ICAM-1 was seen after Mitomycin C treatment. (C) KU19-19 unsorted and ICAM-
1 positive population displayed no enhanced reduction in viability with CVA21 and Mitomycin C combination 
nor did ICAM-1 negative cell-l ine become susceptible to virus induce death. This is possibly due to minimum 
level of ICAM-1 required for CVA21 entry.   
2 4  H o u r s 4 8  H o u r s 7 2  H o u r s  
0
2 0
4 0
6 0
IC A M -1  P o s it iv e  P o p u la tio n
2 4  H o u r s 4 8  H o u r s 7 2  H o u r s  
0
5
1 0
1 5
2 0
2 0
2 5
3 0
3 5
4 0
4 0
4 5
5 0
5 5
6 0
IC A M -1  N e g a t iv e  P o p u la t io n
U n tre a ted
M ito m y c in  C  (0 .5 0  u g /m l)
A 
B 
C 
0
.0
0
0
.7
5
1
.5
6
3
.1
2
6
.2
5
1
2
.5
0
2
5
.0
0
5
0
.0
0
0
2 0
4 0
6 0
8 0
1 0 0
1 2 0
1 4 0
IC A M -1  U n s o rte d  P o p u la t io n
C V A 2 1  M O I
P
e
r
c
e
n
t
a
g
e
 S
u
r
v
iv
a
l 
(
%
)
0
.0
0
0
.7
5
1
.5
6
3
.1
2
6
.2
5
1
2
.5
0
2
5
.0
0
5
0
.0
0
0
2 0
4 0
6 0
8 0
1 0 0
1 2 0
1 4 0
IC A M -1  P o s it iv e  P o p u la tio n
C V A 2 1  M O I
P
e
r
c
e
n
t
a
g
e
 S
u
r
v
iv
a
l 
(
%
)
0
.0
0
0
.7
5
1
.5
6
3
.1
2
6
.2
5
1
2
.5
0
2
5
.0
0
5
0
.0
0
0
2 0
4 0
6 0
8 0
1 0 0
1 2 0
1 4 0
IC A M -1  N e g a t iv e  P o p u la t io n
C V A 2 1  M O I
P
e
r
c
e
n
t
a
g
e
 S
u
r
v
iv
a
l 
(
%
)
V iru s  A lo n e
C o m b in a tio n
2 4  H o u r s 4 8  H o u r s 7 2  H o u r s  
0
5
1 0
1 5
2 0
3 0
4 0
5 0
6 0
IC A M -1  U n s o rte d  P o p u la t io n
M
F
I 
IC
A
M
-1
133 
 
3.3.4.2 Mitomycin C increased ICAM-1 expression on bladder cancer cell lines enhanced 
CVA21 replication 
 
To investigate whether Mitomycin C induced ICAM-1 expression resulted in enhanced CVA21 
replication, viral titers were measured by standard plaque assays on SKMEL-28 cell 
monolayers. T24, TCCSUP and 5637 bladder cancer cell-lines were treated with CVA21 alone 
and in combination with Mitomycin C for 24-72 hours, supernatant and cells were harvested. 
A TCID50 one step growth assay was performed (Section 2.14). The CVA21 resistant cell line 
RT-112 was used as a negative control. An increase in CVA21 replication was observed in T24 
and TCCSUP cell-lines at 72 hours after combination treatment but the 5637 cell-line failed to 
enhance viral replication post CVA21-alone or combination treatment (Figure 3.8). This result 
confirms that the increase in ICAM-1 expression by Mitomycin C pre-treatment enhances 
CVA21 uptake and subsequent replication in T24 and TCCSUP bladder cancer cell -lines. Whilst 
no change in CVA21 replication was observed in the RT-112 control cell-line.   
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3.3.5 Bladder cancer cell-lines undergo apoptosis with CVA21 treatment  
Having defined the factors needed for bladder cancer cell lines to be sensitive to CVA21 
infection, the exact mode of death was then investigated. The second part of this chapter 
Figure 3.8 Virus replication increased in T24 and TCCSUP bladder cancer cell-lines after treatment with 
Mitomycin C. 
 
T24, TCCSUP, 5637 and RT-112 bladder cancer cell -l ines were incubated with Mitomycin C for an hour followed 
by incubation with CVA21 for 24 to 72 hours. The CVA21 resistant cell  l ine RT-112 was used as a negative 
control. An increase in CVA21 replication was seen in T24 and TCCSUP cell -l ines 48 and 72 hours after CVA21 
and Mitomycin C combination treatment as compared to CVA21-alone. The 5637 cell -l ine displayed no increase 
in CVA21 replication with combination treatment. Low background CVA21 TCID50/ml value for RT-112 indicated 
absence of background virus binding. Graphs represent pooled data from two independent experiments and 
two-way ANOVA statistical analysis was performed. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. 
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focused on the mode of cell death induced by CVA21 in bladder cancer cell-lines and whether 
the combination of CVA21 with Mitomycin C enhanced that death.  
To determine the cell death pathways induced as a result of CVA21 treatment, bladder cancer 
cell-lines were left untreated or treated with Mitomycin C, CVA21 alone or in combination for 
24, 48 and 72 hours. At 24-72 hour time-points the cells were stained with Annexin V, and the 
Caspase-Glo® 3/7 Assay was performed to measure caspase-3 and 7 activity. Furthermore, to 
confirm the involvement of particular cell death pathways, cell death inhibitors such as 
Necrostatin-1 and Z-VAD FMK were used. Further confirmation of mode of cell death was 
determined by western blotting for the presence of apoptosis markers and absence of 
necroptosis markers.  
3.3.5.1 Enhancement in apoptosis over-time with CVA21 detected by Annexin V staining  
T24, TCCSUP and 5637 cells were pre-treated with Mitomycin C for an hour and incubated 
with CVA21 for 24, 48 and 72 hours. At each time-point cells were harvested and stained for 
Annexin V and analysed by flow cytometry (Section 2.6.4). At 24 hours post treatment, 
minimum induction of cell death was seen (Figure 3.9). After 48 to 72 hours treatment with 
CVA21 or in combination with Mitomycin C, all cell-lines displayed above 40 % apoptotic cells 
which was significantly greater than the Mitomycin C -only or mock-treated cells. In T24 and 
5637 cell lines, enhanced cell death was observed in combination treatment as opposed to 
CVA21 alone which was in keeping with an increase in ICAM-1 expression in these cell lines 
by Mitomycin C, facilitating enhanced viral entry and subsequent viral-induced death.  
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Figure 3.9 T24, TCCSUP and 5637 bladder cancer cell-lines displayed increase in apoptosis after treatment with 
virus alone and in combination with Mitomycin C. 
 
Bladder cancer cells were left untreated, treated with CVA21-alone, Mitomycin C -alone and in combination for 24, 
48 and 72 hours. Cells were harvested and stained with PE Annexin V in conjunction with the dye, 7 -Amino-
Actinomycin (7-AAD), to detect total percentage apoptosis. 
(A) In T24, TCCSUP and 5637 cell -l ines an increase in total percentage apoptosis was seen 48 -72 hours after CVA21- 
alone and combination treatment compared to untreated and Mitomycin C alone treated cells. (B) A representative 
FACs dot plot for TCCSUP 24, 48, 72 post-treatment shows the increase in cell  death overtime in CVA21 and 
combination treated cells. Data from (A) represents averaged results from two independent experiments  and two-
way ANOVA statistical analysis was performed. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. 
 
B A 
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3.3.5.2 Dependence on caspase activity for the cell-death effects of CVA21  
Cells were treated with Mitomycin C for an hour followed by 24 to 72 hours incubation with 
CVA21 alone and in combination with Mitomycin C. The quantification of caspase 3 and 7 
activity was evaluated by Caspase-Glo® 3/7 Assay (Section 2.11). An increase in activity of 
caspase 3 and 7 was observed in all cell-lines after 48 hours treatment with CVA21 as 
compared to mock and Mitomycin C -alone treated cells (Figure 3.10 (A-C)).  The 5637 cell-
line showed enhanced caspase 3 and 7 activity in combination with Mitomycin C treatment 
compared to T24 and TCCSUP cell-lines. 
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Figure 3.10 T24, TCCSUP and 5637 bladder cancer cell-lines displayed increase in caspase 3/7 activity after 
CVA21-alone and combination treatment. 
  
T24, TCCSUP and 5637 cell -l ines were left untreated, treated with Mitomycin C, CVA21 and the combination 
for 24, 48 and 72 hours. Expression of effector caspases 3 and 7 was quantified using Caspase Glo® 3/7 assay. 
T24 and 5637 cell -l ines displayed increase in caspase 3 and 7 activity when treated with CVA21-alone and in 
combination with Mitomycin C for 48-72 hours as compared to untreated and Mitomycin C -alone treated 
cells. Graphs represent pooled data from two independent experiments  and two-way ANOVA statistical 
analysis was performed. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. 
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3.3.5.3 Bladder Cancer cells rescued from virus-induced death by apoptosis inhibitor  
The apoptosis and necroptosis inhibitors, Z-VAD-FMK and Necrostatin-1, respectively, were 
used to confirm the dependence of caspase activity for the pro-death effects of CVA21. 
Bladder cancer cell lines T24 and TCCSUP were treated with CVA21 alone, Mitomycin C alone 
and combination for 24 to 72 hours and cell viability was analysed using MTS cell viability 
assay (Section 2.5).  
The caspase inhibitor Z-VAD-FMK rescued CVA21 treated cells from death and restored cell 
survival to 80% in T24 cells (Figure 3.11 (A)) and 40 % in TCCSUP cells (Figure 3.11 (B)), after 
72 hours whereas necrostatin-1 failed to have any effect on cell survival. 
 
Figure 3.11 T24 and TCCSUP bladder cancer cells rescued from CVA21 induced death with apoptosis inhibitor. 
 
T24 and TCCSUP cell -l ines were left untreated (UT), treated with Mitomycin C (MMC) - alone, CVA21-alone and 
combination (COMB) for 24, 48 and 72 hours and exposed to necroptosis and apoptosis inhibitors. Cell  viability 
was measured using MTS assay. 
An increase in percentage cell  survival was seen in CVA21 and combination treated cells with Z -VAD-FMK to 
approximately 80 % for T24 (A) and 30 % for TCCSUP (B) whereas Necrostatin-1 failed to protect cells from 
undergoing necroptosis when compared to UT and Mitomycin C -alone treated wells. Graphs represent pooled 
data from two independent experiments  and two-way ANOVA statistical analysis was performed. *P < 0.05, **P 
< 0.01, ***P < 0.001, ****P < 0.0001. 
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3.3.5.4 Increased PARP cleavage and reduction in RIP1 and RIP3 kinases post CVA21 
treatment  
 
In order to exclude the involvement of additional interconnected death pathways, we 
evaluated the expression of proteins involved in downstream necroptosis and apoptosis 
pathways’ execution. T24, TCCSUP and 5637 bladder cancer cell-lines were pre-treated with 
Mitomycin C for an hour followed by CVA21 incubation alone or in combination for 24 and 48 
hours. At each specific time-point, cells were harvested, lysed and protein was extracted 
(Section 2.8). Protein lysates were evaluated for expression of the apoptosis marker, cleaved 
PARP, and the necroptosis markers, RIP1 and RIP3.  
3.3.5.4.1 Expression of cleaved PARP 
For western blotting analysis of whole and cleaved PARP, lysates of Jurkat cells alone and cells 
treated with 25 µM Etoposide for 5 hours were used as positive control (#2043 Cell Signalling) 
(Figure 3.12 (D)). All three cell-lines showed low to no expression of cleaved PARP 24 hours 
post treatment with CVA21 alone or in combination with Mitomycin C (Figure 3.12 (A-C)). 
However, at 48 hours all three cell-lines showed increased expression of cleaved PARP with 
CVA21 alone and in combination. Interestingly,  TCCSUP and 5637 cell-lines showed greater 
expression of cleaved PARP in combination treated cells 48 hours post treatment as compared 
to CVA21 alone wells. This further highlights the beneficial effect of Mitomycin C induced 
ICAM-1 upregulation in virus induced cytotoxicity (Figure 3.12 (B, C)).  
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Figure 3.12 Expression of the apoptosis marker, cleaved PARP increased over-time in T24, TCCSUP and 5637 
bladder cancer cell-lines after CVA21 and combination treatment. 
 
T24, TCCSUP and 5637 bladder cancer cell-l ines susceptible to CVA21 induced death were treated with CVA21-
alone, Mitomycin C -alone and in combination for 24 to 48 hours. Cells were harvested and protein was extracted, 
before expression of the apoptosis marker, cleaved PARP, was evaluated by western blotting. (A) The T24 cell -line 
displayed no PARP cleavage at 24 hours post treatment however an increase in cleaved PARP 48 hours after CVA21 
alone and in combination treatment was observed. (B) TCCSUP and (C) 5637 cell -l ines also showed an increase in 
cleaved PARP after 48 hours CVA21-alone treatment and its expression was further enhanced in combination 
treated wells. (D) Jurkat cell  lysate and Jurkat cells treated with 25 µM etoposide were used as positive control for 
PARP expression. For each sample, GAPDH housekeeping protein was used as a loading control.  
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3.3.5.4.2 Expression of Necroptosis markers RIP1 and RIP3  
To exclude the involvement of necroptosis death pathway, western blotting analysis for the 
necroptosis markers, RIP1 and RIP3 kinase were investigated. Lysates of 3T3 cells alone were 
used as a positive control (Figure 3.13 (D)). 
All three cell-lines showed a reduction in the expression of RIP1 protein by 48 hours post 
treatment with CVA21 alone or in combination with Mitomycin C. RIP3 expression was also 
reduced in all cell-lines except 5637 where RIP3 expression remained unchanged over time 
with treatment (Fig 3.13 A-C).   
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Figure 3.13 Reduction in the expression of necroptosis markers RIP1 and RIP3 was seen after CVA21- alone and 
combination treatment. 
 
T24, TCCSUP and 5637 bladder cell-l ines susceptible to CVA21 induced death were treated with CVA21-alone, 
Mitomycin C -alone and in combination. Cell  lysates were prepared for evaluation necroptosis markers RIP1 and 
RIP3 by western blotting. (A) T24 and (B) TCCSUP cell -l ines showed no change in RIP1 and RIP3 expression 24 hours 
after treatment however, reduction in RIP1 and RIP3 expression was seen 48 hours post treatment in CVA21 alone 
and combination cells. (C) 5637 cells displayed reduction of only RIP1 at 48 hours after combination treatment but 
failed to show any change in RIP3 expression. (D) 3T3 cell  lysate showed RIP1 and RIP3 expression.  For each sample, 
GAPDH housekeeping protein was used as loading control .  
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3.3.6 Expression of ICD determinants in bladder cancer cell-lines treated with CVA21  
The last part of the work in this chapter addressed whether the mode of cell death induced 
by CVA21 was immunogenic as characterised by the release of DAMPs. Expression of ICD 
markers and determinants was analysed by flow cytometry (Section 2.6.3). HMGB1 
expression was quantified by sandwich ELISA whereas extracellular ATP was quantified using 
Cell-Titer Glo® Luminescent assay (Promega) and ATP determination kit (Molecular Probes),  
(Section 2.13).  
3.3.6.1 Induction of calreticulin and HMGB1 in bladder cancer cell-lines treated with 
CVA21 alone or in combination with Mitomycin C 
 
Bladder cancer cell-lines were treated with Mitomycin C for an hour followed by CVA21 or 
combination treatment. Cells and supernatant were harvested at 24, 48 and 72 hours. Flow 
analysis was performed for calreticulin, HSP70, FAS, MHC II and CD80 expression. 
T24 and 5637 cell-lines showed increase in the expression of calreticulin in CVA21 treated 
cells which further enhanced in combination treated cells whereas TCCSUP cell -line showed 
no change (Figure 3.14 (A)).  
All three cell-lines displayed a significant increase in the expression of HMGB1 after CVA21 
and combination treatment (Figure 3.14 (B)). No consistent significant increase over all the 
cell lines was exhibited for HSP70, MHC II, CD80 and FAS. However, FAS was upregulated in, 
5637 cell-line and MHC II expression was higher in the T24 cell-line after treatment with 
CVA21-alone and in combination with Mitomycin C (Table 3.1).  
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Figure 3.14 Selective induction of calreticulin and HMGB1 immunogenic cell death determinants by CVA21 
infection of bladder cancer cell-lines. 
 
The bladder cancer cell l ines T24, TCCSUP and 5637 were either left untreated or treated with Mitomycin C 
for an hour followed by 24-72 hours incubation with CVA21 alone and in combination with Mitomycin C. 
Cells and supernatants were harvested at 24, 48 and 72 hours. Cell surface exposure of the immunogenic 
cell death marker, calreticulin was determined by flow cytometry. HMGB1 accumulation was determined by 
ELISA analysis of supernatants .  (A) T24 and 5637 cell-lines displayed upregulation of calreticulin in CVA21 
alone and combination treated cells after 72 hours. (B) HMGB1 expression was significantly enhanced in all  
three cell-l ines 48-72 hours after CVA21 alone and combination treatment. Graphs represent pooled data 
from two independent experiments and two-way ANOVA statistical analysis was performed. *P < 0.05, **P 
< 0.01, ***P < 0.001, ****P < 0.0001. 
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3.3.6.1.1 Evaluation of calreticulin and HMGB1 expression in bladder cancer cell-lines 
treated with heat inactivated CVA21 
 
Heat inactivated virus was used as an additonal control to demonstrate that any increase in 
immunogenic cell death markers seen with virus treatment was due to presence of live 
replication competent CVA21 (Section 2.5). Two bladder cancer cell-lines, T24 and 5637 were 
treated with live CVA21 and heat inactivated virus. After 72 hours incubation, cells and 
supernatants were harvested and analysed for expression of calreticulin and HMGB1 (Section 
2.6.3,Figure 3.15). No increase in expression of calreticulin and HMGB1 was seen with heat 
inactivated treated virus whereas significant increase in expression of both markers was 
observed with live CVA21 treatment as compared to uninfected cells. 
 
 
 
 
 
 
 
ICD determinants and markers Bladder cancer cell-lines 
 T24 TCCSUP 5637 
Calreticulin Upregulation No change Upregulation 
HSP70 No change No change No change 
HMGB1 Upregulation Upregulation Upregulation 
Extracellular ATP Inconclusive Inconclusive Inconclusive 
CD80 No change No change Inconclusive 
MHC II Upregulated No change No change 
FAS No change No change Upregulated 
 
Table 3.1 Table summarises the expression of all ICD markers and determinants with CVA21-alone, Mitomycin 
C -alone and combination treatment after 24-72 hours. 
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Figure 3.15 No increase in expression of calreticulin and HMGB1 after treatment with heat inactivated CVA21 . 
 
The bladder cancer cell l ines T24 and 5637 were either left untreated or treated with live CVA21 and heat 
inactivated CVA21. Cells and supernatants were harvested at 72 hours. Cell  surface exposure of the 
immunogenic cell  death marker, calreticulin was determined by flow cytometry. HMGB1 accumulation was 
determined by ELISA analysis of supernatants. No increase in expression of calreticulin and HMGB1 was seen 
after treatment with heat inactivated virus whereas live CVA21 treated cells significantly increased both markers 
when compared to uninfected control. Graphs represent pooled data from two independent experiments and 
one-way ANOVA statistical analysis was performed. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. 
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3.3.6.2 Expression of Extracellular ATP 
T24, TCCSUP and 5637 cell-lines were treated with Mitomycin C alone for an hour followed 
by CVA21 and combination treatment for 24 to 72 hours. Extracellular ATP was quantified 
using Cell-Titer Glo® Luminescent assay (Promega) and ATP determination kit (Molecular 
Probes) (Section 2.13). For the 5637 cell-line, the results showed an increase in expression of 
extracellular ATP 72 hours post treatment. However, the same was not observed for the T24 
and TCCSUP cell-lines and thus the release of ATP in response to CVA21 treatment remain 
inconclusive (Figure 3.16). 
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Figure 3.16 Expression of extracellular ATP post treatment with CVA21 alone or in combination with 
Mitomycin C. 
 
The bladder cancer cell  l ines T24, TCCSUP and 5637 were either left untreated or treated with Mitomycin C 
for an hour followed by 24-72 hours incubation with CVA21 alone or in combination with Mitomycin C. At 24, 
48 and 72 hours extracellular ATP was quantified using Cell-Titer Glo® Luminescent assay (Promega). The 
results remain statistically unconvincing even though extracellular ATP expression appeared to be increased 
post CVA21 and combination treatment in TCCSUP and 5637 cell -l ines. Graphs represent pooled data from 
two independent experiments. 
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3.3.7 Mice treated with MB49/ICAM-1 CVA21 lysates protected from tumour rechallenge  
The gold standard approach to studying effect of ICD induction by certain stimuli is using 
syngeneic vaccination murine models (Kepp et al, 2014). The mouse bladder cancer model 
(MB49) was used in the vaccination studies, MB49 cells were transfected with human ICAM-
1 as murine ICAM-1 is unable to bind to virus. The MB49/ICAM-1 cells were treated with 
CVA21 and cells undergoing ICD as characterised by the release of HMGB1 and calreticulin 
were subcutaneously injected in mice (Chapter 5). Thirty C57BL/6 female mice were used for 
the syngeneic vaccination model, mice were divided into 3 groups (10 mice per group) and 
subcutaneously injected with Hanks control, MB49 cell lysates or MB49 cell lysates treated 
with CVA21. At day 0, mice were challenged with live MB49 wildtype cells by subcutaneous 
injection and tumour measurements were performed three times a week. Mice treated with 
the MB49/CVA21 lysates had delayed tumour growth compared to Hanks and MB49 wild-
type cell lysate treated tumours (Figure 3.17). By day 18, 11 days after re-challenge, 100% of 
the mice that had initially received lysates from CVA21-treated MB49/ICAM-1 cells had been 
effectively vaccinated compared to only 50 % of the mice that had initially received untreated 
MB49/ICAM-1 cell lysates. As expected the control mice all developed rapidly growing 
subcutaneous tumours. 
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3.3.8 Protection from tumour rechallenge by CD4+ T cell mediated immune response  
Immune cell population depletion was conducted in the vaccination model in order to 
establish which immune cell subsets were eliciting protection of CVA21 lysate vaccinated mice 
against MB49 tumour rechallenge. Same experimental set up as stated in section 3.3.7 was 
performed and a day before tumour rechallenge, anti-CD8, anti-CD4 or anti-NK depleting 
antibodies were intraperitoneally administered in mice. Mice with CD4 depletion displayed 
rapid tumour outgrowth upon tumour rechallenge with MB49 wild-type cells with average 
tumour volume reaching approximately 1000 mm3 (Figure 3.18). Average tumour volume 
after depleting CD8 and NK cells was similar with no indication of tumour outgrowth. MB49 
untreated lysate vaccinated mice showed significant tumour outgrowth as compared to 
Figure 3.17 MB49/ICAM-1 CVA21 lysate treated mice were protected from tumour rechallenge by MB49 wild-
type cell lysate. 
 
C57BL/6 female mice were subcutaneously pre-treated with Hanks control, MB49 wild-type cell lysate, 
MB49/ICAM-1 CVA21 cell  lysates and rechallenged subcutaneously with l ive MB49 wild-type cells on day 0. Mice 
treated with MB49ICAM-1/CVA21 lysates showed protection against rechallenge. MB49 ICAM-1 CVA21 treated 
mice tumour volumes were approximately 50 mm3 at days 11-15 whereas Hanks control and MB49 wild-type 
cell  lysate treated mice tumour volumes were 150 mm3- 300 mm3 at days 11-15. Graphs represent pooled data 
from two independent experiments and two-way ANOVA statistical analysis was performed. *P < 0.05, **P < 
0.01, ***P < 0.001, ****P < 0.0001. 
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isotype control treated mice. To our knowledge, the therapeutic benefit induced by CD4 
mediated immune response in MB49/ICAM-1 bladder cancer murine vaccination model was 
shown for the first time.  
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Figure 3.18 MB49/ICAM-1 CVA21 lysate treated mice were protected from tumour rechallenge by CD4 + 
mediated immune response.  
 
C57BL/6 female mice were subcutaneously pre-treated with Hanks control, MB49 wild-type cell  lysate, 
MB49/ICAM-1 CVA21 cell  lysates on day -7 followed by administrated of immune cell  subset depleting antibodies 
on day -2. Mice were rechallenged subcutaneously with l ive MB49 wild-type cells on day 0 followed by 5 infusions 
of depleting antibodies. Vaccinated mice treated with CD4 depleting antibody showed rapid tumour outgrowth. 
Whilst, mice treated with CD8 and NK depleting antibodies showed comparable resul ts with lack of tumour 
outgrowth. As expected, MB49 lysate treated control mice displayed tumour outgrowth and palpable tumour 
presence as compared to isotype treated mice. Mice treated with MB49ICAM-1/CVA21 lysates showed 
protection against rechallenge induced by CD4 cells. Graphs represent pooled data from two independent 
experiments and two-way ANOVA statistical analysis was performed. *P < 0.05, **P < 0.01, ***P < 0.001, ****P 
< 0.0001. 
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3.4 Discussion  
The treatment options for NMIBC are limited as conventional therapies have failed to prevent 
advancement of disease due to occurrence of side effects and high percentage of non-
responders. In half of the NMIBC patients treated with TUR, disease recurs and 5-25 % 
develop muscle invasive bladder cancer (Kamat et al, 2017). BCG immunotherapy has limited 
benefits as 30 to 40 % of NMIBC patients fail BCG treatment (Steinberg et al). The anatomical 
structure of the bladder and the therapeutic benefit seen with BCG immunotherapy makes it 
a good model for treatment with oncolytic virotherapy. Many oncolytic viruses such as 
adenovirus (Burke et al, 2012; Ramesh et al, 2006), herpes simplex virus (Cozzi et al, 2001; 
Simpson et al, 2012), reovirus (Hanel et al, 2004) and vaccinia virus (Gomella et al, 2001) have 
already shown promising preclinical and clinical efficacy of such therapy for bladder cancer 
treatment (Delwar et al, 2016; Potts et al, 2012). 
In this study we demonstrate CVA21 oncolytic immunotherapy as a tumour specific agent for 
the treatment of NMIBC. Sensitivity of bladder cancer cell-lines to CVA21 induced cytotoxicity 
was demonstrated by the reduction in cell survival with increasing CVA21 concentration and 
presence of viral protein VP1 inside the cells as shown by immunofluorescent staining. The 
sensitivity to CVA21 induced death and entry into bladder cancer cell-lines largely depended 
on the expression of the viral entry receptor ICAM-1. Previous studies support our findings 
and have reported on the requirement of ICAM-1 expression for lytic CVA21 infection (Bradley 
et al, 2014; Shafren et al, 1997b). In keeping with the role of DAF in CVA21 binding as a co-
facilitator for ICAM-1 induced CVA21 endocytosis (Johansson et al, 2004; Newcombe et al, 
2004), no correlation was observed between DAF expression on bladder cancer cell-lines and 
CVA21 induced death. Bladder cancer cell-lines with high to intermediate ICAM-1 receptor 
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expression VM-CUB-2, 253J, HCV29, T24, TCCSUP, 5637 were sensitive to CVA21 induced 
death. Whereas, cell-lines displaying low ICAM-1 expression KU19-19, VM-CUB 1 and RT-112 
were resistant to CVA21 induced death. J82 had intermediate ICAM-1 expression however, 
failed to undergo CVA21 induced oncolysis. It is possible an antiviral IFNβ response against 
CVA21 led to reduction in virus replication in J82. Previously, Valery et al. demonstrated that 
Vesicular Stomatitis oncolytic virus induced IFNβ anti-viral activity in pancreatic cancer cell-
line and similarly limited virus replication (Moerdyk-Schauwecker et al, 2013; Murphy et al, 
2012).   
The importance of ICAM-1 as a CVA21 entry receptor was reiterated by the KU19-19 cell-line 
which displayed both an ICAM-1 positive and negative population. Whilst the whole KU19-19 
cell population demonstrated minimal sensitivity to CVA21, after cell sorting into purified 
ICAM-1 positive and negative populations, only ICAM-1 positive cells succumbed to CVA21 
induced death. Having shown the importance of ICAM-1 for viral entry, we investigated 
whether ICAM-1 expression could be increased to further facilitate virus induced lysis. A 
commonly used chemotherapy treatment used in NMIBC, Mitomycin C, was used to increase 
ICAM-1 expression. A low, non-cytotoxic dose of Mitomycin C which induced minimum cell  
death was used to induce ICAM-1 with the aim to allow more viral entry thus inducing 
increased lysis.  Whilst, most bladder cancer cell-lines expressed high ICAM-1, the most 
benefit of Mitomycin C pre-treatment was observed in cell-lines that displayed intermediate 
expression of ICAM-1 such as T24, TCCSUP and 5637. Our data revealed an increase in CVA21 
replication and enhanced induction of death after pre-treatment with Mitomycin C followed 
by incubation with CVA21. Cell-lines such as VM-CUB 1, RT-112 and KU19-19 with low to 
minimal ICAM-1 expression failed to stimulate an increase in virus induced cell death after 
Mitomycin C treatment. 
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As well as the direct cytolytic damage induced by an oncolytic virus, the stimulation of an 
adaptive immune response is crucial to the success of the immunotherapy. For the initiation 
of a systemic anti-tumour immune response the immunogenicity of dying and dead cells is of 
utmost importance (Green et al, 2009; Krysko et al, 2012; Prestwich et al, 2008). Our study 
showed that apoptosis was the primary mode of cell death induced by CVA21 in bladder 
cancer cell-lines. This was evidenced by an increase in the total percentage of apoptotic cells, 
caspase 3/7 expression and rescue of dying cells with the apoptosis inhibitor, after CVA21 and 
combination treatment. The increase in expression of cleaved PARP, an important DNA repair 
protein and downstream marker of apoptosis (Oliver et al, 1998) further supported the role 
of apoptotic cell death pathway in CVA21 induced death. The reduction in RIP1 and RIP3 
kinases, crucial for formation of a necrosome, (Linkermann & Green, 2014) ruled out 
necroptosis as a mode of death induced by CVA21.  
The immunogenicity of the CVA21 treatment was validated by quantification of well 
characterised ICD determinants and markers calreticulin, HMGB1, extracellular ATP, HSP70, 
FAS, MHC II and CD80 (Krysko et al, 2012). One of the main ICD determinants induced by 
CVA21 in human bladder cancer cell-lines was HMGB1. The importance of HMGB1 release for 
initiating an anti-tumour response in bladder cancer has previously been demonstrated in 
animal models, tumour cells engineered to have decreased HMGB1 release fail to respond to 
intravesical BCG. This demonstrates the requirement of HMGB1 release by urothelial  
carcinoma cells for an in-vivo anti-tumour effect (Zhang et al, 2013). Our data also showed 
increase in another ICD determinant calreticulin after CVA21 treatment which is crucial for 
induction of ICD. In keeping with our results, a study by Obeid et al. showed CT26 murine 
colon carcinoma treated with anthracyclines stimulated calreticulin exposure on cells 
undergoing immunogenic cell death whilst expression lacked in cells undergoing non-
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immunogenic cell death (Obeid et al, 2007). This study further emphasized the requirement 
of cell surface exposure of calreticulin for phagocytosis by DC/macrophages as by blocking 
calreticulin activity on tumour cells, macrophages could not engulf cancer cells (Obeid et al, 
2007).  
A standard approach used to study induction of ICD in response to specific stimuli is a 
syngeneic vaccination model. We vaccinated mice with MB49/ICAM-1 cells undergoing ICD in 
response to CVA21 induced lysis followed by tumour rechallenge with MB49 wild-type 
tumour cells. Vaccinated mice were protected from tumour rechallenge and exhibited delay 
in tumour outgrowth. Our data indicates this protection against tumour rechallenge was 
driven by a CD4+ T cell mediated immune response and not CD8+ or NK immune cell subsets. 
Our result is in contrast with studies showing DC activated by reovirus enhance cytolytic 
activity of NK cells and cytokine production by T cells (Errington et al, 2008; Rajani et al, 2015). 
Increasing evidence supports the role of CD4+ mediated immune response against cancer and 
infectious diseases as it is crucial for dialogue between innate and adaptive immune system 
pathways (Wang, 2001). A study by Nadira et al has reported activation of helper CD4+ T cells 
in response to oncolytic H-1 Parvovirus infection in PBMCs and has also emphasized it is 
important for tumour clearance (Morales et al, 2012). Future studies need to address the role 
of CD4+ T cell in CVA21 treated MB49/ICAM-1 vaccinated induced protection against tumour 
rechallenge.  
The tumour-rejecting ability induced when dying cells displaying ICD markers are injected in 
to mice bearing syngeneic tumours is considered a prerequisite to an immune inducer (Kepp 
et al, 2014). Therefore, CVA21 can now be added to the list of oncolytic viruses that induce 
ICD. Other viruses such as adenovirus expressing CD40 ligand (Diaconu et al, 2012), 
coxsackievirus B3 (Miyamoto et al, 2012), reovirus (Kelly et al, 2012) and measles virus 
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(Donnelly et al, 2013) show induction in DAMPs and endoplasmic reticulum (ER) stress 
(Workenhe & Mossman, 2014). Adenovirus induced stimulation of calreticulin, HMGB1, and 
extracellular ATP in cell-lines and generated an adaptive cytotoxic CD8+ response and 
macrophage maturation in the MB49 murine bladder cancer model (Diaconu et al, 2012) 
whereas Measles virus induced cytokine production such as IL-6, IL-8 and HMGB1 in 
melanoma cell-lines (Donnelly et al, 2013). Whilst another member of the coxsackievirus 
family, CVB3 induced apoptosis in NSCLC cell-lines which expressed HMGB1, Calreticulin, 
extracellular ATP (Miyamoto et al, 2012).  Additionally, CVB3 intratumoral injection on the 
right flank resulted in tumour regression on the un-injected left flank where virus was 
detected (Miyamoto et al, 2012). Kelly et.al has reported reovirus induced cell death in 
multiple myeloma which led to increase in ER stress and production of pro-apoptosis BCL2 
family member protein (Kelly et al, 2012). 
There was no link between susceptibility to CVA21 and common mutations found in bladder 
cancer cell-lines. Most common genetic mutations in bladder cancer are in TP53 tumour 
suppressor, RAS oncogene, CDKN2A tumour suppressor and in telomerase reverse 
transcriptase which is a subunit of enzyme telomerase (Earl et al, 2015; 
http://cancer.sanger.ac.uk/cosmic). All bladder cancer cell-lines except KU19-19 and HCV29 
carried mutations in TP53. Five bladder cancer cell-lines had mutations in CDKN2A (253J, 
HCV29, T24, 5637, RT-112). VMCUB-2, T24, TCCSUP, 5637, VMCUB-1, RT-112 and J82 bladder 
cancer cell-lines had mutations in telomerase reverse transcriptase. 
In summary, the current study shows the therapeutic potential of CVA21 in vitro resulting in 
increased cytotoxicity in bladder cell-lines. CVA21 induced cytolytic effect mainly relies on 
ICAM-1 expression which was enhanced using Mitomycin C and also increased CVA21 
replication and CVA21 induced death.  In vitro experiments revealed apoptosis as the primary 
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mode of CVA21 induced cell death resulting in induction of calreticulin, HMGB1 production. 
These markers are suggestive of an immunogenic response. Immunogenicity induced by 
CVA21 treatment was tested in a murine vaccine model where protection from tumour 
growth upon MB49 wildtype cell rechallenge was observed post MB49/ICAM-1 CVA21 lysate 
priming and was dependent on CD4+ T cell activation.  
For future clinical use, ICAM-1 receptor could be used as a biomarker and its expression could 
be evaluated by biopsy to determine patients who would gain most benefit from CVA21 
oncolytic virotherapy. Urinary cytology of bladder cancer patients could a lso be used to 
determine ICAM-1 status and suitability for CVA21 therapy. 
The preclinical work performed in this study led to a successful Phase 1 clinical trial, CANON 
(Cavatak in Non-Muscle Invasive Bladder Cancer), NCT02316171 (HS Pandha, 2015; 
https://clinicaltrials.gov/, Accessed 12 Oct 2017). In the first stage of the CANON trial (VLA-
012A) CVA21 was given alone in increasing doses and a complete response was achieved in 
one out of three patients with the highest CVA21 dose.  In the second stage, CVA21 followed 
by Mitomycin C was given (VLA-012B) to treat non-invasive bladder cancer (Figure 3.19). In 
both monotherapy and combination stages of the study the treatment was well tolerated and 
no adverse effects occurred. Potential multi-cycle virus replication within the tumour was 
highlighted by detection of secondary viral load peaks in the urine as evidenced by RT-PCR 
and infectious TCID50 assays. The results of this trial are still to be published. 
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Figure 3.19 Study design for the CANON trial - CAVATAK™ in NON muscle invasive bladder cancer  (HS 
Pandha, 2015).  
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CHAPTER 4: ASSESS MECHANISM OF RESISTANCE TO COXSACKIE A21 
VIRUS INFECTION IN PANCREATIC CANCER 
 
4.1 Introduction 
Pancreatic cancer is an aggressive disease commonly diagnosed at an advanced stage (Deer 
et al, 2010). The 5 year survival rate of pancreatic cancer has only improved marginally to 8 
% in the 2000s from 3 % in the 1970s (Ady et al, 2014; Rahal & Musher, 2017). If measures to 
improve overall patient survival are not made, pancreatic cancer is set to be the second cause 
of cancer related deaths in the United States by 2020 (Rahal & Musher, 2017). Pancreatic 
cancer is a lethal disease, difficult to treat and surgery remains the only treatment for cancer-
free survival (Ady et al, 2014). Most patients are diagnosed at an advanced cancer stage and 
although new adjuvant chemotherapies such as FOLFIRINOX and Gemcitabine provide 
improved median survival, most patients succumb to cancer induced death within 12 to 18 
months post diagnosis (Ady et al, 2014; Rahal & Musher, 2017). Approximately 80 % of 
patients diagnosed with pancreatic cancer harbour unresectable tumours due to advanced 
disease and metastasis (Ady et al, 2014). Patients with unresectable tumour have an 
extremely poor prognosis with an expected survival of just 6 months (Ady et al, 2014).  
The most common form of pancreatic cancer, PDAC develops due to precursor neoplastic 
lesions consisting of intraductal papillary mucinous neoplasia (IPMN) and pancreatic 
intraepithelial neoplasia (PanIN) (Eser et al, 2014). PDAC is a heterogeneous disease with 
genetic mutations found in mainly four genes namely KRAS (viral proto-oncogene), SMAD4 
(tumour suppressor gene), TP53 (tumour suppressor gene encode by p53) and CDKN2A 
(tumour suppressor gene also known as p16) which lead to aberrant signalling pathways such 
as apoptosis, TGFβ and DNA damage control mechanisms  (Ady et al, 2014; Iacobuzio-
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Donahue et al, 2012).  Point mutations in KRAS gene are the most common mutations found 
in pancreatic cancer (>90 %) and can be detected at early stages of the disease (Deer et al, 
2010; Eser et al, 2014).  KRAS along with HRAS and NRAS are members of membrane  
associated proteins RAS which have crucial roles in cell death, apoptosis, migration and 
growth (Cuddington & Mossman, 2014). When RAS is bound to guanosine triphosphate (GTP) 
it is active and an inactive state is initiated upon interaction with guanosine diphosphate 
(GDP). Guanine nucleotide exchange factors (GEFs) convert the GDP to GTP. KRAS inactivation 
is facilitated by GTPase-activating proteins (GAPs) promoting an inactive GDP state (Eser et 
al, 2014). Point mutations found in KRAS mostly detected in human pancreatic cancer patients 
lead to inhibition of KRAS interacting with GAP (Eser et al, 2014). Hence, KRAS is constantly 
expressed and triggers constitutive activation of downstream signalling pathways such as 
tumour growth progression, tumour migration, invasion and metabolic restructure (Deer et 
al, 2010; Eser et al, 2014). The constant activation of KRAS signalling leads to a 
proinflammatory microenvironment which promotes the formation of neoplastic and 
desmoplastic development with the aid of fibroblasts, pancreatic stellate cells and immune 
cells (Eser et al, 2014). 
The thick extracellular matrix provides a hypoxic environment which makes the malignancy 
chemotherapy resistant (Ady et al, 2014). In addition, the immune suppressive tumour 
microenvironment characterised by the presence of stromal cells, MDSCs, regulatory T cells 
and TAMs provide a pro-tumorigenic phenotype (Ady et al, 2014; Clark et al, 2007). The 
complexity of the tumour also makes delivery and effectiveness of systemic therapy 
challenging. Up to 80 % of pancreatic cancer bulk mass consists of inflammatory cells and 
fibrotic tissue surrounded by a thick extracellular matrix which limits the spread of therapies 
due to reduced vascular access (Rahal & Musher, 2017). 
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Cancer immunotherapy is a promising approach to treat pancreatic cancer and recruits TAAs 
to generate a cancer specific immune response. To date, non-specific and specific 
immunotherapies have been evaluated in PDAC. Non-specific immunotherapies such as 
cytokines, adoptive T cell transfer, and immune stimulants have provided little therapeutic 
benefit with no improvement in overall survival in pancreatic cancer patients (Chen et al, 
2017). However specific immunotherapies such as vaccines and monoclonal antibodies 
targeting tumour antigens have displayed promising potential in cancer treatment (Chen et 
al, 2017). Pancreatic cancer is an immunogenically ‘cold’ tumour, as the  absence of tumour 
antigens means an effective immune response is not induced (Rahal & Musher, 2017). In the 
presence of such a hostile tumour microenvironment and dense extracellular matrix, 
immunotherapy-mediated damage to cancer cells is limited (Rahal & Musher, 2017). The 
pancreatic cancer microenvironment makes it challenging for systemic therapies to reach 
tumour cells. A therapy that could breach the thick extracellular matrix, disrupt desmoplastic 
stroma, trigger a local and systemic anti-tumour immune response would be an ideal 
candidate for pancreatic cancer treatment (Ady et al, 2014). One such approach is the use of 
oncolytic virotherapy. Oncolytic virotherapy is an ideal therapy as it not only lyses target cells 
but also induces a systemic anti-tumour immune response. In addition, viruses flourish in the 
presence of aberrant signalling pathways and can disrupt extracellular matrix (Ady et al, 
2014).  
CVA21 oncolytic virus has potential for pancreatic cancer treatment due to its selective ICAM-
1 binding properties. The expression of ICAM-1 on pancreatic cancer according to The Human 
Protein Atlas is high to moderate (https://www.proteinatlas.org/ENSG00000090339-
ICAM1/pathology, assessed on 10 Dec 17) (Figure 1.20) and increased expression of ICAM-1 
receptor on pancreatic cancer cells compared to normal pancreatic cells has also been shown 
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by others (Shimoyama et al, 1997; Tempia-Caliera et al, 2002). Shouji et al. has shown 
overexpression of ICAM-1 in pancreatic cancer cells as compared to normal pancreatic cells 
(Tempia-Caliera et al, 2002) and this was also supported by Shafren et al (Prof Darren Shafren, 
2011). Another study by Adrien et al. investigated ICAM-1 expression on 20 pancreatic tumour 
tissues and normal pancreatic tissue. This study also reported a significant increase in ICAM-
1 mRNA and protein expression in cancerous tissue compared to non-cancerous tissue 
(Tempia-Caliera et al, 2002). 
The current study evaluated CVA21 oncolytic virotherapy as a potential treatment for 
pancreatic cancer and investigated the mechanism of CVA21 resistance seen in some human 
pancreatic cancer cell-lines, reported previously (Lincoln Smith, June 2015). Lincoln Smith et 
al. quantified ICAM-1 and DAF membrane receptor expression on a panel of pancreatic cancer 
cell-lines (Figure 4.1). All pancreatic cancer cell-lines expressed high ICAM-1 and displayed 
sensitivity to CVA21 induced death with the exception of BxPC3, Hs766t and Capan-2 (Lincoln 
Smith, June 2015). BxPC3, Hs766t and Capan-2 had high ICAM-1 expression but exhibited 
resistance to CVA21 induced death.  
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Our previous data using CVA21 in bladder cancer along with results reported by others has 
supported the importance of ICAM-1 as the main CVA21 entry receptor and a defining factor 
for success of CVA21 oncolytic immunotherapy (Bradley et al, 2014; Shafren et al, 1997b; Xiao 
et al, 2005). To our knowledge, the mechanism/s behind the resistance to CVA21 induced 
cytotoxicity in the presence of high ICAM-1 receptor expression has not been previously 
reported and is investigated in this chapter.  
Figure 4.1  High ICAM-1 expressing pancreatic cancer cell-lines displayed resistance to CVA21 induced death, 
adapted from (Lincoln Smith, June 2015).  
 
Human pancreatic cancer cell -l ines express high ICAM-1 and DAF, reliance of CVA21 on ICAM-1 receptor has 
previously been emphasized (Shafren et al, 1997b; Xiao et al, 2005). With the exception of BxPC-3, Capan-2 and 
Hs766t all  of the pancreatic cancer cell-lines displaying high ICAM-1 were sensitive to CVA21 induced cytotoxicity 
and reduction in percentage cell  survival was reported. BxPC-3, Capan-2 and Hs766t showed resistance to CVA21 
induced death and reduction in cell survival was seen at high CVA21 concentration.  
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As previously mentioned oncolytic viruses are sensitive to antiviral actions of interferon and 
grow in cells with aberrant interferon signalling pathways. However, some cancers like 
pancreatic and ovarian have displayed high interferon expression in response to VSV 
treatment (Ebrahimi et al, 2017). The viral genome is detected by binding to RIG-I receptor 
and type I interferons (IFNα and IFNβ) binding to IFN receptors (IFNAR 1/2) (Ebrahimi et al, 
2017; Platanias, 2005) (Figure 4.2). The ligand-receptor interaction initiates Janus activated 
kinase (JAK) and tyrosine kinase (TYK). This results in phosphorylation of signal transducer and 
activator of transcription (STAT) (Ebrahimi et al, 2017; Platanias, 2005). The interferon-
stimulated gene factor 3 (ISGF3) is formed by interaction of STAT1, STAT2 and interferon 
regulatory factor-9 (IRF-9). This complex is translocated to the nucleus (Ebrahimi et al, 2017). 
Once in the nucleus, transcription of target gene and stimulation of downstream signalling 
pathways is triggered. ISGF3 complex binds to interferon stimulated response elements 
(ISREs) which promote interferon stimulated antiviral genes (ISGs) such as MxA (Ebrahimi et 
al, 2017). MxA stimulates antiviral activity by forming oligomeric rings around the viral 
nucleocapsid thus, inhibiting viral replication (Ebrahimi et al, 2017). The interferon mediated 
antiviral response also stimulates PKR in the presence of viral RNA which phosphorylates elF-
2α to its inactive state thus, inhibiting viral protein translation and replication (Cuddington & 
Mossman, 2014). The role of these viral-sensing pathways in mediating an antiviral response 
was demonstrated by Murphy et al., the oncolytic ability of VSV was tested in 13 pancreatic 
cancer cell-lines (Murphy et al, 2012). Cell-lines varied in sensitivity to VSV induced 
cytotoxicity however, some displayed resistance to death and produced IFNβ in response to 
VSV (Murphy et al, 2012). Virus infection in resistant pancreatic cell-lines was restored after 
inhibiting JAK/STAT pathways which reduced ISG levels (Moerdyk-Schauwecker et al, 2013). 
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The current chapter set out to address resistance mechanism of CVA21 infection. CVA21 
oncolytic virotherapy induced cytolytic effect was evaluated in a panel of human pancreatic 
cancer cell-lines followed by studies to confirm viral infection and ICAM-1 receptor 
functioning in one of the cell-lines resistant to CVA21 infection. Lastly, an in-depth literature 
search on mutational background of pancreatic cancer cell-lines and its correlation with 
resistance to virus infection was further evaluated.  
Figure 4.2  Interferon signalling pathway, adapted from (Sadler & Williams, 2008). 
 
Signal transduction is instigated by JAK and TYK upon interferon binding with IFNAR1 and IFNAR2. STAT is 
recruitment which interacts with IRF9 forming IFN-stimulated gene factor 3 (ISGF3). This complex is 
translocated to the nucleus and induces IFN-stimulated response elements (ISREs) such as Mx and PKR. Mx 
and PKR bind to viral RNA leading to steric inhibition of viral protein synthesis. 
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4.2 Objectives 
The first objective of this study was to evaluate the susceptibility of human pancreatic cancer 
cell-lines to CVA21 induced death and revalidate published data (Lincoln Smith, June 2015). 
Secondly, the potential mechanism of resistance to CVA21 infection and death in the 
presence of high ICAM-1 expression was evaluated.  
The objectives were addressed as follows: 
 The susceptibility of a panel of human pancreatic cancer cell-lines BxPC3, PANC-1, PSN-1, 
PL45, Hs766t, Capan-2, HPAF-II and AsPC-1 to varying concentrations of CVA21 was 
evaluated by CellTiter 96® Aqueous One Solution Cell Proliferation Assay (MTS). Virus 
infection was confirmed by immunofluorescent staining and confocal analysis. 
 The cell surface density of viral entry receptors was quantified using flow cytometry with 
QuantiBRITE PE beads (BD Bioscience).  
 Antiviral interferon response after CVA21 treatment was evaluated by IFNβ ELISA. 
 CVA21 binding and endocytosis was evaluated by immunofluorescence and confocal 
analysis. 
 Assessed potential genetic mutations in the ICAM-1 DNA sequence. ICAM-1 receptor gene 
was amplified by PCR and DNA was sequenced by Sanger sequencing at Cambridge 
University. 
 Investigated any correlations of ICAM-1 isoforms with sensitivity to CVA21 induced 
cytotoxicity by western blotting. 
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4.3 Results 
4.3.1 Susceptibility of Pancreatic Cancer cell-lines to CVA21 induced death 
In order to assess CVA21 as a treatment for pancreatic cancer, a panel of 8 pancreatic cancer 
cell-lines were treated with CVA21. Pancreatic cancer cell-lines BxPC3, PANC-1, PSN-1, PL45, 
Hs766t, Capan-2, HPAF-II and AsPC-1 were treated with CVA21 at a MOI ranging from 0 to 50. 
CellTiter 96® Aqueous One Solution Cell Proliferation Assay (MTS) was used to quantify the 
percentage survival of cells 72 hours post virus treatment (Section 2.5). 
CVA21 induced death varied amongst the panel of 8 pancreatic cancer cell-lines (Figure 4.3).  
PANC-1, PSN-1 and PL45 cell-lines were the most sensitive to CVA21 induced death with less 
than 50 % viable cells at the highest CVA21 MOI of 50. Capan-2, HPAF-II and AsPC-1 displayed 
reduced sensitivity to CVA21 induced death with approximately 60 % viable cells at CVA21 
MOI 50. In contrast, two cell-lines BxPC-3 and Hs766t were completely resistant to CVA21 
induced death with 100 % viable cells at CVA21 MOI of 50.  
To confirm virus infection and localisation inside cells, immunofluorescent staining for viral 
protein by confocal analysis was performed. All cell-lines were treated with CVA21 at a MOI 
of 10. After 24 hours cells were immunostained for the presence of enterovirus capsid protein 
1 (green), WGA stain (red), TO-PR0-3 nuclear stain (blue), fixed and fluorescence was detected 
using the confocal microscope (Section 2.7.1).  CVA21 was found to be localised in the cells of 
PANC-1, PSN-1, PL45, HPAF-II and AsPC-1 cell-lines whilst, no viral protein was detected inside 
Capan-2, BxPC3 and Hs766t pancreatic cancer cell-lines (Figure 4.3).  
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Figure 4.3 CVA21 treatment induced death in six out of eight pancreatic cancer cell-lines.  
 
The percentage cell survival of pancreatic cancer cell-lines treated with increasing doses of CVA21 was determined by MTS 
assay 72 hours post virus infection.  
Three (PANC-1, PSN-1 and PL45) of the eight pancreatic cancer cell-lines displayed the highest sensitivity to CVA21 induced 
death and showed reduction in cell  viability with increasing CVA21 MOI. In comparison, Capan -2, HPAF-II and AsPC-1 
showed reduced sensitivity to CVA21 induced death whilst, BxPC3 and Hs766t pancreatic cancer cell -l ines were resistant 
to CVA21 infection even at the highest viral dose of MOI 50. The results represent findings from two independent 
experiments. 
For immunofluorescent viral staining, pancreatic cancer cells were treated with CVA21 for 24 hours at MOI 10. CVA21 
(green-Alexa Fluor 488) was localised around the nucleus (Blue-TOPRO®-3), cell  membrane shown in red (Wheat germ 
agglutinin-Alexa Fluor® 594). CVA21 localisation in the cells was seen in PANC-1, PSN-1, PL45, HPAF-II and AsPC-1 cell-l ines, 
no virus was seen inside BxPC3, Hs766t and Capan-2 cell-l ines. Magnification × 40.  
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4.3.2 Variable expression of ICAM-1 and DAF viral entry receptors on pancreatic cancer 
cell-lines 
 
The importance of ICAM-1 as an entry receptor for CVA21 is supported by our previous  
findings using bladder cancer cell-lines (Chapter 3) and have also been shown by others  
(Shafren et al, 1997b). To investigate the role of ICAM-1 and DAF receptors in CVA21 induced 
cytotoxicity seen in pancreatic cancer cell-lines, the cell surface density of ICAM-1 and DAF 
was quantified using QuantiBRITE™ PE beads and analysed by flow cytometry (Section 2.6.1). 
PANC-1, BxPC-3, PSN-1 and PL45 pancreatic cancer cell-lines displayed the highest expression 
of ICAM-1 with above 100,000 ICAM-1 molecules bound per cell (Figure 4.4 (A)). Hs766t cell-
line had intermediate ICAM-1 expression of approximately 50,000 ICAM-1 molecules/cell 
whilst, Capan-2, HPAF-II and AsPC-1 pancreatic cell-lines exhibited the lowest expression of 
ICAM-1 receptor.  A correlation between ICAM-1 expression levels and susceptibility to virus 
induced death was observed, with cell-lines displaying the highest expression of ICAM-1 most 
sensitive to virus induced death with the exception of BxPC-3. In contrast whilst DAF was 
highly expressed (>1,500,000 molecules bound per cell) on Hs766t and AsPC-1 pancreatic 
cancer cell-lines, no correlation to CVA21 induced cytotoxicity was observed. PANC-1, BxPC-
3, PSN-1, PL45, Capan-2 and HPAF-II pancreatic cancer cell-lines displayed <500,000 DAF 
molecules bound/cell. 
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Figure 4.4 Pancreatic cancer cell-lines display differing levels of ICAM-1 and DAF membrane receptor 
expression. 
 
(A) PE labelled anti-ICAM-1 and anti-DAF antibodies were used with QuantiBRITE™ PE beads to quantify the 
ICAM-1 and DAF molecules bound per cell on all  pancreatic cancer cell -lines. BxPC-3, PANC-1, PSN-1 and PL45 
cell-l ines displayed the highest ICAM-1 expression, followed by intermediate ICAM-1 expression on Hs766t and 
low ICAM-1 expression on Capan-2, HPAF-II and AsPC-1. Whilst DAF was highly expressed on Hs766t and AsPC-1 
cell l ines as compared to the other pancreatic cell -l ines its expression did not correlate with susceptibility to 
CVA21 induced death. Graphs represent pooled data from two independent experiments. 
(B) The mean fluorescence intensity of receptors (grey peak) is displayed as histograms against their unstained 
negative control (black peak).  
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4.3.3 Absence of Interferon β expression in all pancreatic cancer cell-lines, except                  
Hs766t post CVA21 treatment  
 
Two pancreatic cancer cell-lines BxPC-3 and Hs766t expressed the viral entry receptor ICAM-
1 (Figure 4.4) but were resistant to CVA21 induced death and entry (Figure 4.3). The presence 
of an antiviral response could explain the resistance to CVA21 induced death observed in 
these two pancreatic cancer cell-lines. Therefore, the production of the antiviral cytokine, 
IFNβ was investigated by sandwich ELISA (Section 2.10.2). 
Pancreatic cancer cells and PBMC used as positive control cells were pre-treated with CVA21 
at MOI of 5 and 25 or were left untreated. After 24 hours incubation the supernatant was 
collected for Interferon Beta ELISA assay. All of the untreated cell-lines produced a base-line 
level of IFNβ and showed no significant increase in IFNβ post CVA21 treatment, with the 
exception of Hs766t (Figure 4.5). Hs766t and PBMC showed increase in IFNβ expression after 
CVA21 MOI 25 treatment. The resistance to CVA21 induced death observed in Hs766t cell -
line could therefore be explained by stimulation of IFNβ production. However, the CVA21 
resistance observed in the BxPC-3 pancreatic cancer cell-line despite the high expression of 
the viral entry receptor ICAM-1 remained unexplained.  
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Figure 4.5 Interferon Beta antiviral response was absent in all pancreatic cancer cell-lines except Hs766t. 
 
All pancreatic cancer cell-l ines were treated with CVA21 at MOI 5 and 25 or left untreated. After overnight 
incubation, supernatant was harvested. The expression of the IFNβ antiviral cytokine was determined by sandwich 
ELISA.  All  cell-l ines displayed a lack of IFNβ production after CVA21 treatment except Hs766t which showed 
increase in IFNβ post CVA21 MOI 25 treatment. PBMC was used as a positive control and showed increase in IFNβ 
production. The results represent findings from two independent experiments. 
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4.3.4 Absence of CVA21 infection in BxPC-3 pancreatic cancer cell-lines 
All pancreatic cancer cell-lines with high ICAM-1 expression were sensitive to CVA21 induced 
death with the exception of the BxPC-3 cell-line (Figure 4.3). CVA21 was not detected in the 
BxPC-3 cells after 24 hours incubation with MOI 10. In order to confirm the lack of virus 
presence and endocytosis in the BxPC-3 cell-line, the cells were treated with CVA21 MOI of 
25 and 50, incubated for 24, 48 and 72 hours. The presence of CVA21 was investigated by 
immunofluorescent staining for enterovirus capsid protein VP-1 and imaged by confocal 
microscope.  
In comparison with the positive control cell-line, PANC-1, where CVA21 was seen localised 
inside cells after 24 hours incubation, BxPC-3 cells failed to display positivity for viral presence 
(Figure 4.6). Untreated BxPC-3 cell-line without CVA21 treatment was used as a negative 
control for non-specific binding of primary antibody and no positivity was detected.  BxPC-3 
cells treated with CVA21 MOI 25 for 24 to 72 hours showed no viral protein presence which 
was also seen in CVA21 MOI 50 treated cells after 24 to 72 hours. In contrast, CVA21 was seen 
localised in PANC-1 at 48 and 72 hours. These results confirmed the lack of CVA21 endocytosis 
and infection in the BxPC-3 cell-line despite the high ICAM-1 viral entry receptor expression. 
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Figure 4.6 Absence of CVA21 localisation inside BxPC-3 pancreatic cancer cell-line. 
 
BxPC-3 and PANC-1 pancreatic cancer cell-lines were treated with CVA21 MOI 25-50 and 10, respectively. The cells 
were incubated with CVA21 for 24, 48 and 72 hours followed by CVA21 detection by immunofluorescence. Lack of 
CVA21 localisation was seen in BxPC-3 cells treated with virus MOI 25 and 50 after 24 to 72 hours. In contrast, the 
positive control cell -l ine PANC-1 displayed CVA21 (green-FITC) localised around the nucleus (Blue-TOPRO®-3) at 
24 to 72 hours upon treatment with CVA21 MOI 10. Magnification × 40.  
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4.3.5 Absence of CVA21 binding to BxPC-3 pancreatic cancer cell-lines 
According to our results the BxPC-3 cell-line expressed high ICAM-1 receptor but lacked 
CVA21 induced death and endocytosis. Therefore, it was hypothesized that CVA21 was not 
binding to the ICAM-1 receptor expressed on the BxPC-3 cells. In order to confirm our 
hypothesis, immunofluorescent binding studies were performed to determine the presence 
of CVA21 binding to the cell surface of BxPC-3 and the PANC-1 pancreatic cancer cell-line was 
used as a positive control (Section 2.7.2). After 5 to 10 minutes incubation at 4°C with CVA21 
MOI 10, the PANC-1 cell-line displayed CVA21 localisation on the cell surface (Figure 4.7). 
However, BxPC-3 cell-line did not display any positive staining for viral binding to the cell 
surface. These results suggested that the lack of CVA21 induced cytotoxicity in the presence 
of high ICAM-1 receptor expression could be due to the inability of CVA21 to bind to the ICAM-
1 receptor which prevents its endocytosis and replication inside BxPC-3 cells. 
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PANC-1, 4°C, 5 mins, MOI 10 PANC-1, 4°C, 10 mins, MOI 10 
BxPC-3, 4°C, 5 mins, MOI 25 BxPC-3, 4°C, 10 mins, MOI 25 
PANC-1, 4°C, 10 mins, MOI 10  
Figure 4.7 Absence of CVA21 binding to BxPC-3 cell surface. 
 
BxPC-3 cell-l ine and PANC-1 positive control cell -l ine were treated with CVA21 at MOI 25 and 10, respectively. 
The cells were incubated for 5-10 minutes at 4°C and viral protein (green) was detected by immunofluorescence. 
PANC-1 cells after 5-10 minutes incubation with CVA21 showed virus bound to the cell  surface (indicated by white 
arrows), nucleus was stained with Blue-TOPRO®-3. No virus was seen attached to the cell surface of BxPC-3 cells 
after 5 to 10 minutes incubation with CVA21 MOI 25. Magnification × 40. 
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4.3.6 Lack of mutation in the DNA of ICAM-1 receptor on BxPC-3 
The high ICAM-1 expressing pancreatic cancer cell-line BxPC-3 failed to undergo CVA21 
induced death or endocytosis in the absence of antiviral response. Further confocal studies 
showed CVA21 was not binding to the cell membrane of the BxPC-3 cell-line which possibly 
indicated presence of an aberrant ICAM-1 receptor. To further investigate the lack of CVA21 
binding to ICAM-1 which has previously not been reported, the ICAM-1 receptor gene was 
amplified using PCR (Section 2.15.3) from the BxPC-3 cell line and from the positive control 
cell-line PANC-1. The ICAM-1 receptor cDNA from the two pancreatic cancer cell-lines was 
sent to Cambridge University for Sanger sequencing. The sequence was aligned using the 
sequence alignment softwares MEGA6, BioEdit Sequence Alignment Editor and DNA Baser- 
Base Assembler. The aligned sequences were compared with each other and also wild-type 
ICAM-1 mRNA sequence on the NCBI database (NM_000201). 
The DNA sequence alignment of wild-type, PANC-1 and BxPC-3 ICAM-1 showed 100 % 
sequence similarity which was also mimicked by the translated protein sequence (Figure 4.8). 
The displayed DNA sequence encodes ICAM-1 domain 1 which binds to CVA21 leading to viral 
entry. These results indicate that the lack of CVA21 binding to BxPC-3 cell-line was not due to 
an ICAM-1 genetic mutation. Another possible reason for lack of CVA21 binding to ICAM-1 
receptor could be due to the presence of post-translational modification or spliced 
variants/isoforms of ICAM-1 protein.   
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4.3.7 ICAM-1 isoforms do not affect CVA21 infection and induced death  
After eliminating the possibility of an ICAM-1 genetic mutation leading to aberrant ICAM-1 on 
the BxPC-3 pancreatic cancer cell-line, we wanted to identify other possible cause of reasons 
for CVA21 not binding to ICAM-1 receptor. The presence of ICAM-1 isoforms could lead to 
lytic virus infection. Previous work by others reported neutralisation of virus upon binding to 
receptor isoforms which prevented virus attachment to main receptor (Manchester et al, 
1994). Presence of ICAM-1 receptor isoforms could indicate resistance to virus infection 
observed in BxPC-3 cell-line.  In order to identify ICAM-1 isoforms, protein was extracted from 
all pancreatic and seven bladder cancer cell-lines and ICAM-1 was quantified using western 
blotting (Figure 4.9). ICAM-1 has a molecular weight of approximately 93 kDa and was 
expressed in all cell-lines except AsPC-1 bladder cancer cell-line, these results support our 
Wild-type ICAM-1 
DNA sequence  
PANC-1 ICAM-1 
BxPC-3 ICAM-1 
Translated protein sequence  
Wild-type ICAM-1 
PANC-1 ICAM-1 
BxPC-3 ICAM-1 
Figure 4.8 No genetic mutation identified in BxPC-3 ICAM-1 gene sequence. 
 
BxPC-3 and PANC-1 ICAM-1 genes were amplified using PCR and sent for Sanger sequencing to Cambridge 
University Biochemistry department. The subsequent gene sequences were aligned using sequence alignment 
software and compared to wild-type ICAM-1 mRNA sequence on NCBI database (NM_000201).  Alignment of 
wild-type ICAM-1, PANC-1 ICAM-1 and BxPC-3 ICAM-1 displayed 100 % DNA sequence similarity. The highlighted 
DNA and translated protein sequence encode ICAM-1 domain 1 protein sequence which binds to viral capsid 
protein.  
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previous ICAM-1 quantification performed by flow cytometry (Figure 4.4). However, an 
isoform of ICAM-1 was identified at 60 kDa which was highly expressed on PSN-1, PL45 
pancreatic cancer cell-lines and VM-CUB-2 bladder cancer cell-line. These cell-lines succumb 
to CVA21 induced infection and death (Figure 3.1 and 4.3) therefore, presence of an ICAM-1 
isoform does not neutralise CVA21 activity. The ICAM-1 isoform expression lacked in all other 
cell-lines including BxPC-3 pancreatic cancer cell-line. Thus the expression of ICAM-1 isoform 
did not correlate with sensitivity to CVA21 induced cytotoxicity.    
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Figure 4.9 Absence of ICAM-1 isoforms in BxPC-3 pancreatic cancer cell-line. 
 
Protein was extracted from all  the bladder (blue) and pancreatic (red) cancer cell-l ines, ICAM-1 expression and 
presence of isoforms was evaluated using western blotting. The ICAM-1 western blots displayed the same ICAM-1 
expression as seen by flow cytometry quantification and also showed ICAM-1 band at 93 kDa with an additional 
band for a possible isoform at approximately 60 kDa. No correlation between the ICAM-1 isoform and sensitivity to 
CVA21 induced death was observed. Presence and expression of original ICAM-1 band correlated with virus induced 
sensitivity.  
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4.4 Discussion   
Our results in this chapter and others have reported the importance of ICAM-1 receptor for 
CVA21 entry into cancer cells, providing a targeted therapy due to over expressed ICAM-1 on 
cancer cells as compared to normal cells (Bradley et al, 2014; Shafren et al, 1997b; Xiao et al, 
2005). However, resistance to CVA21 induced infection in the presence of high ICAM-1 
expression has not been previously reported. A study by Lincoln Smith et al. showed ICAM-1 
expression of a panel of pancreatic cancer cell-lines and their sensitivity to CVA21 induced 
death (Lincoln Smith, June 2015). The data showed that high ICAM-1 expressing cell-lines 
were resistant to CVA21 induced death therefore, we further evaluated the resistance to 
CVA21 in presence of ICAM-1. We investigated whether a mutation or defect in ICAM-1 
receptor could render the receptor unable to bind to the virus. The detection of such aberran t 
ICAM-1 could be used as a biomarker to identify patients that would benefit from CVA21 
oncolytic immunotherapy.  
In this study CVA21 oncolytic therapy has shown promising efficacy in vitro using human 
pancreatic cancer cell-lines. CVA21 induced death in six of the eight pancreatic cancer cell -
lines with CVA21 clearly localised inside five of the cell-lines. In these cell-lines virus induced 
cytotoxicity depended on the expression of the viral entry receptor ICAM-1 and these results 
were in agreement with findings reported by Lincoln Smith et al (Lincoln Smith, June 2015). 
Our data for expression of ICAM-1 and DAF correlated with the other group’s data for all cell-
lines with the exception of ICAM-1 receptor expression of Capan-2 cell-line which according 
to our results was lower than reported before. Two of the pancreatic cancer cell -lines BxPC-3 
and Hs766t failed to display sensitivity to CVA21 induced death even in the presence of the 
viral entry receptor ICAM-1. Other studies using oncolytic viruses as therapy in pancreatic 
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cancer cell-lines have reported the presence of an intact interferon antiviral response which 
limited expression of early and late viral proteins thus, limiting virus replication (Ebrahimi et 
al, 2017; Moerdyk-Schauwecker et al, 2013; Murphy et al, 2012). In contrast to the clear anti-
viral IFNβ production in response to VSV (Murphy et al, 2012), treatment of pancreatic cancer 
cell lines with CVA21 did not result in IFNβ production. Only a slight increase in IFNβ 
expression was seen after CVA21 MOI 25 treatment in Hs766t cell-line. However, this IFNβ 
expression in response to CVA21 could explain the resistance to virus induced death seen in 
Hs766t cell-line. 
In order to identify the cause of resistance to CVA21 induced death in the presence of high 
ICAM-1 expression with no IFNβ production, we firstly confirmed by immunofluorescent 
confocal studies that no virus was entering the BxPC-3 cells. Confocal studies confirmed both 
the lack of CVA21 infection in BxPC-3 cells and binding of CVA21 to BxPC-3 cell surface. 
Published data has shown that the ICAM-1 domain 1 (amino acid residues 1 to 83) binds to 
the CVA21 capsid protein. Site induced mutagenesis and use of monoclonal antibodies has 
revealed that mutations in domain 1 of ICAM-1 can alter the interaction and binding of virus 
(McClelland et al, 1991; Staunton et al, 1990; Xiao et al, 2005; Xiao et al, 2001). Thus we 
hypothesized that a genetic mutation in domain 1 of ICAM-1 of the BxPC-3 cell-line was 
hindering CVA21 binding to the cells. However, genetic sequencing disproved this as no 
mutation in the BxPC-3 ICAM-1 receptor was present and the aligned BxPC-3 ICAM-1 DNA 
sequence was 100 % identical to the positive control cell-line PANC-1 and ICAM-1 wild-type 
sequence.  
Rhinovirus also belongs to the Picornaviridae family and share the ICAM-1 receptor with 
CVA21 (Marlin et al, 1990).  A study by Steven et al. reported that presence of soluble ICAM-
1 neutralises virus which inhibits virus infection and binding (Greve et al, 1991; Marlin et al, 
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1990). Jeffery et al. supported this finding and showed soluble ICAM-1 competes with 
membrane bound ICAM-1 and limits rhinovirus uncoating leading to its neutralisation (Greve  
et al, 1991). However, this factor was not relevant and the potential of soluble ICAM-1 was 
eliminated in our experiments because the cell media was replaced before adding any virus. 
Therefore, the possibility of soluble ICAM-1 produced by BxPC-3 hindering CVA21 binding was 
eliminated. 
Previous work showed membrane receptor isoforms hindered virus binding to its main entry 
receptor (Manchester et al, 1994; Ramos et al, 2014). We further addressed the possibility of 
ICAM-1 isoforms playing a role in resistance to CVA21 induced infection in BxPC-3 pancreatic 
cancer cell-line. Following alternative ICAM-1 protein splicing, 6 membrane bound and one 
soluble ICAM-1 isoforms are generated (Ramos et al, 2014). Additionally, the binding ability 
of LFA-1 ICAM-1 domain 1 varies depending on which ICAM-1 domain is absent in each 
isoform (Ramos et al, 2014). Measles virus is also internalised into cells by CD46 receptor 
mediator endocytosis, virus tropism is highlighted by its abil ity to bind to four MV isoforms 
resulting in lytic infection (Manchester et al, 1994). The western blot quantification of ICAM-
1 receptor of 7 bladder cancer and 8 pancreatic cancer cell-lines displayed the expression of 
primary ICAM-1 isoform at 90 kDa and reported another isoform at 70 kDa. However, no 
correlation between sensitivity to CVA21 induced cytotoxicity and presence of second isoform 
was observed in any of the cell-lines tested. Therefore, the possibility of multiple ICAM-1 
isoforms neutralising CVA21 and inhibiting its binding to membrane ICAM-1 of BxPC-3 was 
also ruled out.  
In the absence of factors such as ICAM-1 gene mutation, presence of soluble ICAM-1 and 
isoforms that could explain resistance to CVA21 observed in BxPC-3 cell-line, we also looked 
at mutational profile of pancreatic cancer cell-lines. An extensive literature research on 
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genetic mutations commonly found in human pancreatic cancer cell-lines using the Catalogue 
Of Somatic Mutations In Cancer (COSMIC) database, ATCC cell-line mutation catalogue and a 
literature review by Emily et al (Deer et al, 2010; http://cancer.sanger.ac.uk/cosmic; 
https://www.atcc.org/~/media/PDFs/Culture%20Guides/Cell_Lines_by_Gene_Mutation.ash
x, accessed on 30 Oct 2017)  revealed that all the pancreatic cancer cell-lines carry one or 
more of the four most commonly found mutations in human pancreatic cancer, KRAS, SMAD4, 
CDKN2A and TP53 (Table 4.1). BxPC3 pancreatic cancer cell-line carried mutations in tumour 
suppressor genes, CDKN2A, SMAD4 and TP53 genes but lacked mutations in proto-oncogene 
KRAS. All other pancreatic cancer cell-lines namely, PANC-1, PSN-1, PL45, Hs766t, Capan-2,  
HPAFII and AsPC-1 carried mutations in KRAS. 
  
The effectiveness of oncolytic virotherapy in cell-line with mutant KRAS has previously been 
demonstrated in many studies (Deng et al, 2017; Gong & Mita, 2014; Xu et al, 2012). A recent 
study by H.Deng et al. using coxsackievirus B3 on NSCLC cell-lines showed enhanced cell death 
Genetic Mutation  CDKN2A SMAD4 TP53 KRAS 
 
 
 
 
Cell-lines 
BxPC-3 ✓ ✓ ✓ × 
PANC-1 ✓ ✓ ✓ ✓ 
PSN-1 × × × ✓ 
PL45 × × ✓ ✓ 
Hs766t × ✓ ✓ ✓ 
Capan-2 ✓ × ✓ ✓ 
HPAF-II ✓ × ✓ ✓ 
AsPC-1 ✓ ✓ ✓ ✓ 
Table 4.1 Four most common mutations found in human pancreatic cell-lines, adapted from (Deer et al, 
2010). 
 
The four most commonly found mutations in human pancreatic cancer are summarised based on the 
pancreatic cancer cell -line they are present in. The data was collected from COSMIC database, ATCC cell -
l ine mutation catalogue and literature review by Emily et al., (✓= presence of mutation and × = absence of 
mutation). CDKN2A, tumour suppressor protein was mutated in 5 out of 8 pancreatic cancer cell -lines 
whereas SMAD4 proto-oncogene was aberrant in 4 out of total 8 cell -l ines. Additionally, two tumour 
suppressor genes TP53 and KRAS were mutated in most cell -l ines, 1 out of 8.  
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and presence of high viral titer in KRAS mutant cell-lines as compared to normal lung cell-lines 
(Deng et al, 2017). Furthermore, increased reovirus protein expression in RAS mutated cells 
has also been reported. The antiviral PKR protein remains inactive in the presence of RAS 
mutation (Gong & Mita, 2014). Upon virus infection, viral components are detected by 
receptors and leads to activation of interferon stimulated gene such as PKR. Activated PKR 
phosphorylates elF2α leading to viral protein synthesis inhibition. In RAS mutant cells PKR 
remains inactive, the link between RAS mutation and PKR inactivation is unclear. However, 
mutated active RAS prevents PKR auto-phosphorylation which inhibits phosphorylation of 
elF2α thus averting shut down of viral protein synthesis (Cuddington & Mossman, 2014). 
Additionally, PKR knockdown studies led to increased virus susceptibility in cancer cell -lines 
(Gong & Mita, 2014). Breanne et al. has also demonstrated enhanced Bovine Herpesvirus 
replication in KRAS mutated cancer cell-lines (Cuddington & Mossman, 2014). In another 
virus, an adenovirus expressing lipocalin-2, a protein involved in the innate immune response 
showed greater cytolytic effect in PANC-1 cell-line (mutated KRAS) as compared to BxPC-3 
cell-line (intact KRAS) (Xu et al, 2012). In light of evidence supporting role of KRAS mutational 
status in oncolytic virus sensitivity, future work needs to address whether lack of KRAS 
mutation in BxPC-3 cell-line lead to CVA21 infection resistance.  
In summary, the current study showed that the majority of pancreatic cancer cell -lines were 
sensitive to CVA21 induced death which correlated to their expression of the ICAM-1 viral 
entry receptor with the exception of BxPC-3 and Hs766t cell-lines. Hs766t displayed increased 
antiviral IFNβ production after virus treatment thus possibly explaining the CVA21 induced 
resistance in this cell line. However in the case of BxPC-3, despite displaying high ICAM-1 
expression it failed to undergo CVA21 infection or virus binding even in the absence of an 
antiviral IFNβ response. Lack of any ICAM-1 genetic mutation, absence of soluble ICAM-1 and 
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no unique ICAM-1 isoforms that may correlate with virus sensitivity were shown in this 
investigation. Based on the mutational profiling findings, more studies need to address 
whether the lack of KRAS mutation in BxPC-3 cell-line led to CVA21 induced resistance.  
Further studies need to be undertaken to confirm role of KRAS mutation in sensitivity to 
CVA21 infection, a cell-line microarray to reaffirm the lack of KRAS mutation in BxPC-3 
followed by an in-depth evaluation of the PKR signalling pathway. Additional cell-lines which 
lack KRAS mutation and have high ICAM-1 expression should be evaluated for sensitivity to 
CVA21.  In conclusion, CVA21 oncolytic virus has the potential to be an effective therapy in 
pancreatic cancer however the role of the KRAS mutation in virus induced sensitivity needs 
to be determined. CVA21 has already shown promising potential in vivo using the SCID BALB/C 
pancreatic cancer model displaying reduction in tumour burden after intravenous and 
intratumoural administration (Prof Darren Shafren, 2011).  If any further studies support a 
correlation between KRAS mutation and sensitivity to CVA21 infection it would have 
implications in the clinic. The selection of patients for CVA21 treatment would benefit by 
screening to exclude patients without a KRAS mutation.  
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CHAPTER 5 
 
Evaluation of CVA21 therapeutic efficacy in an 
in vivo murine bladder cancer model 
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CHAPTER 5: EVALUATION OF CVA21 THERAPEUTIC EFFICACY IN AN 
IN VIVO MURINE BLADDER CANCER MODEL 
 
5.1 Introduction 
The therapeutic potential benefit of CVA21 oncolytic virotherapy has already been evidenced 
by its cytolytic effect on bladder cancer cell-lines and CD4+ T cell mediated protection from 
tumour rechallenge seen in a syngeneic murine vaccination model (Chapter 3, Figure 3.18). In 
addition, CVA21 has shown promising therapeutic efficacy in multiple preclinical in vivo 
murine models of pancreatic cancer (Prof Darren Shafren, 2011), melanoma (Au et al, 2005), 
lung cancer (Y.W.Vern, July 2011), prostate cancer (Linda J.Berry, 2006) and breast cancer 
(Skelding et al, 2009). Complete tumour clearance was reported in a PC3 prostate cancer 
xenograft murine model after intravenous CVA21 administration (Berry et al, 2008; Linda 
J.Berry, 2006) whilst reduced tumour burden was evidenced in a NSCLC SCID lung model with 
intratumoral CVA21 inoculation (Y.W.Vern, July 2011). Delay in tumour growth was also seen 
in a melanoma SCID model and a PANC-1 SCID pancreatic model when CVA21 was 
administered via intratumoural and intravenous routes (Au et al, 2005; Shafren et al, 2004). 
Furthermore, a SCID murine xenograft breast cancer model also displayed tumour regression 
with a single dose of intravenous CVA21 administration (Skelding et al, 2009). Thus the aim 
of the work in this chapter was to evaluate the therapeutic effect of CVA21 on bladder cancer 
using an intratumoural administration of CVA21 in a murine subcutaneous bladder cancer 
model. 
In the current study, we assessed whether the in vitro CVA21 oncolytic effect seen in human 
bladder cancer cell-lines could be translated to an in vivo murine bladder cancer model. In 
order to evaluate the oncolytic potential of intratumoural CVA21 as a monotherapy and 
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establish a platform for future combinational studies in vivo, we set out to optimise a 
subcutaneous syngeneic bladder cancer murine model. One of the most commonly used 
bladder cancer murine models is the mouse bladder-49 (MB49).The carcinogen induced 
MB49 tumour cells originated from a primary culture of male C57BL/6 mice bladder cells 
(Summerhayes & Franks, 1979). The murine bladder cells were co-cultured with DMBA for 24 
hours (Summerhayes & Franks, 1979). To test the therapeutic potential of CVA21 in vivo which 
can be easily transferred to clinical settings requires a model that mirrors human cancer 
pathogenesis. Daher C. Chade et al. demonstrated using an MB49 orthotopic murine model 
that it mimicked human bladder cancer progression and was similar in pathology to its human 
counterpart (Chade et al, 2008). We and others have clearly demonstrated that the ICAM-1 
receptor is crucial for CVA21 induced cytolytic effects  and in its absence target cells do not 
undergo infection and subsequent lysis (Shafren et al, 1997b; Skelding et al, 2009; Xiao et al, 
2005). The MB49 murine cell-line lacks ICAM-1 expression therefore, human ICAM-1 was 
transfected into the cell-line by Dr Guy Simpson. The MB49 wild-type and MB49/ICAM-1 cells 
were transplanted in mice at various seeding densities to obtain an optimised bladder cancer 
model with which we could study the therapeutic effects of CVA21 treatment. Before using 
the MB49 cells in vivo the cytolytic effect and immunogenicity of CVA21 in the MB49/ICAM-
1 cells was established in vitro.  
While oncolytic viruses provide therapeutic benefit as an anti-cancer agent, their efficacy can 
be limited due to the presence of an antiviral immune response which could shut down virus 
replication or in addition, the regulatory immune-suppressive tumour microenvironment 
could restrict virus spread. Furthermore, tumour specific adaptive immune responses could 
be hindered within the tumour microenvironment by negative regulatory pathways also 
known as immune checkpoints. In order to gain maximum therapeutic benefit from oncolytic 
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viruses and enhance their efficacy, combination approaches with additional immunotherapy 
agents are being investigated. One such combination approach to prolong tumour specific 
immune responses generated by oncolytic viruses is targeting immune checkpoints. The 
ability of oncolytic viruses to release tumour antigens by direct cell lysis thus priming an 
immune response, together with the proven ability of immune checkpoint blockade agents 
to further prolong OV-induced responses provides the rationale for a combination therapy of 
the two. Immune checkpoint inhibitors release T cell inhibition and help to maintain T cell 
responses. Multiple studies in murine models of cancers using oncolytic viruses in 
combination with immune checkpoint inhibitors have shown promising results. One such 
study combining Newcastle disease virus (NDV) with anti-CTLA-4 antibody in a B16-F10 
murine melanoma model showed rejection of distant tumours, as well as rejection upon re-
challenge in 80 % of mice treated with combination therapy with long term survival (Figure 
5.1) (Zamarin et al, 2014).  
 
 
Figure 5.1 C57BL/6 B16-F10 melanoma murine model showed improved survival with Newcastle disease  
virus and anti-CTLA-4 antibody combination, adapted from (Zamarin et al, 2014). 
 
Anti CTLA-4 antibody injected into B16-F10 mouse melanoma model in combination with Newcastle 
disease virus (NDV) delayed tumour growth and showed prolonged overall  survival which was significantly 
better than PBS isotype control, NDV isotype control and anti -CTLA-4 with PBS. 
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Another study combining reovirus with anti-PD-1 in a B16-F10 melanoma murine model 
enhanced the percentage survival of mice treated with combination therapy as compared to 
mice treated with either therapy alone (Figure 5.2) (Rajani et al, 2015).  
 
 
Other viruses have also been used in combination with immune checkpoint inhibitors in in 
vivo models, for instance vaccinia virus used in combination with anti-CTLA-4 in renal and 
colorectal mouse models showed better therapeutic efficacy than either agent used alone 
(Rojas et al, 2015). Another study conducted in our own laboratory using a mouse prostate 
cancer model (TRAMP-C2) has also shown greater therapeutic effect and controlled tumour 
growth using reovirus in combination with anti-PD-1 therapy as compared to either agent 
used alone (unpublished data). The promising results from these preclinical studies have now 
been translated into the clinic. A phase I clinical trial in patients with unresectable melanoma 
showed 50 % objective response rate with intratumoural administration of the  genetically 
engineered oncolytic herpes virus, T-VEC used in combination with Ipilimumab (anti-CTLA-4) 
(Puzanov et al, 2016). This study has now progressed to a Phase II clinical trial (NCT01740297) 
Figure 5.2 B16-F10 melanoma model showed improved survival with reovirus and anti-PD-1 antibody 
combination, adapted from (Rajani et al, 2015).  
 
B16-F10 murine model treated with reovirus and IgG isotype control delayed tumour growth whereas PBS 
and anti-PD-1 treatment failed to show any tumour regression. Intravenous injection of anti-PD-1 antibody 
7 days post reovirus injection not only prolonged the percentage overall survival but also protected treated 
mice from relapse for 100 days. 
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(https://clinicaltrials.gov/, Accessed 12 Oct 2017; Swart et al, 2016). Furthermore, a phase III 
clinical trial currently recruiting patients with unresectable melanoma is using Pembrolizumab 
(anti-PD-1) in combination with T-VEC (NCT02263508) (https://clinicaltrials.gov/, Accessed 12 
Oct 2017). Currently, four phase I clinical trials are recruiting patients to evaluate the safety, 
efficacy, anti-cancer activity and response rate of CVA21 in combination with immune 
checkpoints. CVA21 in combination with Pembrolizumab (anti PD-1) is currently being 
evaluated in NSCLC and bladder cancer (STORM-Systemic Treatment of Resistant Metastatic 
disease –NCT02043665). Anti PD-1 and CVA21 combination is also being tested in advanced 
NSCLC (NCT02824965). Additionally, phase I clinical trials in advanced melanoma patients 
treated with CVA21 in combination with Ipilimumab, anti-CTLA-4 (MITCI-Melanoma Intra-
Tumoural CAVATAK and Ipilimumab–NCT02307149) and Pembrolizumab (CAPRA-CAVATAK 
and Pembrolizumab in Advanced Melanoma–NCT02565992) are underway 
(https://clinicaltrials.gov/, Accessed 12 Oct 2017). In light of the promising results provided 
by combination of oncolytic viruses and immune checkpoint inhibitors, the combination of 
CVA21 anti-viral therapy with immune checkpoint inhibitors is a promising prospect in the 
future of oncolytic immunotherapy against cancer. 
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5.2 Objectives 
The objectives of this chapter were to evaluate the therapeutic benefit of CVA21 in vivo in an 
optimised murine bladder cancer model. The primary study goal was to establish an in vivo 
bladder cancer murine model to investigate future combinational therapeutic approaches  
using CVA21 and immunomodulatory agents. The murine bladder cancer cell-line, MB49 was 
studied in vitro to determine the immunogenicity of CVA21 infection and death. The 
secondary study outcomes were evaluation of virus-induced reduction in tumour volume and 
improvement in overall survival. The objectives were addressed as follows:  
 MB49 wild-type and MB49 cell-line transfected with human ICAM-1 receptor were used. 
The cell surface density of viral entry receptors was quantified using flow cytometry with 
QuantiBRITE PE beads (BD Bioscience) and western blotting. 
 CellTiter 96® Aqueous One Solution Cell Proliferation Assay (MTS) was used to determine 
viability post virus treatment in MB49 wild-type and MB49/ICAM-1 murine bladder cancer 
cell-lines.   
 To determine the immunogenic potential of CVA21 treatment in MB49/ICAM-1 cell-line, 
calreticulin and HSP70 expression were analysed by flow cytometry. HMGB1 release was 
determined by ELISA (IBL International). 
 The murine bladder cancer model was optimised using male and female mice along with 
inoculation with varying MB49 cell seeding densities to obtain the ideal tumour 
outgrowth.  
 Therapeutic benefit of CVA21 intratumoural administration was determined in the 
MB49/ICAM-1 murine bladder cancer model.  
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 Induction of immune checkpoints on murine PBS and CVA21 treated tumours was 
determined by immunohistochemistry. 
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5.3 Results 
5.3.1 Expression of ICAM-1 on MB49 cell-line transfected with human ICAM-1 
The MB49 wild-type murine bladder cancer cell-line lacked human ICAM-1 expression which 
as previously shown is crucial for CVA21 entry. In order to allow CVA21 to enter these cells 
and replicate, human ICAM-1 was stably transfected by Dr Guy Simpson to produce the 
MB49/ICAM-1 cell-line. The expression of ICAM-1 on the MB49/ICAM-1 cell-line was 
quantified using flow cytometry and western blotting. Whilst the wild-type MB49 cells clearly 
lacked expression of ICAM-1, the transfected MB49/ICAM-1 cells expressed a significant level 
of ICAM-1 (Figure 5.3).  
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Figure 5.3 ICAM-1 expressed on MB49 murine bladder cancer cell-line transfected with human ICAM-1. 
 
PE labelled anti -ICAM-1 antibody was used to quantify the ICAM-1 receptor expression on MB49 wild-type and 
MB49/ICAM-1 murine bladder cancer cell-l ines. (A) Flow cytometric analysis displaying mean fluorescence intensity 
(MFI) of the cells showed the presence of ICAM-1 on the MB49 cell -l ine transfected with human ICAM-1 and lack of 
receptor expression by the MB49 wild-type cell-l ine. Graph represents pooled data from two independent 
experiments. (B) Representative histograms of ICAM-1 expression by MB49 wild-type and MB49/ICAM cells (grey 
peak) compared to unstained negative control (black peak). (C) ICAM-1 expression by western blotting showing 
absence of ICAM-1 in MB49 wild-type and high ICAM-1 expression on MB49/ICAM-1 cell-l ine. For each sample, 
GAPDH housekeeping protein was used as a loading control . 
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5.3.2 Susceptibility of MB49 wild-type and MB49/ICAM-1 to CVA21 induced death 
CVA21 as a treatment for bladder cancer had previously been assessed in human bladder 
cancer cell-lines and showed sensitivity to CVA21 induced death with increasing virus titres 
(Section 3.3.1). In order to determine susceptibility to CVA21 induced death in the murine 
bladder cancer cell-lines, MB49 wild-type and MB49/ICAM-1 were treated with an increasing 
concentration of CVA21 from 0 to 50 MOI and incubated for 72 hours. CellTiter 96® Aqueous  
One Solution Cell Proliferation Assay (MTS) was used to quantify percentage survival of cells 
72 hours post virus treatment (Section 2.5). The CVA21 induced cytotoxicity was further 
quantified using ViViD-live dead stain (Section 2.6.2) and Annexin PE apoptosis assay (Section 
2.6.4). 
The MTS cell viability assay results (Figure 5.4 (A)) clearly demonstrated that the MB49 wild-
type cell-line was resistant to CVA21 induced death whereas the MB49/ICAM-1 cell viability 
reduced to 50 % at the lowest CVA21 MOI of 0.78. MB49/ICAM-1 cell survival percentage 
remained constant with increasing CVA21 MOI with a 10 % increase in percentage of dead 
cells at the highest CVA21 MOI of 50. The lack of a survival curve and stable cell survival 
percentage with increasing CVA21 MOI made it difficult to calculate the IC50 therefore, other 
cell viability assays were performed. For further experiments, to obtain MB49/ICAM-1 IC50 
CVA21 MOI 0-12.5 was used as the MTS results had showed less than 50 % cells surviving at 
CVA21 MOI 50. Annexin results showed an exponential increase in total percentage apoptosis 
in the MB49/ICAM-1 cell-line with 50 % cell death at CVA21 MOI 12.5 (Figure 5.4 (B)). As 
expected, increasing CVA21 concentration did not affect total percentage apoptosis in MB49 
wild-type cells with <20 % cells undergoing apoptosis. These results were in agreement with 
ViViD live dead cell staining data where 90 % cells remained viable in the MB49 wild-type cell-
line whilst only 50 % survived in the MB49/ICAM-1 cell-line at CVA21 MOI 12.5 (Figure 5.4 
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(C)). The IC50 for MB49/ICAM-1 cell-lines was obtained using the CalcuSyn software, giving a 
CVA21 MOI of 6.25. These results reiterate the crucial role of ICAM-1 receptor for CVA21 
induced cell death.  
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Figure 5.4 MB49/ICAM-1 murine bladder cancer cell-line is sensitive to CVA21 induced death. 
 
To determine sensitivity to CVA21 induced death MB49 wild-type and MB49/ICAM-1 cell-l ines were treated with 
CVA21 MOI 0-50. Cell  viability was analysed using MTS assay, ViViD live dead stain and annexin V-PE apoptosis 
kit. (A) MTS cell survival plot showed lack of CVA21 induced sensitivity in MB49 wild -type cell-l ine whereas 
MB49/ICAM-1 cell-l ine succumbed to CVA21 induced death after 72 hours incubation. (B) Total percentage 
apoptosis remained <20 % in MB49 wild-type cell-l ine with increasing CVA21 MOI whereas MB49/ICAM-1 had 50 
% total percentage apoptosis at CVA21 MOI 12.5. (C) ViViD live dead staining results supported the annexin results 
and showed 50 % cells survived at CVA21 MOI 12.5 in the MB49/ICAM-1 cell-l ine whereas 90% cells were viable 
in the MB49 wild-type cell-l ine. Graphs represent data from one experiment. 
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5.3.3 Expression of ICD determinants by MB49/ICAM-1 murine bladder cancer cell-line 
treated with CVA21 
 
It was further addressed whether the mode of cell death induced by CVA21 in murine bladder 
cancer cell-line was immunogenic. ICD is characterised by the release of DAMPs such as 
calreticulin, HSP70 and HMGB1. Expression of ICD markers and determinants was analysed 
by flow cytometry (Section 2.6.3). HMGB1 expression was quantified by sandwich ELISA.  The 
MB49/ICAM-1 murine bladder cancer cell-line was treated with CVA21 and incubated for 24-
72 hours. Cells and supernatants were harvested at 24, 48 and 72 hours. Flow analysis was 
performed for calreticulin and HSP70 expression. The MB49/ICAM-1 cell-line showed a 
significant increase in the expression of calreticulin after 24 hours CVA21 treatment (Figure 
5.5 (A)). HSP70 expression reduced in both untreated and CVA21 treated cells over time 
however, there was no significant difference between the two (Figure 5.5 (B)), whilst the 
expression of HMGB1 significantly increased after 48-72 hours CVA21 treatment (Figure 5.5 
(C)). 
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Figure 5.5 Selective induction of calreticulin and HMGB1 immunogenic cell death determinants by CVA21 
infection in MB49/ICAM-1 murine bladder cancer cell-line. 
  
The murine bladder cancer cell  line MB49/ICAM-1 was treated with CVA21 for 24-72 hours. Cells and supernatants 
were harvested at 24, 48 and 72 hours. Cell  surface exposure of the immunogenic cell  death marker, calreticulin 
and HSP70 was determined by flow cytometry. HMGB1 secretion was determined by ELISA analysis of 
supernatants. (A) MB49/ICAM-1 cell-l ine displayed significant upregulation of calreticulin in CVA21 treated cells 
at 24 hours. (B) The expression of HSP70 reduced overtime in both untreated and CVA21 treated cells . (C) HMGB1 
expression was significantly enhanced in MB49/ICAM-1 cell-l ine 48-72 hours after CVA21 treatment. Graphs 
represent pooled data from two independent experiments and two-way ANOVA statistical analysis was 
performed. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. 
 
2 4  H o u r s 4 8  H o u r s 7 2  H o u r s  
0
1
2
3
M
F
I 
H
S
P
7
0
U n tre a ted
C V A 2 1
2 4  H o u r s 4 8  H o u r s 7 2  H o u r s  
0 .0
0 .1
0 .2
0 .3
0 .4
M
F
I 
C
a
lr
e
ti
c
u
li
n
U n tre a ted
C V A 2 1
** 
2 4  H o u r s 4 8  H o u r s 7 2  H o u r s
0
2 0
4 0
6 0
8 0
1 0 0
1 2 0
1 4 0
1 6 0
1 8 0
2 0 0
2 2 0
U n tre a ted
C V A 2 1
H
M
G
B
-1
 c
o
n
c
e
n
tr
a
ti
o
n
 (
n
g
/m
l) ** 
* 
A
B
C
201 
 
5.3.4 Optimisation of the MB49/ICAM-1 murine bladder cancer model 
In this section we address the experiments undertaken to optimise an in vivo bladder cancer 
model to study the oncolytic effects of CVA21. The murine bladder cancer model was used to 
investigate the therapeutic benefit of CVA21 oncolytic therapy and also provides a platform 
to test future combination studies to further enhance treatment efficacy. Firstly, we 
determined the difference in growth of MB49/ICAM-1 cell transplanted tumours based on 
the gender of the mice. As previously reported, MB49 cancer cells grow rapidly in male mice 
as compared to female mice due to the origin of these cells being from a male mouse (Loskog 
et al, 2005; White-Gilbertson et al, 2016). Secondly, we optimised the outgrowth of the 
tumour observed in mice as the aggressiveness of the MB49 bladder cancer model has 
previously been reported (Loskog et al, 2005). The immune response against human ICAM-1 
transfection in the MB49 mouse cells and its effect on tumour outgrowth was also 
determined. Lastly, the therapeutic benefit of CVA21 administration in this model was 
evaluated. The endpoints of the study were delay in tumour growth and reduction in tumour 
burden.  
5.3.4.1 Lack of tumour growth in female mice transplanted with MB49/ICAM-1 cells 
The current experiment set out to evaluate the tumour growth in C57BL/6 female mice to 
establish a model for CVA21 oncolytic virus therapy. Six, 5 week old, female mice were used 
in this experiment. Three mice were placed in each cage and acclimatised for one week to the 
experimenter and the surrounding. The mice were anaesthetised using isoflurane and 1×106 
MB49/ICAM-1 cells per mouse were subcutaneously injected in the right flank of the animal 
(Section 2.17.3.1). The average tumour volume (mm3) of the group was determined 
approximately every two days till day 16 (Figure 5.6). MB49/ICAM-1 cells administered into 
C57BL/6 female mice established tumours approximately 70 mm3 in size on day 1 of 
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measurement. However, the tumours failed to grow and average tumour volume remained 
constant at approximately 100 mm3 from days 2 to 16. On day 16 the experiment was 
terminated and mice were euthanised.  
 
Having had no tumour outgrowth of MB49/ICAM-1 cells in female mice we further 
investigated the possible cause of this finding. A.Loskog et al. have previously shown 
detection of a palpable tumour in both male and female mice upon transplantation of MB49 
cells, however due to the male origin of the tumour cells the presence of the HY antigen made 
the cells immunogenic in female mice (Loskog et al, 2005). Despite the initial reduced tumour 
growth observed in female mice as compared to male mice, once established the tumour 
grew rapidly. (Loskog et al, 2005). In light of these findings by A.Loskog et al. the lack of 
tumour growth observed in MB49/ICAM-1 transplanted female mice could be due to immune 
rejection of the male-derived MB49 cell-line.  
Figure 5.6 Lack of tumour outgrowth in female C57BL/6 after MB49/ICAM-1 cell transplantation. 
  
C57BL/6 female mice were injected subcutaneously with 1×10 6 MB49/ICAM-1 cells. Tumour growth was 
measured every two days til l  day 16 when the animals were euthanised. The average tumour volume measured 
on day 1 was approximately 70 mm3. The tumour volume remained constant at approximately 100 mm3 from 
days 2 to 16. Graph represents data from one experiments, n = 6 mice in group. 
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5.3.4.2 Reduced tumour growth in mice transplanted with MB49/ICAM-1 cells 
Due to the lack of tumour growth in female C57BL/6 mice, the MB49/ICAM-1 cells were 
transplanted in male C57BL/6 mice. In order to eliminate the possibility of human ICAM-1 
inducing an immune response in the mice and rejecting tumour outgrowth, the difference 
between tumour growth by MB49 wild-type cells and MB49/ICAM-1 cells was evaluated. Two 
seeding densities, 1×106 and 1×104 cells/ mouse, of both the cell-lines were used. Tumour 
outgrowth using both seeding densities had been previously reported in an earlier study using 
the MB49 murine bladder cancer model (Loskog et al, 2005).  Male C57BL/6 mice (41-49 
weeks old) were divided into four groups consisting of 6 mice in each group. Groups were 
injected with MB49 wildtype cells at 1×104 cells/mouse and 1×106 cells/mouse, or 
MB49/ICAM-1 cells at 1×104 cells/mouse and 1×106 cells/mouse. The cells were injected 
subcutaneously in the right flank diluted in 100 µl of PBS. Tumours were measured twice a 
week. Palpable tumours were not detected in mice injected with either MB49 wildtype or 
MB49/ICAM-1 cells at 1×104 cells/mouse (Figure 5.7 (A)). In contrast, palpable tumours were 
detected in mice injected with MB49 wildtype or MB49/ICAM-1 cells at 1×106 cells/mouse, on 
day 4 which then showed exponential tumour growth to approximately 550 mm3 and 350 
mm3 respectively by day 14. However, MB49 wildtype transplanted tumour outgrowth was 
significantly greater than MB49/ICAM-1 transplanted tumour growth. This limitation could be 
overcome by injecting more MB49/ICAM-1 cells to obtain the same tumour growth. The 
reasons for difference in growth kinetics between MB49 wildtype and MB49/ICAM-1 
transplanted tumours is not clear. However, both MB49/ICAM-1 and MB49 wildtype 
transplanted mice developed ulcers in their tumours (representative image, Figure 5.7 (B)). A 
previous study had also reported the presence of ulceration and hypoxic tumour core in MB49 
transplanted tumours (Loskog et al, 2005). The hypoxic and limited blood supply in the 
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tumour could limit CVA21 replication and growth when injected intratumourally. Thus, in the 
subsequent experiments a cell seeding density of 7.5×105/mouse was used to reduce tumour 
outgrowth and ulceration. 
 
 
Figure 5.7 Exponential tumour growth in mice transplanted with MB49/ICAM-1 cells. 
  
C57BL/6 male mice were injected subcutaneously with 1×10 6 and 1×104 MB49/ICAM-1 cells/mouse or 1×106 
and 1×104 MB49 wildtype cells/mouse. Mice were kept in four groups consisting of six mice each. Tumour 
growth was measured every two days ti l l  day 14 when the animals were euthanised. (A) Mice transplanted with 
1×104 MB49/ICAM-1 and MB49 wildtype cells/mouse failed to develop any palpable tumours. Whilst, 1×106 
MB49/ICAM-1 and MB49 wildtype cells/mouse transplanted mice developed tumours. On day 14, 1×106 MB49 
wildtype cells/mouse tumour average was  approximately 600 mm3 whereas 1×106 MB49/ICAM-1 cells/mouse 
tumour average was 300 mm3. Two-way ANOVA statistical analysis was performed. *P < 0.05, **P < 0.01, ***P 
< 0.001, ****P < 0.0001. (B) Representative image displaying ulceration (indicated by black arrows) in 
MB49/ICAM-1 transplanted mouse. 
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5.3.4.3 CVA21 administration delayed tumour growth in MB49/ICAM- 1 transplanted mice 
Having shown that MB49/ICAM-1 cells transplanted in male C57BL/6 mice resulted in 
exponential growth of the tumour, the therapeutic benefit of administering CVA21 oncolytic 
virotherapy in this cancer model was then investigated. 7×105 MB49/ICAM-1 cells per mouse 
were subcutaneously injected in the right flank of the animal. This reduced cell seeding was 
chosen to try to prevent ulceration of tumours and reduce the rapid increase in tumour 
volume over a short time.  24 C57BL/6 male mice were divided into 3 groups consisting of 8 
mice in each group. All mice were injected with 7×105 cells/mouse diluted in 100 µl of PBS. 
CVA21 was administered intratumourally when the average tumour size reached 50-100 mm3  
for each group (Figure 5.8). 50 µl of PBS, or two CVA21 concentrations (1.88×106 pfu/ml and 
3.75×106 pfu/ml) were injected into the tumour bearing mice.  A total of three doses of CVA21 
were given, on day 5, 8 and 11, respectively. As expected, the PBS control mice displayed 
exponential growth of tumour with 300 mm3 maximum average tumour reported on day 15. 
Delayed tumour growth was seen in CVA21 1.88×106 pfu/ml and 3.75×106 pfu/ml treated 
mice which showed similar tumour growth curves. The first two doses of CVA21 controlled 
the tumour growth and maintained average tumour volume at 50 mm3 however, after the 
third CVA21 dose average tumour volume increased to 200 mm3 on day 15. No ulceration was 
observed in any of the animals and they were euthanized on day 15.  
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5.3.5 Expression of Immune checkpoints after CVA21 treatment  
In order to design future combination treatments that would enhance the therapeutic benefit 
of CVA21 oncolytic virotherapy in bladder cancer, the presence of potential targets for 
immune-modulatory agents was investigated in the murine tumour tissues. The tumours from 
the mice used in the previous experiment (Section 5.3.4) were harvested, fixed in formalin 
and paraffin embedded (Section 2.9.1). The tumour sections obtained from PBS and CVA21 
1.88×106 pfu/ml treated mice were stained for the immune checkpoint ligands PD-L1, 
Galectin-9 (binds to Tim-3 resulting in T cell exhaustion) and the immunosuppressive enzyme 
Indoleamine 2, 3-dioxygenase (IDO). The slides were also reviewed by an independent 
pathologist, Dr Izhar Bagwan, at the Royal Surrey County Hospital.   
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Figure 5.8 Delayed tumour growth in CVA21 treated mice compared to PBS treated mice. 
  
C57BL/6 male mice were injected subcutaneously with 7.5×105 MB49/ICAM-1 cells/mouse. Mice were divided 
into three groups and once average tumour volume reached 50-100 mm3 mice were injected intratumourally 
with PBS, CVA21 1.88×106 pfu/ml and CVA21 3.75×106 pfu/ml. Three doses CVA21 were administered in total 
on day 5, 8 and 11 (represented by purple arrows). Tumour growth was measured every two days ti l l  day 15 
when animals were euthanised. Delayed and controlled tumour growth was seen in CVA21 treated mice as 
compared to PBS treated mice. The first two doses of CVA21 controlled the tumour growth and maintained 
average tumour volume at 50 mm3 however, after the third CVA21 dose average tumour volume increased to 
200 mm3 on day 15. Two-way ANOVA statistical analysis was performed. *P < 0.05, **P < 0.01, ***P < 0.001, 
****P < 0.0001. 
 
**** 
**** 
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5.3.5.1 PD-L1 expression on murine tumour tissue 
The anti-PD-L1 antibody was optimised on mouse thymus and a dilution of 1 in 100 was used 
for murine tumour tissue staining (Section 2.9). PD-L1 positive staining was detected in the 
epithelial cells of the medullary region of the thymus. Staining on the murine thymus was 
detected within the germinal centre on the T cells. In murine tumours, PD-L1 staining was 
seen in 4 out of 8 CVA21 treated mice and 3 out of 8 PBS treated mice (Figure 5.9).  However, 
the PD-L1 positivity was localised to small areas only on the tumour infiltrating lymphocytes  
in particular, on macrophages. Tumour cells remained negative for PD-L1 staining and no 
difference in staining pattern between PBS and CVA21 treated murine tumours was observed.  
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Figure 5.9 Examples of PD-L1 expression in PBS and CVA21 treated murine bladder cancer tumour tissue. 
  
C57BL/6 male mice with subcutaneous MB49/ICAM-1 bladder cancer tumour were injected intratumourally with PBS and 
CVA21 1.88×106 pfu/ml. Three doses of CVA21 were administered in total. Tumour growth was measured every two days 
ti l l  day 15 when animals were euthanised. The tumour tissues were harvested, paraffin embedded and sectioned. The 
sections were stained for PD-L1 expression. Small localised areas displaying PD-L1 positive staining on T cells was observed 
with no difference between staining pattern in the PBS and CVA21 treated mice. In the mouse thymus, used as a positive 
control, PD-L1 expression was seen on the T cells in the medullary epithelial cells and tumour infi ltrating lymphocytes. The 
positive PD-L1 staining is displayed by the brown colour in the above images (indicated by the red arrows).Magnification 
×20 and ×40. 
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5.3.5.2 Galectin 9 expression on murine tumour tissue 
The anti-Galectin 9 antibody was optimised on mouse spleen and a dilution of 1 in 500 was 
used for murine tumour tissue staining  (Section 2.9). The murine spleen is split into two areas, 
red pulp consisting mainly of erythrocytes and white pulp which contains lymphocytes , 
macrophages and dendritic cells. Most of the epithelial cells found in the white pulp of the 
murine spleen stained positive for Galectin 9 expression. In the spleen, dot positive and 
membranous staining was observed mainly on the macrophages and the natural killer T cells. 
However, Galectin 9 staining on the murine tumours consisted of background and had 
technical artificial staining which made it difficult to interpret results. Although no tumour 
cells stained positive for Galectin 9, necrotic inflammatory cells were darkly stained for 
Galectin 9 on all of the CVA21 and PBS treated murine tumours (Figure 5.10).   
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Figure 5.10 Examples of Galectin 9 staining pattern in PBS and CVA21 treated murine bladder cancer tumour tissue. 
  
C57BL/6 male mice with subcutaneous MB49/ICAM-1 bladder cancer tumour were injected intratumourally with PBS 
and CVA21 1.88×106 pfu/ml. Three doses CVA21 were administered in total. Tumour growth was measured every 
two days ti l l  day 15 when animals were euthanised. The tumour tissues were harvested, paraffin embedded and 
sectioned. The sections were stained for Galectin 9 expressi on. Considerable expression of Galectin 9 was observed 
all of the PBS and CVA21 treated murine tumours. Mouse spleen was used as a positive control for Galectin 9 and 
showed positive staining in cells located in the white pulp of murine spleen. The positiv e Galectin 9 staining is 
displayed by the brown colour in the above images (indicated by the red arrows).Magnification ×20 and ×40 . 
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In this study, expression of IDO was also evaluated however, the positive control tissue did 
not give the expected IDO staining pattern and therefore the lack of IDO positivity found on 
the tumour tissues could not be trusted. In the future, other IDO antibodies need to be tested 
and validated before an evaluation of IDO expression in the tumours can be made. 
Additionally, more techniques need to be explored such as nanostring to analyse the potential 
role of immune checkpoints in response to CVA21 treatment. 
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5.4 Discussion 
We established the sensitivity of a murine bladder cancer cell-line to CVA21 infection and 
confirmed the effectiveness of CVA21 as an inducer of ICD in these murine bladder cancer 
cells. Having already proven the immunogenic potential of CVA21 oncolytic therapy in vivo in 
a syngeneic murine model we went on to optimise a subcutaneous bladder cancer murine 
model to study the effect of intratumoural CVA21 administration on tumour volume and 
growth.  
The MB49 murine bladder cancer cell-line lacked ICAM-1 expression which is crucial for 
CVA21 entry therefore, human ICAM-1 receptor was transfected into these cells. After stable 
human ICAM-1 expression on MB49 murine bladder cancer cells, the cells became sensitive 
to CVA21 induced cytolysis. The MB49/ICAM-1 cells underwent CVA21-induced immunogenic 
cell death as evidenced by a significant increase in expression of calreticulin and release of 
HMGB1 following viral treatment. Initial experiments to optimise the subcutaneous bladder 
cancer murine model showed that upon inoculation of MB49/ICAM-1 cells in female C57BL/6 
mice, no exponential tumour growth was observed and the average tumour volume remained 
at approximately 50 mm3 over a period of 14 days. In contrast to our findings, others have 
reported a reduced but exponential increase in tumour volume in female mice as compared 
to male mice (Loskog et al, 2005; White-Gilbertson et al, 2016). The reduced tumour growth 
in female mice transplanted with MB49 murine bladder cancer cells in comparison to male 
mice was most likely due to the fact that the MB49 cells originate from a male mouse resulting 
in an immune response induced in female mice to the HY antigen thus preventing tumour 
outgrowth (Loskog et al, 2005; Summerhayes & Franks, 1979). This finding was confirmed by 
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our results displaying exponential MB49 transplanted tumour growth in male C57BL/6 mice 
in contrast to the lack of tumour outgrowth in female mice.  
Importantly, the murine ICAM-1 amino acid sequence has 50 % homology to the human 
ICAM-1 (Horley et al, 1989; Register et al, 1991) and raises the possibility of an immune 
mediated attack against human ICAM-1 which could reject the tumour cells upon 
implantation. However no tumour rejection was observed in MB49/ICAM-1 transplanted 
mice but our results showed a significant difference of approximately 200 mm3 between the 
average tumour volume of MB49 wild-type (550 mm3) and MB49/ICAM-1 (350 mm3) in 
transplanted mice. The reasons for difference in tumour growth characteristics between 
MB49 wild-type and MB49/ICAM-1 transplanted tumours is not clear. In contrast to our 
results where no tumour outgrowth was reported after transplantation of 1×104 MB49 cells 
in mice, A. Loskog et al. detected palpable tumour in mice transplanted with 1×104 MB49 cells 
(Loskog et al, 2005). Although, we were unable to identify palpable tumour in mice injected 
with 1×104 MB49 wild-type or MB49/ICAM-1 cells, rapid tumour growth was observed in mice 
inoculated with 1×106 MB49 wild-type or MB49/ICAM-1 cells. 
A limitation with the MB49 model regardless of human ICAM-1 presence was the formation 
of ulcers and a hypoxic tumour core in rapidly growing tumours which limited the time span 
of the model to 14-16 days, also reported previously (Loskog et al, 2005). In order to reduce 
tumour burden and prolong the model time-span we injected less tumour cells.  Upon 
inoculation of 7.5×105 MB49/ICAM-1 cells per mouse no tumour ulceration were observed. 
Intratumoural CVA21 injection resulted in reduced tumour burden and delay in tumour 
growth in CVA21 treated mice as compared to the PBS control group. A significant difference 
in average tumour volume of the PBS treated and CVA21 treated mice was seen, with CVA21 
treated mice having 100 mm3 less average tumour volume from 8-15 days. No significant 
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difference was reported between the two concentrations of CVA21 (1.88×106 and 3.75×106 
pfu/ml) and a third virus inoculation displayed no therapeutic benefit which led to rapid 
increase in average tumour volume. One of the possible reasons for rapid tumour growth 
after the third dose of virus could be escape of less immunogenic tumour variants due to 
selective pressure imposed by the virus. That could have led to evasion of tumour specific 
immune response leading to outgrowth of cells with high mutational burden capable of 
maintaining an inhibitory microenvironment. A study by Theresa et al. has demonstrated 
tumour control in a pancreatic murine model after first dose of NDV followed by rapid tumour 
growth and increase in the presence of an anti-inflammatory phenotype with cells expressing 
less MHC I, more TGF β and FoxP3 after following viral doses (Schwaiger et al, 2017). This 
highlights the heterogeneity amongst cancer cells and in future studies the role of virus 
induced selection pressure leading to tumour cell escape from immune mediated control 
needs to be investigated.  
In order to identify possible targets of immune-modulatory agents which could be used in 
conjunction with CVA21 oncolytic virotherapy to potentially provide enhanced therapeutic 
benefit, we harvested the murine tumours and stained for some of these targets. Our results 
showed expression of PD-L1 (ligand for PD-1, provides peripheral tolerance and inhibitions of 
T cell activation) and Galectin 9 (ligand for Tim-3, interaction leads to reduced T cell 
infiltration) on both PBS and CVA21 1.88×106 pfu/ml treated mice. Previous studies using 
oncolytic viruses in animal models have reported an increase in expression of immune 
checkpoints after oncolytic virus administration (Shim et al, 2017; Zamarin et al, 2014). The 
increase in the expression of immune checkpoints such as Tim-3, LAG-3, IDO and PD-L1 was 
also observed within the tumour microenvironment of CANON trial patients treated with 
CVA21 as compared to untreated NMIBC patients (unpublished data). The evidence that 
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targeting immune checkpoints can improve therapeutic efficacy is clearly supported by 
clinical studies using CVA21 in combination with Ipilimumab and Pembrolizumab in 
melanoma and NSCLC (AACR, 2017). In these clinical studies intra-lesional CVA21 injections 
combined with Ipilimumab led to 50 % objective response in melanoma patients with no 
reported serious adverse events (AACR, 2017) and complete/partial response in 8 of the 11 
melanoma patients treated with CVA21 in conjunction with Pembrolizumab was observed 
(AACR, 2017). However, Vile et al. have shown that presence of immune checkpoints alone is 
not the defining feature of immunotherapy success and functional capacity of the target T 
cells needs to be studied (Shim et al, 2017).  This study utilised another virus, VSV modified 
to express a tumour associated antigen, gp100 when administered in a B16 melanoma model 
induced CD8 T cell expansion displaying an increase in expression of Tim-3 and PD-1 immune 
checkpoints (Shim et al, 2017). However, the study failed to show improved treatment 
outcomes with VSV used in combination with anti-PD-1 and anti-Tim-3 although both markers  
were highly expressed on tumours post virus treatment (Shim et al, 2017). The authors further 
emphasized that expression of immune checkpoints on tumour cells is not necessarily due to 
acute T cell activation or expansion but could be due to immune cell dysfunction or exhaustion 
(Shim et al, 2017). This highlights the need to screen murine tumours for the presence of 
immune checkpoints on immune cell subtypes to uncover its full therapeutic potential.  
Before combining CVA21 with immune checkpoint inhibitor therapy in the MB49 murine 
bladder cancer model, further studies need to address whether the lack of increased immune 
checkpoint expression in virus treated murine tumours is due to the short life span of the 
MB49/ICAM-1 model. Combination studies performed by others on murine melanoma 
models lasted for approximately 60 - 150 days and our current MB49/ICAM-1 bladder cancer 
murine models lasts for 16 days maximum (Rajani et al, 2015; Shim et al, 2017; Zamarin et al, 
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2014). The time span of the MB49/ICAM-1 model is a limitation for future combination 
studies, it not a good in vivo model system to allow us to fully explore the therapeutic 
potential of such treatments and does not mirror tumour development in humans. In future 
studies alternative murine bladder cancer models should be explored. Other syngeneic 
bladder cancer murine models include AY-27 and MBT-2 which are both induced by feeding 
N- [4- (5-nitro-2-furyl) -2-thiazolyl] formamide (FANFT) to Fisher 344 rats and C3H/He mice 
(Ding et al, 2014).However, these cell-lines will need to be transfected with human ICAM-1 as 
its murine counterpart cannot bind to rhinoviruses (Register et al, 1991). 
In summary, we tested a bladder cancer murine model which showed delayed tumour growth 
in CVA21 treated mice as compared to PBS treated mice. However, the current model has 
several limitations. This model enables virus to hold tumour growth for only a short span of 
time followed by unrestricted tumour growth which is not controlled by further virus 
inoculations. In the short span of the model we were unable to evaluate the effect of virus on 
induction of potential markers to be targeted by immune-modulatory agents in a combination 
approach.  Further work needs to be done to address these limitations mainly by evaluating 
other bladder cancer murine models.  
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CHAPTER 6: CONCLUSION AND GENERAL OVERVIEW 
6.1 Conclusion 
Oncolytic viruses are a promising treatment option for both local and advanced cancers as 
they not only lyse tumour cells directly but also induce a tumour antigen specific immune 
response (Choi et al, 2016; Lichty et al, 2014). Oncolytic virotherapy has already 
demonstrated promising potential in the treatment of multiple cancers. The success of two 
oncolytic viruses in phase III clinical trials led to approval for use in the clinic, T-VEC for the 
treatment of melanoma and use of Adenovirus (H101), only in China, for head and neck 
cancers (Kaufman et al, 2015). Novel alternative cancer therapies such as oncolytic 
virotherapy are being sought as conventional therapies provide limited therapeutic benefit 
and disease free survival. For instance, the rate of cancer recurrence in NMIBC is 60-70 % after 
treatment and 20-30 % of cases progress to advanced disease (Aldousari & Kassouf, 2010). 
Additionally current treatments fail to tackle pancreatic cancer which is an aggressive disease 
with poor prognosis (Deer et al, 2010). The therapeutic potential of targeting these 
malignancies with oncolytic viruses is promising. 
This thesis set out to evaluate CVA21 as a treatment for bladder and pancreatic cancers, due 
to the natural ability of CVA21 to selectively target cancer cells. The cytolytic  ability of CVA21 
has been tested in multiple cancers which highlighted that the sensitivity to CVA21 induced 
death depends on expression of membrane bound ICAM-1 and DAF receptors (Bradley et al, 
2014). However, recent studies have highlighted a more crucial role of ICAM-1 receptor in 
CVA21 mediated endocytosis (Shafren et al, 1997b; Skelding et al, 2009). Our results support 
the previous findings as bladder and pancreatic cell-lines expressing high ICAM-1 receptor 
succumbed to CVA21 induced death whereas cell-lines with low ICAM-1 expression remained 
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resistant to CVA21 infection (Bradley et al, 2014; Shafren et al, 2004; Skelding et al, 2009). 
Furthermore, the expression of DAF receptor did not correlate with CVA21 induced sensitivity 
or resistance in any of the bladder and pancreatic cancer cell-lines studied. This result 
reiterates the role of DAF receptor as a co-facilitator and ‘concentration’ receptor which is 
unable to induce a lytic infection as previously shown by others (Newcombe et al, 2004; 
Shafren et al, 1997b; Skelding et al, 2009). Although ICAM-1 is overexpressed in many cancers 
and most of the cell-lines we tested displayed high ICAM-1 expression, there were a few 
bladder and pancreatic cancer cell-lines that exhibited low ICAM-1 expression and remained 
insensitive to CVA21 induced lysis. In a clinical setting the lack of ICAM-1 expression in some 
patient’s tumours will limit the effectiveness of CVA21 virotherapy. However, this limitation 
could be overcome with the use of a recently developed bioselected CVA21 variant which 
binds to DAF resulting in lysis and infection of target cells (Johansson et al, 2004). Such 
variants of CVA21 with differing specificity for ICAM-1 or DAF will aid in expanding this therapy 
to a larger range of cancer types.   
As the presence of ICAM-1 is of fundamental importance to CVA21 infection and its 
overexpression has been reported on multiple cancers, the application of CVA21 oncolytic 
therapy has the potential to be extended to more cancers. The viral entry receptor, ICAM-1, 
is highly expressed on bladder and pancreatic cancers as compared to normal cells , as we and 
others have previously shown (https://www.proteinatlas.org/ENSG00000090339-
ICAM1/pathology, assessed on 10 Dec 17; Shimoyama et al, 1997; Tempia-Caliera et al, 2002). 
Tissues from melanoma, lung cancer, lymphoma, ovarian cancer, liver cancer, thyroid cancer, 
head and neck cancers, cervical cancer and stomach cancer have been shown to display high 
to moderate ICAM-1 expression (https://www.proteinatlas.org/ENSG00000090339-
ICAM1/pathology, assessed on 10 Dec 17). Preclinical studies using CVA21 oncolytic therapy 
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have already shown tumour regression in murine models of various cancers (melanoma, 
breast cancer, prostate cancer, lung cancer) which display higher ICAM-1 expression in cancer 
cells compared to normal cells (Berry et al, 2008; Shafren et al, 2004; Skelding et al, 2009; 
Y.W.Vern, July 2011). Additionally, clinical studies in NMIBC and late stage melanoma have 
already shown a therapeutic benefit of using CVA21 in cancers with high expressing ICAM-1. 
A phase II study, CALM (CAVATAK in Late stage Melanoma) conducted in 57 late stage 
melanoma showed 75.4 % one year survival rate and 39 % immune related progression free 
survival at six months (NCT01227551)  (https://clinicaltrials.gov/, Accessed 12 Oct 2017; 
https://www.viralytics.com/our-pipeline/cavatak/cavataktm/, assessed on 7 Dec 17; Robert 
Hans Ingemar Andtbacka, ESMO 2015, September 25-29, Vienna,Austria; Robert Hans 
Ingemar Andtbacka, ASCO 2016, June 3-7, Chicago,USA). Another phase I/II clinical trial, 
CANON (CAVATAK in Non-Muscle Invasive Bladder Cancer) resulted in one complete 
response, virus induced apoptosis and virus replication detection in the urine of all virus 
treated patients (NCT02316171) (HS Pandha, 2015; https://clinicaltrials.gov/, Accessed 12 Oct 
2017; https://www.viralytics.com/our-pipeline/cavatak/cavataktm/, assessed on 7 Dec 17).  
Importantly, in this thesis we have also shown that the tumour selective death induced by 
CVA21 oncolytic therapy is immunogenic as characterised by the increase in expression of 
immunogenic cell death markers i.e. calreticulin and HMGB1 on human and murine bladder 
cancer cell-lines. In addition to the expression of molecular ICD signatures on human bladder 
cancer cell-lines, MB49/ICAM-1 bladder cancer cells treated with CVA21 undergoing 
immunogenic cell death led to MB49 tumour rejection in a syngeneic murine bladder cancer 
model. This protection was provided by activation of CD4+ T cells. These findings are 
supported by data from the CANON trial which displayed an increase in HMGB1 levels in the 
urine of CVA21 treated patients and induction of apoptotic cell death genetic markers in 
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CVA21 treated patients’ tumours (unpublished data). Therefore, CVA21 can be added to a 
growing list of oncolytic viruses including measles virus (Donnelly et al, 2013), coxsackievirus 
B3 (Miyamoto et al, 2012), adenovirus (Diaconu et al, 2012), newcastle disease virus (Koks et 
al, 2015) and vaccinia virus (Whilding et al, 2013) capable of inducing immunogenic cell death. 
This induction of ICD by oncolytic viruses further supports the ability of these viruses to induce 
a potent systemic tumour specific immune response leading to increased therapeutic benefit. 
In order to use CVA21 in the clinic, it is important to understand the resistance mechanisms 
to CVA21 in tumour cases which display high ICAM-1 receptor expression yet fail to undergo 
CVA21 induced cytolysis. This will enable identification of patients who will gain the most 
therapeutic benefit by screening for predictive biomarkers of viral sensitivity prior to 
administration of CVA21 oncolytic therapy. In Chapter 4 resistance to CVA21 infection was 
observed in high ICAM-1 expressing cell-line. Whilst, we were unable to identify the specific 
mechanism of resistance to CVA21 infection observed in BxPC-3 pancreatic cancer cell-line, 
one factor that may play a role is the mutational background of the cancer cell line. Mutations  
in KRAS enable evasion of anti-viral immune responses however, in the absence of KRAS 
mutations, interferon induced PKR shuts down virus replication. Future studies need to 
investigate whether the absence of KRAS mutation in the BxPC-3 cell-line plays a role in the 
resistance to CVA21 infection despite the presence of high ICAM-1 expression.  
Clinical evidence has clearly shown therapeutic benefit of CVA21 is enhanced by using 
combination therapeutic approach. In order to investigate whether such an approach will be 
beneficial in bladder cancer, this thesis set out to develop an MB49/ICAM-1 murine bladder 
cancer subcutaneous model in which this could be tested. CVA21 treatment led to delay in 
tumour growth in mice as compared to PBS treated mice. Tumour regression using CVA21 has 
already been displayed in other cancer murine models of lung (Y.W.Vern, July 2011), 
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pancreatic (Prof Darren Shafren, 2011), melanoma (Shafren et al, 2004), breast (Skelding et 
al, 2009) and prostate (Berry et al, 2008; Linda J.Berry, 2006). The MB49/ICAM-1 murine 
bladder cancer subcutaneous model showed delayed tumour growth in CVA21 treated mice 
but had its limitations. The model is very short-lived (approximately 14-16 days) which does 
not give sufficient time to study combinational approaches with immune-modulatory agents. 
Other models using oncolytic viruses in combination with immune-modulatory agents have a 
life-span of 60-150 days (Rajani et al, 2015; Shim et al, 2017; Zamarin et al, 2014). Additionally, 
the occurrence of tumour ulceration and hypoxic tumour core would limit virus replication 
and spread in the tumour microenvironment. In the future, other murine bladder cancer 
models such as AY-27 and MBT-2 (Ding et al, 2014) should be tested to see whether they 
overcome the issues encountered using the MB49/ICAM-1 model. Upon development of a 
murine bladder cancer model with extended life span, technologies that easily allow the 
profiling of the immune environment such as the nanostring pan-cancer immune gene 
expression panel should be used to investigate the induction of immune checkpoints by virus 
infection on the tumour. Notably, an increase in the expression of immune 
checkpoints/immunosuppressive molecules such as IDO, TIM-3 and PD-L1 was also reported 
within the tumour microenvironment of CANON trial patients treated with CVA21 as 
compared to untreated NMIBC patients (unpublished data).  Although we did not do further 
combination studies with CVA21, preliminary data from  other clinical studies using CVA21 in 
combination with Ipilimumab and Pembrolizumab have shown enhanced therapeutic efficacy 
in melanoma and NSCLC (AACR, 2017). In a clinical study combining intra-lesional CVA21 
injections with Ipilimumab, 7 partial responses (50 % objective response) and 4 compete 
responses in a total of 22 melanoma patients with no reported serious adverse events was 
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observed (AACR, 2017). Another trial combining CVA21 with Pembrolizumab displayed 
complete or partial response in 8 of the 11 enrolled melanoma patients (AACR, 2017).  
As well as immune checkpoint inhibitors there are other combinational approaches that can 
used with oncolytic virotherapy to provide greatest treatment benefit. Oncolytic viruses can 
also be combined with chemotherapy, radiotherapy, surgery, and adoptive T cell therapy or 
can be genetically modified to express anti-inflammatory cytokines (Kaufman et al, 2015; 
Ottolino-Perry et al, 2010). Few examples of combination studies with viruses include, 
parvovirus, herpes simplex, adenovirus, vaccinia virus, vesicular stomatitis virus and reovirus  
used in conjunction with chemotherapy, radiotherapy, adoptive T cell therapy and surgical 
resection (Angelova et al, 2014; Harrow et al, 2004; Kaufman et al, 2015; Lolkema et al, 2011; 
VanSeggelen et al, 2015). Reovirus used in conjunction with Gemcitabine and was safely 
tolerated in Phase I clinical trial in solid cancer patients (Lolkema et al, 2011). Similarly, 
parvovirus was also used in combination with Gemcitabine in pancreatic cancer cell -lines 
(Angelova et al, 2014). No toxicity was observed when HSV was injected next to site of 
resected glioma and was safely tolerated (Harrow et al, 2004). A study demonstrated both 
vaccinia virus and vesicular stomatitis virus can be loaded on chimeric antigen receptor 
engineered-T (CAR-T) cells, this did not alter CAR expression and also results in protection of 
viruses from neutralising antibodies (VanSeggelen et al, 2015). 
In light of data in the literature and our own results from the NMIBC clinical trial (CANON) it 
is clear that the future of CVA21 will be in combination therapy. The tumour specific cytolysis 
and anti-tumour immune response generated by oncolytic viruses can be further enhanced 
by combination with immune modulatory agents prolonging treatment therapeutic efficacy. 
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6.2 General Overview   
We are at a point in the cancer immunotherapy field where we have a greater understanding 
of which tumours will respond to cancer immunotherapy and can start to predict responses 
to therapy. Whilst, we do not know exactly what makes certain tumours respond to 
immunotherapy better than others, we have identified certain factors that influence the 
immunity-cancer cycle and affect response to immunotherapy (Chen & Mellman, 2017). The 
tumour immune environment can be segregated into three phenotypes namely, a deserted 
tumour, an immune excluded tumour and an inflamed tumour (Chen & Mellman, 2017; 
Hegde et al, 2016). Oncolytic viruses have the ability to target each of these tumour-immune 
phenotypes when used as either a monotherapy or in combination with other immune 
modulatory agents (Figure 6.1).  
Immune 
deserted 
tumours 
Inflamed 
tumours 
Immune 
excluded 
tumours 
Cancer-immune phenotypes Oncolytic Virotherapy 
No priming (no danger signals, no T cells). 
Tolerance (Treg, suppressive cytokines). 
Immunogenic ignorance (no presentation 
and antigens). 
Strong stromal interactions and 
extracellular matrix. 
Immune cells present but l imited 
penetration into tumours. 
Abundant CD4
+
 and CD8
+ 
T cells with 
exhausted phenotype surrounded by 
MDSCs and Treg cells. 
Tumour cell  lysis leads to production of TAAs 
and viral antigens. 
DAMPs and PAMPs prime T cells and break 
tolerance. 
Lead to disruption of tumour vasculature 
allowing infi ltration of immune cells into the 
tumour 
Induce tumour kil l ing and antigen specific T 
cells in presence of anti -inflammatory 
environment (TNFα, IFNγ and IL-12). Target 
for immune modulatory agents to further 
enhance treatment benefit. 
 
Figure 6.1 Oncolytic virotherapy targets cancer-immune phenotypes, adapted from (Chen & Mellman, 2017). 
  
Three cancer-immune phenotypes have been defined: immune deserted, immune excluded and inflamed, all  of 
which can be targeted by oncolytic virotherapy. Immune deserted tumours have no immune cell  priming and are 
immunogenically ignorant, oncolytic viruses induce tumour cell lysis producing TAAs, DAMPs and PAMPs thus, 
priming cancer specific T cells. Immune excluded tumours have abundant T cells but they cannot reach tumour 
core due to strong stromal l inks and barriers which can be disrupted by oncolytic vir uses. Inflamed tumours 
contain tumour specific T cells but in the presence of MDSCs, T regulatory cells and anti -inflammatory tumour 
microenvironment they become exhausted and their activation is restrained. Oncolytic viruses provide an anti -
tumour and pro-inflammatory tumour microenvironment with stimulatory cytokines, however, further 
combinational approaches with immune-modulatory agents are required to overcome the exhaustive T cell  
phenotype. Combination studies will  provide enhanced and long-term therapeutic benefit.  
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An immune deserted tumour lacks pre-existing immunity, is deficient in T cell priming and has 
tolerance due to suppressive cytokines. Oncolytic viruses induce tumour cell lysis which 
produces TAAs, viral antigens, DAMPs and stimulatory cytokines which can target such non-
inflamed tumours. Additionally, an immune excluded tumour has  abundant immune cell 
infiltrates which are limited to the tumour edges due to strong stroma and extracellular 
matrix. These tumours are great candidates to be treated with virotherapy which disrupts the 
tumour endothelial vasculature leading to influx of immune cells into the tumour. Lastly, 
inflamed tumours carry abundant CD4+ and CD8+ T cells however, they are surrounded by a 
milieu of pro-tumorigenic and anti-inflammatory cells such as MDSCs and regulatory T cells. 
This leads to an exhausted T cell phenotype which can be reversed by ‘lifting the brakes’ from 
T cell inactivation by using immune checkpoint inhibitors or other immunomodulatory 
combinations. However, the pre-existence of a cancer specific T cell response is important for 
the clinical success of immune checkpoints inhibitors, and hence this supports the ability of 
oncolytic viruses to break down immune tolerance and overcome suppression. The cancer 
specific immunity generated by oncolytic viruses can be further strengthened and prolonged 
by combination with immunomodulatory agents or other combinational approaches . Thus, a 
multi-parametric approach using oncolytic virotherapy will shift the immunosuppressive, 
non-inflamed tumour microenvironment towards an effector, inflamed immune cell 
phenotype.  
Whilst, CVA21 has clearly shown its therapeutic potential as an anti-cancer agent in human 
bladder and pancreatic cell-lines and in various clinical trials, the full potential of this agent 
lies in combination approaches. In the future personalised cancer immunotherapy can be 
provided with the aid of biomarkers to identify the best therapeutic combination approaches  
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that will provide the greatest treatment benefit. A multi-targeted approach to dampen cancer 
progression and outsmart tumour immune evasion has promising potential.  
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6.3 Future Work 
The aim of this study was to evaluate sensitivity to CVA21 induced death in bladder and 
pancreatic cancer cell-lines, means of selective replication in cancer cells, mechanism of 
resistance in presence of high viral receptor expression, mode of cell death and 
immunogenicity induced by the therapy. Additionally, to assess whether the cancer cell death 
induced in vitro would provide therapeutic benefit in an in vivo system, a subcutaneous 
bladder cancer model was established.  However, some questions regarding mechanism of 
action and occurrence of resistance to CVA21 induced infection still remain and need to be 
addressed in future studies.  
Firstly, the cause of resistance to CVA21 infection in the presence of high ICAM-1 receptor 
was not fully determined. In order to confirm the role of lack of KRAS mutation in resistance 
to CVA21 infection in BxPC-3 pancreatic cell, a microarray to reaffirm the absence of KRAS 
mutation in this cell-line needs to be performed followed by an in-depth evaluation of the 
PKR signalling pathway. Also, more cell-lines with high ICAM-1 expression, carrying KRAS 
mutations need to be evaluated for CVA21 infection and induced death.  
Secondly, the current subcutaneous bladder cancer murine model is short-lived which makes 
it challenging to fully evaluate CVA21 induced therapeutic benefit. Another bladder cancer 
murine model needs to be established to study the therapeutic benefit of CVA21 
administration intratumourally and assess the induction of immune markers which can be 
targeted to further enhance therapeutic benefit of CVA21. Additionally, an orthotopic bladder 
cancer model needs to be developed to mimic the growth characteristics and morphology of 
clinical bladder cancer. An orthotopic model will be used to better assess the treatment 
benefit, study tissue specific pathology and stimulation of immune markers.  
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Lastly, although this study has emphasised on the importance of ICAM-1 receptor in 
sensitivity to CVA21 induced infection and death in human bladder and pancreatic cancer cell-
lines, the expression of ICAM-1 on human patient tissue slices needs to be assessed. 
Additionally, urine cytology can also be evaluated to test for ICAM-1 presence. This will aid in 
selecting patients who will benefit most of CVA21 oncolytic virotherapy.  
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